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ABSTRACT 
 
Follistatins are extracellular inhibitors of TGF-β family ligands like activin A, 
myostatin and bone morphogenetic proteins. Follistatin-like 3 (Fstl3) is a potent 
inhibitor of activin signalling and antagonises the cardioprotective role of activin A in 
the heart. The expression of Fstl3 is elevated in patients with heart failure and 
upregulated by hypertrophic stimuli in cardiomyocytes. However its role in cardiac 
remodelling is largely unknown. The aim of this thesis was to analyse the function of 
Fstl3 in the myocardium in response to hypertrophic stimuli using both in vivo and in 
vitro approaches. 
 
To explore the role of Fstl3 in cardiac hypertrophy, cardiac-specific Fstl3 knock-out 
mice (Fstl3 KO) were subjected to pressure overload induced by trans-aortic 
constriction. They showed attenuated cardiac hypertrophy and improved cardiac 
function compared to wild type littermate control mice. Knock-out of Fstl3 specifically 
from cardiomyocytes was sufficient to reduce the total expression of Fstl3 in the heart 
following pressure overload, implying that cardiomyocytes are the major source of Fstl3 
in the heart after TAC. Fstl3 KO mice also showed reduced expression of typical 
hypertrophic markers including ANP, BNP, α-skeletal actin and β-MHC. Similarly, 
treatment of neonatal rat cardiomyocytes with Fstl3 resulted in hypertrophy as measured 
by increased cell size and protein synthesis. This was also accompanied by activation of 
p38 and JNK signalling pathways. Microarray analysis of ventricular samples from 
these mice indicated reduced expression of genes involved in protein binding and 
extracellular matrix. Verification by quantitative real-time RT-PCR revealed reduced 
expression of collagens and TGF- β1 in the myocardium, indicating reduced fibrosis. 
This was supported by histological analysis showing reduced interstitial fibrosis. 
 
As an in vitro model of pressure overload, cardiomyocytes were subjected to 
mechanical stretch, which elevated the expression of Fstl3. In order to explore the role 
of cardiomyocyte-derived Fstl3 in modulating fibroblast function, cardiac fibroblasts 
were treated with the conditioned medium from stretched cardiomyocytes and collagen 
synthesis was measured. Fstl3 was found to be necessary for conditioned medium to 
induce an increase in collagen synthesis in fibroblasts. Fstl3 was also shown to induce 
low levels of cell death in cardiac fibroblasts. In order to identify stretched 
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cardiomyocyte derived factors necessary for Fstl3 action on fibroblast collagen 
synthesis, a yeast two hybrid analysis was undertaken. Results indicated that Fstl3 may 
act, at least in part, through binding to proteins of the extracellular matrix as well as 
pro-fibrotic factors, including connective tissue growth factor (CTGF). While CTGF did 
not affect fibroblast collagen synthesis in the presence of Fstl3, it inhibited Fstl3 
induced cell death, indicating a protective role. In summary, data presented in this thesis 
demonstrates that Fstl3 is upregulated after cardiac injury and functions by activating 
the pro-hypertrophic and pro-fibrotic responses in the myocardium, making it an 
attractive therapeutic target for intervention of cardiac pathologies. 
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CHAPTER 1: Introduction 
 
1.1 Epidemiology of cardiovascular diseases 
 
Cardiovascular diseases (CVD) encompass a number of pathologies such as coronary 
heart disease (CHD) including angina and myocardial infarction, stroke, 
cardiomyopathies, rheumatic and inflammatory heart diseases, hypertension, etc. CVDs 
are the most common cause of death with an estimated 17.5 million deaths per year 
globally [1]. In Europe, CVDs account for about 4.3 million deaths per year, 
representing about 48% of all deaths [2]. In the UK alone, about 35% of the deaths each 
year are accounted for by CVD, wherein about half of these (48%) are due to CHD and 
28% due to stroke [3]. Currently, 23% of all disability-adjusted life years (DALYs) are 
lost to CVD in Europe [2]. Thus it is not surprising that the overall costs of CVD in the 
EU are about 192 million € per year with about 57% of these due to direct healthcare 
costs [4].  
 
1.2 Cardiac hypertrophy 
 
In most cases, cardiovascular diseases eventually lead to heart failure where the ability 
of the heart to adequately pump blood in response to systemic demands is 
compromised. However, initial compensation of the heart to increased systemic 
demands is provided in the form of cardiac hypertrophy, where individual 
cardiomyocytes grow in length and/or width in order to increase cardiac pump function 
and reduce ventricular wall tension [5-7]. Although cardiac hypertrophy is most 
commonly observed in cases where the underlying CVD leads to hemodynamic 
overload, it is also seen as an adaptive phase following myocardial infarction or due to 
genetic disposition [8-12]. Cardiac hypertrophy can be broadly classified into 
physiological and pathological hypertrophy. Physiological cardiac hypertrophy is 
commonly seen in response to exercise training or during pregnancy, where the 
increased workload is matched by preserved contractility [13]. In contrast, hypertrophic 
growth due to arterial hypertension, aortic stenosis or regurgitation develops initially as 
a compensatory mechanism gradually leading to contractile dysfunction and is called as 
pathological hypertrophy [6, 14]. These definitions are not taken absolutely, as the 
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mechanisms that drive cardiac growth responses are often common in physiological and 
pathological hypertrophy.  
 
Both physiological and pathological hypertrophy can be sub-classified into concentric 
and eccentric hypertrophy. Concentric hypertrophy develops in response to pathological 
stimuli such as hypertension or aortic stenosis in order to normalize the increased wall 
stress. This results in thickening of the ventricular walls due to parallel addition of 
sarcomeres and also results in smaller ventricular chamber dimensions [15, 16]. 
Concentric hypertrophy is also seen as an adaptation to isometric or static physical 
exercises such as weight lifting [13]. On the other hand, eccentric hypertrophy develops 
in response to increased diastolic wall stress and is characterized by chamber dilation 
and wall thinning due to addition of sarcomeres in series [15, 17]. It develops in 
response to isotonic exercise training as well as pathological stimuli such as aortic or 
mitral regurgitation resulting in volume overload [18, 19]. Hypertrophy following 
myocardial infarction shows the characteristics of both concentric and eccentric 
hypertrophy due to a combination of pressure and volume overload [10, 20]. These 
patterns of ventricular geometry are summarized below in Figure 1.1 based on the left 
ventricular (LV) mass and relative wall thickness defined as the ratio of LV wall 
thickness to diastolic chamber diameter. Besides concentric and eccentric hypertrophy, 
a third type of LV geometry is also observed i.e. concentric remodelling, characterized 
by normal LV mass but increased relative wall thickness, and is often seen in chronic 
hypertension [21]. 
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Figure 1.1: Classification of left ventricle geometry in pathological cardiac 
hypertrophy. Relative wall thickness is the ratio of LV mass to diastolic diameter. The 
striped area represents LV wall thickness and the area of the inner circle represents LV 
volume. Concentric hypertrophy is present when LV mass increases and is accompanied 
by increased relative wall thickness. In eccentric hypertrophy, LV mass increases while 
relative wall thickness is maintained. Concentric remodelling is characterized by 
increased relative wall thickness with normal LV mass. Source: Drazner, M. H. 
Circulation 2011;123:327-334 [22]. 
 
At the cellular level, a combination of hypertrophic stimuli, both mechanical and 
neurohumoral, initiate the cardiac growth response in the absence of hyperplasia. These 
have been extensively studied using neonatal cardiomyocytes as model systems [23, 
24]. The cardiomyocyte growth response is characterized by the activation of immediate 
early genes such as c-jun, c-fos, jun B and egr family. Following this, the ‘fetal gene 
program’ is activated, wherein elevated expression of genes normally involved in 
developmental processes is observed. These include atrial natriuretic peptide/factor 
(ANP or ANF), α - skeletal actin and isoform switch from α – myosin heavy chain (α-
MHC) to β – myosin heavy chain (β-MHC or Myh7) [24-26]. This is accompanied by 
an increase in protein synthesis and cell size as well as sarcomeric organization, thus 
initiating cardiomyocyte hypertrophy [24, 27-30].  
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1.3 Initiation of pathological cardiac hypertrophy 
 
Cardiac hypertrophy is initiated by various biomechanical and neurohumoral stress 
stimuli coming from the underlying CVD. These lead to changes in the intracellular 
signalling cascades resulting in increased protein synthesis/stability thereby leading to 
increase in the size of individual cardiac myocytes. It is possible that mechanical stress 
is the primary stimulus for cardiac hypertrophy as blockade of adrenoreceptors 
(humoral stimuli) or sympathectomy (neural stimuli) does not affect development of 
cardiac hypertrophy in response to hemodynamic overload [31].  
 
1.3.1 Mechanosensors in the heart 
 
Increased hemodynamic load is sensed by specific classes of mechanosensors including 
integrins, cytoskeleton and sarcolemmal proteins as well as guanine nucleotide binding 
proteins (G proteins). Integrins are a family of cell-surface receptors that link the 
extracellular matrix to the cytoskeleton and intracellular signalling proteins like focal 
adhesion kinase (FAK). Mechanical stretch of cardiac fibroblasts was shown to activate 
the extracellular regulated kinase (ERK) and Jun N-terminal protein kinase (JNK) 
pathways in an integrin-dependent manner [32], thus proving the ability of integrins to 
act as mechanotransducers. Integrins can also influence the hypertrophic response of 
cardiomyocytes, as overexpression of β1 integrin in cardiomyocytes was shown to 
increase protein synthesis and atrial natriuretic peptide (ANP) expression [33]. 
Moreover, integrins may be directly involved in activating signalling cascades by 
recruiting non-receptor tyrosine kinases such as FAK and Src, cytoskeletal proteins (α-
actinin) and signal transducing molecules (Grb2, Sos, Ras, Raf, PLCγ, ERKs, and 
SAPKs) as part of the focal adhesion complexes (FACs) [34, 35]. In fact integrins can 
activate FAK through Src [36] which can further activate the ERK pathway through 
Grb2-Sos-Ras-Raf or through PLCγ [35, 37]. These signalling molecules can activate 
various downstream cascades such as those involving p21ras, mitogen-activated protein 
kinases (MAPK), protein kinase C and p70S6K [38, 39], leading to increased protein 
synthesis and activation of the hypertrophic response. Moreover, FAK has been shown 
to mediate sarcomeric organization as well as activation of hypertrophic genes like 
ANP, in co-ordination with Src substrate protein p130Cas [40]. Other ECM proteins in 
contact with integrins such as collagens, laminin and fibronectin may also be involved 
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in triggering signals. For example, mechanical stretch was shown to induce the 
activation of JNK1 in cardiac fibroblasts cultured on fibronectin, laminin or vitronectin 
whereas activation of ERK2 could only be observed if fibroblasts were cultured on 
fibronectin [32].  
 
Cytoplasmic proteins like melusin and MLP have also been implicated as sensors of 
mechanical stretch in cardiomyocytes. Melusin is an integrin interacting protein and is 
essential for attenuation of cardiac hypertrophy in response to hemodynamic load but 
not to humoral stimuli, via the phosphorylation (inactivation) of glycogen synthase 
kinase - 3β (GSK-3β) [41]. The muscle LIM domain protein (MLP) is anchored to the 
Z-disc and may act as an internal stretch-sensor as mutations in MLP have been 
associated with dilated cardiomyopathy and heart failure [42]. Mechanical stretch can 
also lead to the expression and release of various growth factors and hormones that can 
directly activate the cardiac growth response [43]. These include endothelin 1 (ET-1) 
[44], angiotensin II (Ang-II) [45], transforming growth factor β (TGF-β) [46, 47], 
insulin-like growth factor 1 (IGF-1) [46], etc. Thus, integrins can establish a well-
coordinated cardiac growth response to stretch by integrating the various signalling 
pathways activated by ECM and growth factors.  
 
Sarcolemmal proteins that can act as mechanosensors in the heart include enzymes such 
as phospholipases C, D and A2 (PLC, PLD, PLA2) and protein kinase C (PKC), stretch 
activated ion channels and ion exchange channels like the Na+/H+ exchanger (NHE). 
Phospholipases are enzymes that catalytically breakdown plasma membrane 
phospholipids in a Ca2+ dependent manner to generate various lipid-derived second 
messengers [48]. In cardiomyocytes, mechanical stretch is shown to activate PLC 
within 1 min and also PLD and PLA2. Activated phospholipases can hydrolyse 
phospholipids to release second messengers like inositol-1,4,5-trisphosphate (IP3), 
diacyl glycerol (DAG), arachidonic acids, and phosphatidic acid [49]. IP3 causes the 
release of Ca2+ from intracellular Ca2+ stores, which can then activate some isoforms of 
PKC (α, β, γ) as well as other signalling intermediates like calmodulin and calcineurin. 
PKC (α, β, γ, δ, ε, η, θ, μ) can also be activated by DAG [50], and is involved in the 
expression of stretch-induced immediate early genes like c-fos and early growth 
response 1 (Egr-1) [49, 51].  
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Stretch-activated channels (SAC) and ion exchange channels allow the passage of free 
ions like Na+, K+ and Ca2+ into the cell cytoplasm. Opening of SAC leads to an influx of 
Ca2+ ions into the cells which is known to cause Ca2+ induced Ca2+ release [52]. At 
resting membrane potentials, this can lead to depolarisation of the membrane thereby 
increasing its excitability. Whole cell stretch experiments have shown that stretch 
affects a variety of ion channels including K+ ATP channel [53], L-type Ca2+ channel 
[54] and Na+/K+ pump current [55].  In guinea pig ventricular myocytes, it has been 
reported that whole-cell uniaxial stretch causes a time-independent current, most likely 
through a Ca2+-activated non-selective cation channel or the Na+/Ca2+ exchanger [56]. 
However, it is yet unclear if SAC can function as the initial mechanosensors for stretch-
induced cardiac hypertrophy as they may be activated secondarily by Ca2+ release or 
fatty acids [56, 57]. 
 
The Na+/H+ exchanger (NHE) is located in the sarcolemma and regulates the exchange 
of Na+ (influx) for H+ (efflux), thereby increasing intracellular pH [58]. In cultured 
cardiomyocytes, specific inhibition of NHE was shown to attenuate stretch-mediated 
MAP kinase activation as well as protein synthesis independently of Ang II and ET-1. 
Similarly, acid loading of cardiomycoytes was also found to reduce MAP kinase 
activation [59]. Enhanced activity of NHE and the subsequent increase in intracellular 
Na+ can activate the Na+/Ca2+ exchange (NCX) channel and thereby cause an increase in 
intracellular Ca2+ [60], which is known to activate Ca2+/calmodulin-dependent kinase II 
(CaMKII) and calcineurin. To this effect, it was reported that ANP through its receptor 
activates guanylyl-cyclase A (GC-A) to moderate the hypertrophic response to pressure 
overload by inhibiting excessive activation of NHE and the subsequent increase in 
intracellular Ca2+ and activity of CaMKII and Akt/ protein kinase B (PKB) [61]. Thus, 
NHE may play an important role in converting mechanical stress into intracellular 
biochemical signals. 
 
Guanine nucleotide binding proteins (G proteins) couple cell surface receptors to 
intracellular signalling intermediates by switching between an inactive guanosine 
diphosphate (GDP) bound state and an active guanosine triphosphate (GTP) bound state 
[62]. G proteins exist in two forms – the ‘small G proteins’ and the ‘heterotrimeric G 
proteins’. The small G proteins are single polypeptides consisting of five families – 
Rho, Ras, ARFs, Rab, Ran [63]. Ras can promote activation of Raf-1, phosphoinositide 
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3-kinase (PI3K) [64], small GTPase Ral proteins and GTPase activating proteins (GAP) 
p120GAP and p190GAP, thereby leading to activation of Rho [65]. In addition, Ras can 
also activate all three MAPK pathways – ERK1/2 [66], JNK and p38 [67]. Ras, when 
expressed in a constitutively active form in mice, was sufficient to induce cardiac 
hypertrophy and diastolic dysfunction [68]. Thus, activation of Ras can contribute 
significantly to multiple MAPK signalling responses in the heart, as shown by the 
phenotype of Ras overexpressing transgenic mice [69]. The Rho family is involved in 
organisation of the actin cytoskeleton and the formation of focal adhesion complexes by 
regulation of integrin clustering [38, 70]. Also, some members of the Rho family (Rac 
and cdc42) have been shown to activate the Jun N-terminal protein kinase (JNK) and 
p38 MAP kinase pathways [71]. RhoA can also activate Rho kinase (ROCK) which 
leads to sarcomeric organisation by activation of myosin light chain kinase (MLCK) 
[72]. Phenylephrine (PE) and endothelin-1 (ET-1) mediated cardiomyocyte hypertrophy 
can also be blocked using either dominant negative mutant of RhoA or ROCK inhibitor 
[73, 74]. However, overexpression of RhoA in mice was not sufficient to cause 
ventricular hypertrophy. It resulted in conduction abnormalities and atrial fibrillation 
leading to ventricular dilation and heart failure [75]. Similarly, overexpression of the 
Rab family member Rab1a in transgenic mice was found to be sufficient for cardiac 
hypertrophy leading to dilation and heart failure through activation of PKC [76]. Thus, 
small G proteins are important mediators of cardiac hypertrophy and act by converting 
membrane signals to intracellular biochemical signals in the heart. 
 
Heterotrimeric G proteins consist of Gα and Gβγ subunits and transduce stimulatory or 
inhibitory signals originating from cell surface receptors – G protein coupled receptors 
(GPCR). Activation of G proteins results in exchange of GDP for GTP on the Gα 
subunit and dissociation of Gα from the Gβγ subunits, which can then activate 
downstream signalling effectors – typically adenylyl cyclase, phospholipase C, MAPK, 
PI3K, etc. [77, 78]. G proteins, specifically the Gαq and Gαi1 subunits in the adult rat 
cardiac fibroblasts have been shown to be activated within 1 min of mechanical stretch 
and this response was modulated by the amount and duration of the strain applied [79]. 
Moreover, transient overexpression of constitutively active Gαq in the heart of mice was 
found to be sufficient to induce cardiac hypertrophy leading to heart failure through 
calcineurin-dependent and independent mechanisms [80]. Also, specific inhibition of 
Gαq signalling by overexpression of a carboxyl terminal Gαq peptide transgenically in 
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mice was shown to attenuate the cardiac hypertrophy response to pressure overload 
[81]. These studies indicate a crucial role of G proteins in the mechanotransduction of 
stretch signals in the heart leading to cardiac hypertrophy and heart failure.  
 
1.3.2 Neurohumoral stimuli  
 
Neurohumoral stimuli that initiate hypertrophic signalling include endocrine hormones 
and growth factors such as catecholamines (noradrenaline and adrenaline), endothelin-1, 
angiotensin-II, insulin-like growth factor (IGF-1), etc. These ligands are sensed by 
cardiomyocytes through various receptors such as GPCRs, receptors with intracellular 
tyrosine kinase domains (RTK), serine/threonine kinase domains and gp-130 linked 
receptors. Activation of receptors in turn initiates various signalling cascades that are 
central in controlling the cardiac growth and remodelling response.  
 
G protein coupled receptors (GPCRs) are a family of seven transmembrane domain 
containing receptors that couple to intracellular heterotrimeric G proteins and mediate 
stimulatory or inhibitory signals from the cell surface. They exist primarily as three 
functional classes of receptors depending on the class of Gα protein that they couple to. 
These are the β-adrenergic receptors that mainly couple to Gαs, the muscarinic 
cholinergic receptors coupled to Gαi and the α-adrenergic receptors, endothelin receptor 
and angiotensin receptors that are coupled to Gαq proteins. Examples of GPCR agonists 
include β-adrenergic agonists adrenaline, noradrenaline and isoproterenol, cholinergic 
receptor agonist acetylcholine and α-adrenergic agonists adrenaline, noradrenaline, 
endothelin-I (ET-1) and angiotensin-II (ang-II). When an agonist binds the extracellular 
or transmembrane domain of the receptor, it results in the catalysis of GDP to GTP 
exchange on the Gα subunit and its dissociation from the Gβγ subunits. These G protein 
subunits then transmit the intracellular signals via activation of effector proteins - Gαs 
and Gαi activate adenylyl cyclase (AC) while Gαq activates phospholipase C [82]. This 
signal is further propagated by production of second messengers like cyclic AMP 
(cAMP), IP3 and DAG. Adenylyl cyclase activity leads to the accumulation of cAMP 
and consequent activation of protein kinase A (PKA), which can phosphorylate several 
proteins involved in cardiomyocyte contraction such as the L-type calcium channel, 
ryanodine receptors and phospholamban, thereby augmenting cardiac contractility. 
Phospholipase C hydrolyses PIP2 to IP3 and DAG, which in turn activates protein 
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kinase C – an important mediator of GPCR mediated cardiac hypertrophy [83]. In 
addition, free Gβγ subunits directly enhance MAPK signalling, PI3-K and Ras activity 
[78, 84]. Figure 1.2 shows a schematic of various GPCRs signalling through their 
respective G proteins. 
 
 
 
Figure 1.2: G protein mediated intracellular signalling pathways in cardiac 
hypertrophy. Various G protein coupled receptors activate different classes of G 
proteins such as Gαq, Gαs and Gαi to initiate intracellular signalling pathways mainly 
activating phospholipase C (PLC) and adenylyl cyclase (AC). Source: Molkentin JD, 
Dorn GW. Annual Review of Physiology 2001; 63: 391-426 [85] 
 
G proteins and GPCRs have been extensively studied and implicated in the 
development of cardiac hypertrophy. Since Gαi mediated inhibition of AC can attenuate 
contractility, its expression has been hypothesized and proven to be elevated in the 
pathogenesis of cardiac hypertrophy and heart failure in patients as well as animal 
models [86-88]. Thus, upregulation of Gαi and the subsequent reduction in AC activity 
may be an important step in the transition from compensated hypertrophy to 
decompensated heart failure. The role of Gαs in heart failure is controversial as AC 
activity has been shown to be unaffected by transgenic overexpression of Gαs in the 
heart [89]. Although agonist induced contractility was elevated in these mice, it did not 
affect basal contractility but increased cellular necrosis, cardiac fibrosis and 
hypertrophy [90]. In contrast, Gαq has been shown to play a significant role in cardiac 
disease as demonstrated by its direct and necessary action on cardiac hypertrophy [81, 
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91, 92]. This is further exemplified by the clinical success of angiotensin receptor 
blockers in prevention or regression of cardiac hypertrophy [93, 94]. G-protein 
mediated signalling by agonist-activated GPCRs can be inhibited by desensitization of 
the receptor through phosphorylation by GPCR kinases (GRKs), leading to receptor 
internalisation and its uncoupling from the G proteins [95]. In addition, regulator of G 
protein signalling (RGS) proteins, which activate GTPase and induce GTP hydrolysis, 
have also been shown to inhibit GPCR signalling and subsequent cardiac hypertrophy 
[96, 97]. Thus GPCR mediated signalling functions to transmit the cardiomyocyte 
response to various hypertrophic stimuli. 
 
Receptors with intrinsic tyrosine kinase activity (RTK) have been implicated to play a 
role in both physiological and pathological response of the heart. Examples of RTK 
involved in hypertrophy regulation include insulin-like growth factors (IGF-I and II) 
receptor and epidermal growth factor (EGF) receptor amongst others [98]. IGF receptor 
binding leads to activation of the receptor tyrosine kinase, which phosphorylates insulin 
receptor substrates (IRS-1 and 2). This subsequently leads to activation of 
phosphoinisitide-3 kinase (PI3-K) which further activates Akt (or protein kinase B) and 
p70/85 S6K. Other signalling intermediates are also activated by IGF receptor, 
including Ras and PLC which can later activate MAPK proteins as well as protein 
kinase C (PKC) (Reviewed in  [99]). The role of IGFs in regulation of cardiac 
hypertrophy is controversial. In vitro studies on cardiomyocytes have shown 
hypertrophy in response to IGF-1 stimulation [100]. Transgenic overexpression of IGF-
1 has been reported to increase cardiomyocyte numbers and therefore cardiac mass 
without causing cardiomyocyte hypertrophy [101]. In contrast, local expression of IGF-
1 in the heart was shown to induce cardiac hypertrophy and age dependent systolic 
dysfunction [102]. Due to the pleiotropic nature of IGFs, a cardioprotective role has also 
been documented [103-107]. Another RTK implicated in cardiac hypertrophy is the 
EGF receptor, which can be activated by EGF, heparin binding EGF (HB-EGF) and 
TGF-α amongst others [108]. Furthermore, transactivation of EGF receptor has been 
shown to be necessary for hypertrophic signalling following angiotensin II type I (AT1) 
receptor activation [109, 110]. It has since been suggested that GPCRs such as AT1 
receptor, which lack intrinsic kinase activity may use RTK to transduce hypertrophic 
signals in the myocardium [111, 112]. Activation of EGF receptor by HB-EGF 
shedding, which can be induced by a disintegrin and metalloproteinase – 12 
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(ADAM12), has also been shown to induce cardiac hypertrophy [113, 114]. Thus, 
receptor tyrosine kinases play a central role in the development of cardiac hypertrophy. 
 
The best studied receptors with intrinsic serine/threonine kinase activity involved in 
cardiac pathologies are the TGF-β superfamily receptors and will be discussed in 
Section 1.8.1. Another example of receptors involved in sensing neurohumoral stimuli 
in cardiac hypertrophy is the gp130 linked receptors which are activated in response to 
IL-6 family cytokines including cardiotrophin-1 (CT-1), leukemia inhibitor factor (LIF) 
and IL-6 [115]. Signalling pathways activated by gp130 linked receptors include the 
janus kinase (Jak)-signal transducer and activator of transcription (Stat) pathway and the 
MAPK pathway. CT-1 induced cardiac hypertrophy is transduced predominantly 
through the MEK5-ERK5 signalling axis while LIF induced hypertrophy is transduced 
through Ras-ERK1/2 signalling [116-118]. Moreover, continuous activation of gp130 
pathway by constitutive overexpression of both IL-6 and IL-6 receptor was shown to 
cause cardiac hypertrophy in transgenic mice [119]. It is interesting to note that in 
contrast with adrenergic receptor stimulation, gp130 mediated hypertrophy (CT-1 
stimulation) is mainly manifested by increase in cell length of individual 
cardiomyocytes by addition of sarcomeres in series [120]. Furthermore, 
interdependence of angiotensin II mediated signalling and IL-6/gp130 pathway has 
recently been recognized. In this respect, IL-6 signalling was shown to be necessary for 
angiotensin II mediated hypertension and cardiac hypertrophy via gp130 linked receptor 
[121]. Similarly, CT-1 induced cardiac hypertrophy was shown to be more pronounced 
in hypertensive hearts with increased angiotensinogen [122]. In addition to regulation of 
cardiac hypertrophy, gp130 signalling also promotes cardiomyocyte survival and may 
thus be crucial to regulating the progression to heart failure [123, 124]. 
 
These various receptor mediated pathways activated by both mechanical and 
neurohumoral stimuli converge on specific intracellular signal-transduction circuits that 
mediate the hypertrophic response of cardiomyocytes. These signalling pathways 
further coordinate the hypertrophic growth regulating nuclear gene expression. 
Subsequently, this leads to augmented rates of protein translation and reduced rates of 
protein degradation in the cytoplasm. 
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1.4 Intracellular signalling cascades  
 
Most hypertrophic stimuli transduce their effects via major intracellular signalling 
cascades such as protein kinase C (PKC), Calcineurin – nuclear factor of activated T 
cells (NFAT), mitogen activated protein kinase (MAPK) and Akt/PKB pathways. A 
schematic of activation of these pathways is shown in Figure 1.3. 
 
 
Figure 1.3: Major intracellular signalling cascades activated by hypertrophic 
stimuli. Mechanical and neurohumoral stimuli are sensed by receptors in the 
sarcolemmal membrane of cardiomyocytes (top purple panel). These then activate 
intracellular protein signalling pathways, eventually culminating in signal transduction 
to the nucleus (lower brown panel). Major pathways include PKC, Calcineurin-NFAT, 
MAPK such as JNK, ERK and p38 and Akt/PKB. Source: Heineke et al. Nature 
Reviews Molecular Cell Biology 2006; 7: 589–600 [125] 
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1.4.1 MAPK signalling pathway  
 
MAPK pathways are organized as a three member protein kinase cascade. In the core 
module, MAPKs are phosphorylated by MAPK kinases (MKK), which are themselves 
activated via phosphorylation by serine/threonine kinases MKKKs. MAPK proteins 
include the JNK, ERK and p38 family members while MKK are MEK family proteins. 
Low molecular weight G proteins as well as other protein kinases form the MKKK 
family. MAPK pathways are activated in cardiomyocytes in response to a number of 
stimuli such as mechanical loading, GPCR agonists, RTK agonists like IGF-1, EGF, 
serine/threonine kinase receptor activation by TGF-β family ligands as well as IL-6 
family ligands mediated gp130 linked receptor activation (reviewed in [126]). MAPK 
proteins p38, JNK and ERK have been implicated in cardiomyocyte hypertrophy. 
Cardiomyocytes expressing constitutively active MKK3 or MKK6, which specifically 
activate p38 MAPK, showed characteristic hypertrophic responses including sarcomeric 
organization and expression of skeletal α-actin and ANF. MKK3 also increased 
apoptosis upon overexpression, coordinating with p38α but not p38β, which has been 
suggested to regulate hypertrophy rather than apoptosis [30, 127]. The in vivo data 
concerning the role of p38 in cardiac pathologies is however conflicting with the in 
vitro data. Transgenic overexpression of activated MKK3 and MKK6 in 
cardiomyocytes was shown to cause age-dependent fibrosis and heart failure, with no 
evidence of cardiac hypertrophy [128]. Moreover, cardiac specific dominant negative 
p38α and p38β transgenic mice displayed either similar or enhanced cardiac 
hypertrophy compared to wild type mice following pressure overload [129]. Similarly, 
dominant negative expression of MKK3, MKK6 or p38α in the heart of transgenic mice 
resulted in an enhanced hypertrophic response to pressure overload, in addition to 
exhibiting age dependent cardiac hypertrophy via activation of NFAT pathway [130]. 
Thus the p38 pathway may serve a protective function against cardiac hypertrophy but 
may also promote cardiac remodelling and heart failure progression. Similarly, while 
JNK expression in cardiomyocytes has been shown to induce hypertrophic responses, it 
may function as an inhibitor of in vivo cardiac hypertrophy in mice. Expression of 
constitutively active MKK7 in cardiomyocytes was shown to specifically activate JNK 
signalling and hypertrophic responses [131]. However, transgenic overexpression of 
MKK7 in the heart resulted in age dependent cardiomyopathy in the absence of cardiac 
hypertrophy [132]. Loss of function analysis using dnMKK4 demonstrated reduced 
 26 
activation of JNK in response to ET-1 stimulation or in vivo pressure overload, thereby 
reducing hypertrophy [133, 134]. In contrast, both cardiac specific dnJNK1/2 transgenic 
mice and JNK1 and JNK2 null mice showed enhanced cardiac hypertrophy with age or 
in response to pressure overload, via activation of calcineurin-NFAT signalling pathway 
[135]. Thus JNK signalling may serve to inhibit cardiac growth responses. 
 
In contrast to the roles of p38 and JNK, ERK signalling has been established to play a 
central role in mediating cardiac hypertrophy. ERK proteins are activated in response to 
GPCR stimulation by angiotensin II, endothelin-1 and adrenergic agonists, RTK 
activation by IGF-1 as well as mechanical loading (reviewed in [136]). Cardiac specific 
overexpression of activated MEK1 was shown to specifically induce constitutive 
ERK1/2 activation and was sufficient for the development of age dependent concentric 
hypertrophy without decompensation over time [137]. In contrast, simple ERK2 
overexpression in the heart did not induce cardiac hypertrophy but showed synergistic 
hypertrophic responses when crossed with MEK1 transgenic mice [138]. Thus 
activation of MEK1-ERK1/2 pathway in the heart may be sufficient to induce cardiac 
hypertrophy. Knock-out of dual specificity phosphatase-6 (Dusp6), a specific regulator 
of ERK1/2 dephosphorylation, showed increased basal but not agonist induced activity 
of ERK1/2 in the heart amongst other tissues. These mice exhibited increased cardiac 
size due to cardiomyocyte hyperplasia and resistance to pressure overload induced 
hypertrophy [139]. Taken together, these results suggest that the phenotype of MEK1 
transgenic mice may simply be a result of non-physiological constitutive activation of 
ERK1/2 in contrast with the physiological increase in ERK1/2 activity which did not 
induce hypertrophy [140]. Moreover ERK1/2 are not necessary for the development of 
cardiac hypertrophy in response to physiological or pathological stimuli, as 
demonstrated with Erk1-/- and Erk2+/- mice [141]. However, these mice exhibited 
increased cardiomyocyte apoptosis and progression to heart failure following chronic 
pressure overload. Recently, ERK5 has been identified as an atypical MAPK protein 
activated in the stressed heart and has been demonstrated to play a critical role in 
pressure overload induced cardiac hypertrophy. Erk5 knock-out in the heart was shown 
to reduce hypertrophy following pressure overload, accompanied by increased apoptosis 
and expression of p53 and Bad proteins [142]. Thus, ERK signalling has been 
increasingly implicated to play an anti-apoptotic role in the myocardium [137, 141-
143].  
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1.4.2 Calcineurin-NFAT signalling axis  
 
Calcineurin (Cn) is a Ca2+ dependent heterodimeric protein with serine/threonine 
phosphatase activity. It consists of two subunits, the catalytic subunit CnA and the 
regulatory subunit CnB. Calcineurin is activated by binding of the Ca2+ dependent 
adaptor protein calmodulin upon its saturation with Ca2+. Activated calcineurin 
dephosphorylates transcription factors of the NFAT family, which translocate to the 
nucleus and activate target genes involved in hypertrophy [144]. CnA catalytic subunit 
is encoded by three genes i.e. CnAα, CnAβ and CnAγ, while the regulatory subunit CnB 
is encoded by two genes, CnB1 and CnB2. Out of these only CnAα, CnAβ and CnB1 
expression is detected in the heart [145]. Four out of five NFAT transcription factors 
have been shown to be regulated by calcineurin, NFATc1 to NFATc4 [145]. Numerous 
studies have shown that calcineurin signalling is sufficient to induce cardiac 
hypertrophy. Overexpression of activated calcineurin catalytic subunit in the heart of 
transgenic mice was shown to induce extensive cardiac hypertrophy as well as 
interstitial fibrosis. Moreover, cardiac expression of constitutively active NFATc3, the 
molecular target of calcineurin, was sufficient to replicate this phenotype [146]. 
Similarly, inhibition of calcineurin-NFAT signalling axis in the heart by genetic means 
in CnAβ-/-, Nfatc3-/- and Nfatc2-/- mice or by transgenic overexpression of myocyte-
enriched calcineurin-interacting protein (MCIP1), an endogenous inhibitor of CnA, has 
demonstrated the necessary role of this pathway in cardiac hypertrophy development in 
response to neurohumoral agonist infusion or mechanical loading [145, 147-149]. 
Moreover, as mentioned above, the calcineurin-NFAT pathway is also used by MAPK 
proteins to induce hypertrophic responses. It is interesting to note that inhibition of 
calcineurin signalling by overexpression of MCIP1 reduced cardiac hypertrophy while 
preserving ventricular systolic function [147]. In contrast, MCIP2 overexpression in the 
heart also reduced cardiac hypertrophy in response to pressure overload, but resulted in 
diastolic dysfunction and cardiac stiffness [148]. Similarly, in the mouse model of 
dilated cardiomyopathy from muscle lim protein (Mlp) knock-out, inhibition of 
calcineurin function by knock-out of CnAβ, calcineurin was suggested to function in a 
cardioprotective manner by reducing cardiac remodelling [149]. Thus the calcineurin-
NFAT signalling axis is a key regulator of cardiac hypertrophy and remodelling. 
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1.4.3 PI3K - Akt/PKB pathway  
 
Phosphoinositide 3-kinase (PI3K) can be activated by stimulation of RTK or GPCRs 
with their agonists [150-152]. Upon activation, PI3K subunit Iα (called p110α) 
phosphorylates phosphatidylinositol 4, 5-biphosphate, which leads to recruitment of 3-
phosphoinositide-dependent kinase-1 (PDK1) and Akt/PKB to the membrane. PDK1 
then activates Akt by phosphorylation of Thr308 residues. Further phosphorylation of 
Akt on Ser473 by the mTORC2 complex can activate Akt or define its substrate 
specificity for phosphorylation of glycogen synthase kinase 3 (GSK-3α or GSK-3β, 
inactivated by phosphorylation) and Forkhead transcription factors (Foxo) amongst 
others [152, 153]. The PI3K-Akt pathway has been implicated in regulation of basal 
cardiac growth and physiological hypertrophy. Expression of constitutive active PI3K 
lead to increased heart size while that of dnPI3K or Akt1-/- lead to smaller sized hearts in 
transgenic and knock-out mice, with neither model showing signs of fibrosis and 
cardiac dysfunction [154, 155]. Moreover, transgenic mice with expression of dominant 
negative p110α in the heart demonstrated a necessary role for PI3K in development of 
physiological hypertrophy in response to exercise training. However, pathological 
hypertrophy was observed following pressure overload which lead to cardiac 
dysfunction and heart failure, suggesting a protective action of PI3K [156]. Analysis of 
transgenic mice with constitutively active Akt1 in the myocardium demonstrated 
cardiac hypertrophy with preserved or enhanced systolic function and protection from 
ischemic injury and cell death [157-159]. In contrast, overexpression of Akt3 in the 
heart resulted in compensated hypertrophy and cardioprotection in the short term, which 
progressed to reduced contractility and loss of cardioprotection in an age dependent 
manner [160]. Similarly, constitutive active Akt1 expression in the myocardium was 
shown to induce adaptive cardiac hypertrophy with preserved cardiac function in the 
short term. Sustained activation of Akt1 in these mice lead to cardiac dilation and heart 
failure attributed to insufficient angiogenic responses [161]. Loss of function study on 
Akt1-/- hearts showed exacerbated cardiac hypertrophy and dysfunction following 
pressure overload [155]. An important target of Akt mediated phosphorylation and 
inactivation is GSK-3β, which is known to inhibit cardiac hypertrophic transcriptional 
regulators such as GATA-4, NFAT and β-catenin [162-164]. Transgenic mice 
overexpressing active GSK-3β were shown to inhibit cardiac hypertrophy in response to 
a number of stimuli including β-adrenergic stimulation, calcineurin activation as well as 
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pressure overload [165, 166]. Thus PI3K-Akt signalling represents an important 
molecular switch which may regulate both physiological and pathological hypertrophic 
responses of the heart.  
 
In summary, signalling pathways MAPK, PI3K and TGF-β may play an important role 
in progression of cardiac hypertrophy. They also variably regulate physiological vs. 
pathological hypertrophy and may thus be involved in regulating their development. 
Whilst the p38 and JNK pathways may play a protective role against cardiac 
hypertrophy, they may also regulate progression to heart failure. Similarly, the PI3K-
Akt pathway may also play a protective role against cardiac hypertrophy, but may also 
regulate decompensation and progression to heart failure due to its role in angiogenesis. 
The calcineurin-NFAT pathway however, seems to play a central role in the 
development of cardiac hypertrophy. Similarly, the TGF-β pathway may be central to 
regulation of both hypertrophy and fibrosis in the myocardium. These signalling 
cascades are also multi-functional and are involved in regulating a number of cellular 
processes such as proliferation, differentiation, protein synthesis, cell death, etc. thereby 
making therapeutic targeting ineffective by itself. Owing to the complexity of these 
signalling cascades and their extensive cross-regulation by each other, essential 
downstream targets of these pathways need to be identified in order to delineate their 
exact function whilst avoiding activation of other pathways. 
 
1.5 Markers of cardiac hypertrophy and heart failure  
 
Initiation of the cardiac hypertrophic program is marked by re-expression of the ‘fetal 
gene program’ wherein genes normally expressed in the developing heart and repressed 
in the adult myocardium are reactivated during conditions of stress. These include 
natriuretic peptide genes (ANF, BNP), skeletal α-actin (SKA) as well as isoform switch 
from α-myosin heavy chain (α-MHC) to β-MHC. Reactivation of the fetal gene program 
permits a compensatory response of the stressed myocardium to increase protein 
synthesis and cell size as well as activation of appropriate pathways to maintain cardiac 
function while meeting the increased contractile or cardiac output demands. However, 
fetal gene program activation is mostly seen with pathological hypertrophy and not with 
physiological hypertrophy [25, 156, 167-170]. This indicates that physiological 
hypertrophy induces variable gene expression responses to compensate increases in 
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systemic demands while preventing decompensation. Also, in this respect, the fetal gene 
program induction is probably insufficient to maintain cardiac function and eventually 
leads to ventricular dysfunction. Both ANF and BNP are recognised as markers of 
pathological hypertrophy and their expression levels have useful prognostic rationale 
towards disease severity [171]. Elevated ANF and BNP levels play a compensatory role 
against cardiac overload through their natriuretic, diuretic and vasodilatory actions 
which serve to reduce both preload and afterload [172]. Under conditions of cardiac 
stress, contractile proteins also undergo an isoform switch from the fast α-MHC to slow 
β-MHC, thereby altering the α-MHC/β-MHC ratio [173], which can dramatically affect 
cardiac contractility and output. In fact, constitutive overexpression of β-MHC in mouse 
hearts was found to be sufficient to reduce systolic function [174]. Moreover, treatment 
of patients with dilated cardiomyopathy with β-blocker therapy lead to recovery 
accompanied by increased α-MHC and reduced β-MHC expression [175]. Similarly, 
increased expression of α-skeletal actin (SKA) has been reported following pressure 
overload at the compensated hypertrophic phase where cardiac contractility is 
maintained in response to increased pressure [176]. This has been shown to generate 
enough force of contraction despite the mechanical load and without affecting cell 
shortening. However, cardiomyocytes are unable to maintain the increased levels of 
SKA in chronic pressure overload and this may be crucial in the transition from 
compensated hypertrophy to decompensated heart failure [177]. Thus, increased α-
skeletal actin expression serves as a marker for cardiac hypertrophy.  
 
1.6 Metabolic remodelling in the hypertrophied heart 
 
Reactivation of the fetal gene programme in cardiac hypertrophy and heart failure is 
accompanied by a switch to fetal myocardial energy substrate preference - increased 
glucose utilisation and reduced fatty acid oxidation (FAO) [178-180]. This switch 
enables the hypertrophied heart to meet the enhanced energy requirements under cardiac 
stress while optimising oxygen consumption and maintaining cardiac contractility 
[181]. Reduced fatty acid oxidation and increased glucose utilisation is a characteristic 
of pathological cardiac hypertrophy [178, 182] and is necessary for immediate cell 
survival. Glucose oxidation requires less oxygen than fatty acid oxidation (FAO), 
although it generates less energy than FAO, and is thus important in conditions of 
cardiac stress to provide sufficient energy in an oxygen-efficient manner. This also 
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increases the glycogen stores in the heart, thereby promoting cell survival and providing 
sufficient energy during conditions of decreased substrate availability [183-185]. 
 
Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is a ligand-
activated transcription factor that is involved in modulating the expression of genes 
involved in fatty acid uptake and oxidation. These include muscle-type carnitine 
palmitoyltransferase I (mCPT1 or CPT1β) and medium-chain acyl-coA dehydrogenase 
(MCAD) [186-188]. PPAR gamma coactivator-1 (PGC-1α) is involved in mitochondrial 
biogenesis and functions as a coactivator of PPARα, cooperatively inducing the 
expression of PPARα target genes involved in FAO [189]. PPARα expression is 
normally enriched in tissues where oxidative energy demands are high, like heart and 
liver, and mitochondrial FAO is the primary source of energy [190]. CPT1β plays a 
crucial role in importing long-chain acyl-CoA into the mitochondria while MCAD 
catalyses the first step in the mitochondrial β-oxidation of fatty acids. The expression of 
PPARα and its target genes CPT1β and MCAD is reduced in response to hypertrophic 
stimuli such as pressure overload [191-193].  
 
Although compensatory at first, increased glycolysis may contribute to cardiac 
remodelling and pathological hypertrophy, eventually leading to heart failure due to 
diminished energy production compared to FAO as well as accumulation of intracellular 
lipids and metabolic intermediates [191, 194]. Altered metabolic homeostasis in the 
heart has itself been suggested to be a primary cause for the development of 
pathological hypertrophy and heart failure. This is further supported by the observation 
that treatment of patients with heart failure using β-adrenergic receptor blockers resulted 
in functional improvement accompanied by increased FAO [195, 196]. Knock-out of 
PPARα was shown to reduce the expression of its target genes in the heart while leading 
to age dependent cardiac fibrosis [197]. In contrast, cardiac specific overexpression of 
PPARα induced cardiac dysfunction exhibiting a diabetic cardiomyopathy phenotype 
[198]. Similarly, downregulation of PPARα expression in the hypertrophied heart was 
shown to be necessary for preserving cardiac contractility, as reactivation was shown to 
induce cardiac dysfunction [199]. PGC-1α has emerged as a key regulator of metabolic 
responses owing to its control of the expression of FAO enzymes. Overexpression of 
PGC-1α in the heart was shown to cause dilated cardiomyopathy [200]. In contrast, loss 
of PGC-1α resulted in age dependent cardiac dysfunction and remodelling [201, 202]. 
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Mutations in MCAD have been associated with hypertrophic cardiomyopathy and 
sudden death [203]. Similarly, inhibition of fatty acid import into the mitochondria 
resulted in cardiomyocyte hypertrophy [204, 205], suggesting that any alteration in the 
myocardial energy substrate may be sufficient to induce cardiac hypertrophy. Thus the 
PPAR-PGC system is crucial in controlling the myocardial metabolic phenotype and 
any alterations are likely to cause maladaptive cardiac pathologies. 
 
1.7 Decompensation and progression to heart failure (HF) 
 
The state of ‘compensated hypertrophy’ in the long run progresses to decompensation 
and is associated with an increased risk of sudden death and/or development of heart 
failure, independent of the underlying cause of myocardial hypertrophy [206]. 
Similarly, inhibition of cardiac hypertrophy using drugs such as angiotensin-converting 
enzyme (ACE) inhibitors was shown to reduce the risk of death and progression to heart 
failure in high risk patients [207]. These observations raise the question if stress-
induced adaptive hypertrophy is beneficial initially and detrimental if prolonged. 
Molecular and cellular changes during cardiac hypertrophy progression eventually lead 
to alterations in excitation-contraction coupling in myocytes, fibrosis and ECM 
remodelling, angiogenesis mismatch and cell death by apoptosis and necrosis, resulting 
in chamber dilation, cardiac dysfunction and eventually heart failure. A detailed 
understanding of the mechanisms of heart failure progression will help identifying 
therapeutic targets to prevent or reverse pathological remodelling. The following 
sections briefly summarize these potential mechanisms of heart failure progression. 
 
1.7.1 Alterations in excitation-contraction coupling in cardiomyocytes 
 
Excitation-contraction coupling (ECC) is responsible for the generation of contractile 
force of cardiomyocytes via calcium-induced calcium release followed by activation of 
ryanodine receptors (RyR) which further cause Ca2+ entry from the sarcoplasmic 
reticulum. The increase in Ca2+ concentration leads to conformational changes in the 
myofilaments, thus causing contraction. Relaxation is initiated by the removal of 
Ca2+ from the cytosol via the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 
(SERCA2a) and the Na+/Ca2+ exchanger (NCX) (reviewed in [208]). During normal 
function, the amount of Ca2+ entering the cell during contraction is exactly matched by 
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the amount of Ca2+ leaving it. A number of alterations have been described during 
cardiac hypertrophy which alter the calcium homeostasis and may play a role in 
progression to heart failure. 
 
Reduced SR Ca2+ release, reduced Ca2+ rate as well as increased diastolic Ca2+ levels 
have been observed in heart failure [209]. These are affected by reduced expression 
and/or activity of RyR and SERCA2a, which are both prominent in heart failure [210, 
211]. SERCA2a gene therapy has been shown to restore contractile function in heart 
failure in animal models [212-215] and is currently being tested in a clinical trial for 
patients with heart failure [216]. Dyssynchrony at the organ as well as the cellular level 
has been suggested as one of the mechanisms for contractile dysfunction leading to 
heart failure. At the cellular level, Ca2+ release from the SR and contraction are 
dyssynchronized, possibly due to alterations in t-tubule geometry and expression and 
function of RyRs and L-type Ca2+ channels in the sarcolemma (reviewed in [217]). A 
role for PKCα has been demonstrated in the regulation of Ca2+ handling in heart failure. 
Elevated expression and activity of PKCα has been noted in heart failure in different 
models [218-220]. Moreover, mice lacking PKCα showed cardiac hypercontractility 
which was cardioprotective against pressure overload induced heart failure or cardiac 
dilation in a genetic mouse model. Similarly, overexpression of PKCα resulted in 
hypocontractility, hypertrophy and cardiac dysfunction, possibly via activation of 
protein phosphatase inhibitor -1 (PP I-1) which indirectly affects phospholamban and 
therefore SERCA [221]. Inhibition of PKCα by pharmacological or genetic means was 
also shown to protect against heart failure while improving contractility [222, 223]. The 
calcium sensor S100A1 protein, which is downregulated in heart failure, can interact 
with SERCA/phospholamban and acts as a regulator of RyR and calcium homeostasis 
[224]. Mice lacking S100A1 show increased cardiac dysfunction induced by ischemia 
or pressure overload, while those overexpressing S100A1 are hypercontractile and 
maintain cardiac function following myocardial infarction [225, 226]. Thus alterations 
in regulators of excitation-contraction coupling contribute to impaired cardiac function 
in progression of heart failure. 
 
1.7.2 Angiogenesis mismatch 
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Cardiac hypertrophy is accompanied by an increased demand for myocardial oxygen 
and the adaptive phase of hypertrophy usually shows increased capillary density. 
However, sustained hypertrophy and the ensuing molecular changes lead to a mismatch 
between the required capillary density and cardiac growth. This may result in hypoxia 
or micro-ischemic areas that lead to further damage [227]. Angiogenesis mismatch has 
been suggested as one of the major mechanisms for transition to heart failure. Following 
severe pressure overload in the heart, the compensatory phase of hypertrophy showed 
increased capillary density, which progressively reduced in the pathological state, and 
could be reversed by the induction of angiogenic signalling [228]. Similarly, the central 
role of vascular endothelial growth factor (VEGF) was demonstrated by its inhibition 
using soluble VEGF receptors, which lead to reduced capillary density following 
pressure overload and faster transition to chamber dilation and heart failure. Thus 
VEGF was shown to be essential for the vascular network growth during adaptive 
hypertrophic responses [229]. In this respect, Akt signalling is implicated in the 
angiogenic responses in the stressed heart. Acute Akt activation in the heart was shown 
to cause reversible compensatory hypertrophy without affecting the myocardial 
capillary density. However, prolonged Akt activation lead to chamber dilation and heart 
failure, accompanied by reduced capillary density. Interestingly, inhibition of 
angiogenesis in physiological hypertrophy state by blocking VEGF action also led to 
cardiac dysfunction and failure [161]. At the molecular level, hypoxia-inducible factor-
1α (Hif-1α) is known to regulate the expression of pro-angiogenic factors VEGF and 
angiopoietin-2. In a model of pressure overload, initial adaptive hypertrophy was 
associated with an increase in Hif-1α and its target angiogenic proteins. Transition from 
hypertrophy to heart failure was dependent on inhibition of angiogenesis and increased 
p53 expression, which inhibited Hif-1α and the angiogenic response [228]. Thus, 
reduced angiogenesis plays an important role in the transition to heart failure. 
 
1.7.3 Cardiac fibrosis and extracellular matrix remodelling 
 
Cardiac structure is maintained by the extracellular matrix (ECM), which provides 
support for maintaining proper contractile function of the heart. The ECM is composed 
of fibrillar collagens (predominantly type I and type III), basement membrane 
components like fibronectin and laminin, proteoglycans and glucosaminoglycans [230]. 
Adaptation to myocardial stress induces a number of cellular and molecular alterations 
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which lead to changes in the ECM composition and the collagen network as well as the 
cardiac structure, together called remodelling. During conditions of chronic 
hypertension and pressure overload, cardiac hypertrophy gradually decompensates and 
reactive interstitial fibrosis is observed, which increases ventricular stiffness and 
progressively affects contractility and diastolic chamber filling capacity [231-233]. The 
ECM structure is maintained by a balance between the synthesis and degradation of 
matrix components, which is regulated by matrix metalloproteinases (MMPs) and their 
tissue inhibitors (TIMPs). Increased collagen deposition takes place as a result of 
increased collagen synthesis and reduced collagen degradation, which is commonly 
observed in pathological remodelling [234, 235]. Progression to heart failure is often 
associated with increased matrix degradation due to altered activities of MMPs and 
TIMPs, thereby causing chamber dilation and contractile dysfunction [236-238]. This 
was also demonstrated in a mouse model of mutated collagen type I, which made it 
resistant to degradation by MMPs and lead to age dependent cardiac fibrosis and 
contractile dysfunction [239]. In fact, inhibition of MMP activity in a number of animal 
models of heart failure has demonstrated beneficial effects on cardiac remodelling and 
function [240-242]. Similarly, gene targeted MMP2 and MMP9 mice exhibited reduced 
cardiac rupture, ventricular remodelling and dilation following myocardial infarction 
[243, 244]. However, MMPs are also known to regulate angiogenesis and MMP2 in 
particular promotes VEGF expression during compensatory hypertrophy, while MMP9 
is anti-angiogenic [245]. In this respect, hydrogen sulphide therapy of pressure 
overloaded hearts was shown to inhibit the transition to heart failure by inducing MMP2 
while inhibiting MMP9 in the heart [246]. 
 
TGF-β is an important mediator of cardiac fibrosis and is induced in response to a 
number of stress stimuli including angiotensin II [247, 248]. The hypertrophic and 
fibrotic functions of angiotensin II in the heart have been shown to be mediated by 
TGF-β [249-251]. TGF-β increases ECM synthesis by cardiac fibroblasts and also 
induces cardiomyocyte hypertrophic responses, as demonstrated by mice 
overexpressing TGF-β1 [252]. It has also been shown to inhibit MMPs expression and 
activity and induce TIMP expression, further contributing to remodelling [253-255]. 
TGF-β1 signal transduction takes place via Smad-dependent and independent pathways 
in cardiomyocytes and fibroblasts and is extensively discussed below (section 1.8.2). 
While inhibition of TGF-β signalling using soluble TGF-β receptor was shown to be 
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beneficial initially following infarction, it lead to progressive dysfunction characterized 
by chamber dilation [255]. In contrast, in a pressure overload model, inhibition of TGF-
β by neutralizing antibody therapy was shown to have beneficial effects by attenuation 
of fibrosis and diastolic dysfunction [256]. This may be due to the pleiotropic nature of 
this cytokine. Thus, experimentation with its downstream signalling components may 
be useful in delineating the exact physiological effects of each of them. In this respect, 
knock-out of Smad3 in the myocardium resulted in reduced fibrosis and improved 
cardiac function in mouse models of angiotensin II infused hypertension, pressure 
overload and myocardial infarction [257-259]. It is interesting to note that in the 
pressure overload model, mice lacking Smad3 developed increased cardiac hypertrophy 
but showed reduced fibrosis and better survival rates, indicating compensated 
hypertrophy in the absence of Smad3 [257]. In contrast, knock-out of co-activator 
Smad4 from the myocardium resulted in age dependent cardiac hypertrophy, fibrosis 
and reduced contractility, while causing spontaneous death in some mice between the 
age of 5-12 months [260]. Thus, the TGF-β-Smad pathway plays a significant role in 
cardiac remodelling and progression to heart failure. 
 
 
1.7.4 Cell death 
 
Cardiomyocyte cell death occurs during pathological remodelling and has been 
implicated in the transition to chamber dilation and heart failure [261]. Cardiomyocyte 
loss due to apoptosis, necrosis as well as autophagy is extensively being studied in 
attempts to identify new targets for therapeutic intervention. Cardiomyocyte apoptosis 
has been observed in animal models of heart failure as well as in patients with heart 
failure [262-264]. Apoptosis signal-regulating kinase (ASK)1 is an upstream MAPKKK 
protein that regulates cell death via effector proteins of the MAPK family [265]. 
Although its role in cardiac hypertrophy is contested [266-268], it has been shown to 
play an important role in myocardial remodelling following injury. Cardiac specific 
induction of ASK1 expression was shown to increase apoptosis and fibrosis in response 
to pressure overload and ischemic injury, further progressing to cardiac decompensation 
[269]. Similarly, knock-out of Ask1 resulted in reduced apoptotic cell death and 
ventricular remodelling following ischemic injury, pressure overload or angiotensin II 
infusion [266, 267, 270]. Bcl family proteins like Bnip3 and Nix have also been 
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implicated in modulating cell death in cardiac remodelling. Cardiac Nix deletion was 
shown to attenuate cardiomyocyte death, ventricular remodelling and cardiac 
dysfunction following pressure overload, while Nix overexpression resulted in variable 
age dependent apoptotic cardiomyopathy [271, 272]. Similarly, knock-out of Bnip3 
resulted in reduced post-infarction ventricular remodelling without affecting infarct size 
and preserved cardiac function associated with reduced apoptosis [273]. Another key 
regulator of apoptosis is the tumor suppressor gene p53, whose expression is elevated 
during the transition phase to heart failure. In addition to inhibiting angiogenesis, p53 
also induces apoptosis and knock-out of p53 was shown to inhibit heart failure 
progression and improved cardiac function in the myotrophin transgenic mouse model 
[274]. Thus, cardiomyocyte apoptosis inhibition is a clinically relevant therapeutic 
option which is being explored.  
 
1.8 TGF-β superfamily 
 
TGF-β superfamily is involved in regulating a numerous cellular processes such as 
proliferation, differentiation, cell adhesion, growth, development, apoptosis, migration, 
immune responses, etc. and any alterations in their function can result in serious 
pathologies such as cancer, wound-healing defects and fibrosis (reviewed in [275, 276]).  
 
1.8.1 Ligands and Receptors  
 
The ligands of the TGF-β superfamily are synthesized as dimeric pre-proproteins and 
are characterized as having a conserved ‘cysteine knot’ structure formed by three 
disulphide bonds between six conserved cysteine residues. The ligands can be 
subdivided into TGF-β isoforms, activin, bone morphogenetic proteins (BMPs), growth 
and differentiation factors (GDFs) and nodal. TGF-β exists in three isoforms - TGF-β1, 
TGF-β2 and TGF-β3; while four activin β monomers exist and form homo or 
heterodimers like activin A (βA-βA) and activin AB (βA-βB). A total of 10 BMPs and 11 
GDFs have been identified until now. All TGF-β superfamily members bind to dimeric 
transmembrane serine/threonine kinase receptors of two functional subclasses – type II 
and type I (also called activin receptor like kinases ALKs). Ligands of the TGF-
β/activin subclass bind the type II dimeric receptors which induces recruitment and 
phosphorylation of type I receptor dimeric complex and initiates the conserved 
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intracellular signalling pathway via Smad proteins (reviewed in [277]). Figure 1.4 
below shows the different TGF-β superfamily ligands and their receptors. 
 
 
Figure 1.4: TGF-β family ligands, receptors and intracellular Smad proteins. 
Ligands of the TGF-β superfamily like TGF-β, Activin, Nodal, BMPs and GDFs bind to 
different combinations of type II and type I receptors and initiate intracellular signalling 
via various R-Smad proteins. Smad2 and Smad3 are preferentially phosphorylated by 
ALK4, 5, 7 while Smad1, Smad5 and Smad8 are phosphorylated by ALK1, 2, 3, 6. 
 
1.8.2 Intracellular signalling mechanisms 
 
Signal transduction by the TGF-β family ligands is mediated mainly by intracellular 
Smad proteins. Some Smad-independent pathways have also been identified in specific 
tissues. Smad proteins can be subdivided into three functional classes: Receptor 
activated Smad (R-Smad), common mediator Smad (co-Smad) and inhibitory Smad (I-
Smad). Type II receptor binding by TGF-β/activin subclass ligands and subsequent type 
I receptor activation leads to the recruitment and phosphorylation of the R-Smad by the 
type I receptor. R-Smads include Smad2 and Smad3 which are activated by TGF-
β/activin ligands via type I receptors ALK4, ALK5 and ALK7; as well as Smad1, 
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Smad5 and Smad8 activated mainly by BMPs and GDFs via ALK1, 2, 3 and 6. 
Phosphorylation of R-Smad induces its binding to Smad4 as well as homomerization 
with another R-Smad. This complex then translocates to the nucleus where it can 
function as a transcriptional regulator of the target genes (reviewed in [277, 278]). 
Figure 1.5 below shows a schematic of the intracellular signal transduction via Smad 
proteins. Inhibition of the Smad pathway is mediated by inhibitory Smad6 and Smad7 
by a number of potential mechanisms including competitive binding to Type I receptors, 
receptor inactivation by dephosphorylation or degradation as well as transcriptional 
inhibition [279-282]. While ligands of the TGF-β family are numerous and multiple 
type I and type II receptor combinations exist, their signalling mechanisms converge on 
a limited number of intracellular Smad proteins. Thus, signalling specificity is generated 
via regulation of signal type, duration and magnitude as well as inhibitory pathways 
(reviewed in [283]). 
 
 
Figure 1.5: Schematic of TGF-β family signal transduction by Smad proteins. 
Ligands of the TGF-β superfamily bind type II receptors which recruit and 
phosphorylate type I receptors. This leads to phosphorylation of R-Smad which then 
forms a complex with another R-Smad and Smad4 common mediator. This complex 
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enters the nucleus and induces transcription control of target genes. Source: Schmierer 
B and Hill CS; Nature Reviews Molecular Cell Biology 2007; 8: 970-982 [283] 
 
In addition to signalling via Smad pathway, TGF-β ligands can also activate a number 
of different signalling pathways including MAPK via activation of TGF-β activated 
kinase 1 (TAK1), Ras and RhoA (reviewed in [278]). 
 
1.8.3 TGF-β family ligands in cardiac disease 
 
TGF-β family members have been widely implicated in the pathogenesis of heart 
failure. TGF-β1 is a profibrotic cytokine and stimulates the production of extracellular 
matrix proteins in many tissues, thereby promoting fibrosis [284-287]. In both 
hypertrophic and dilated cardiomyopathies, TGF-β1 is found to be elevated at the 
mRNA and protein levels [288, 289]. Angiotensin II is known to increase the expression 
of TGF-β1 in the myocardium and TGF-β1 is the primary mediator of Angiotensin II 
induced cardiac fibrosis [290]. Thus the beneficial effects of ACE inhibitors are 
partially dependent on their ability to reduce TGF-β1 expression [250, 291]. Similarly, 
direct blocking of TGF-β1 action in rats subjected to pressure-overload induced cardiac 
hypertrophy was found to reduce cardiac fibrosis and diastolic dysfunction without 
affecting cardiac hypertrophy [256]. Regulation of fibrosis by TGF-β was discussed in 
section 1.7.3. 
 
Activins are homodimeric cytokines of the TGF-β superfamily and are known to 
modulate diverse pathophysiological processes including inflammation and wound 
healing, cell proliferation, differentiation, metabolism and fibrosis (reviewed in [292]). 
Activins function by binding to a complex of two serine/threonine kinase receptors 
(Type I and Type II) which then activate pathway-restricted Smad proteins and 
propagate the signal to the nucleus (reviewed in [293]). In patients with heart failure 
caused by coronary artery disease or dilated cardiomyopathy, elevated serum levels of 
Activin A were detected as well as increased expression of Activin βA subunit was 
found in the T cells. Similarly, increased expression of Activin A was observed in the 
myocardium of animals subjected to coronary artery ligation, pressure-overload induced 
cardiac hypertrophy as well as ischemia/reperfusion injury [294]. In vitro studies on 
cardiomyocytes treated with Activin A showed increased expression of markers of 
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cardiac remodelling and hypertrophy including ANP, BNP, TGF-β1, MCP-1, MMP-9 
and TIMP-1 [295]. Activin A was also found to inhibit the increase in cardiomyocyte 
length and sarcomeric organisation induced by leukocyte inhibitory factor (LIF) [296]. 
Thus, activin functions to regulate both cardiac hypertrophy and remodelling and may 
present an important therapeutic target. 
 
1.9 Follistatin-like 3 (FSTL3) 
 
The follistatin family of proteins, whose founding member is follistatin (FST), are 
potent inhibitors of activin signalling. Follistatin-like 3, also known as follistatin-related 
gene (FLRG) or follistatin-related protein (FSRP) is a member of the follistatin-module 
family of proteins with characteristic cysteine-rich follistatin domains (FSD). Both 
follistatin and follistatin-like 3 (FSTL3) can bind activin with a high affinity and 
neutralise its action by preventing its binding to the activin receptors [297]. FSTL3 was 
identified as the target of a chromosomal translocation t(11;19)(q13;p13) observed in B-
cell chronic lymphocytic leukemia, wherein the CCND1 gene was found to be 
juxtaposed to the coding region of FSTL3 resulting in an aberrant transcript [298]. 
 
1.9.1 Domain organisation of FSTL3 
 
FSTL3 contains a signal peptide, N-terminal domain, followed by two FSD and a C-
terminal domain enriched in acidic residues. The overall structure of FSTL3 is similar 
to FST, which contains three FSD, and they share 45% primary sequence identity with 
FSTL3 [299]. Figure 1.6 shows the alignment of FST and FSTL3 proteins indicating 
high sequence homology. Domain sequence arrangement of FST and FSTL3 is shown 
in Figure 1.7. Conserved cysteine residues in a characteristic arrangement within the 
follistatin domains are highlighted ‘C’ and the heparin-binding sequence in FST, which 
is absent in FSTL3 is shown. The lack of heparin-binding sequence in FSTL3 makes it 
the dominantly available protein in the serum compared to FST [300, 301]. 
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Figure 1.6: Sequence alignment of FST and FSTL3. Protein sequences of human 
FST and FSTL3 were obtained from Ensemble database and aligned using Clustal W 
1.83 software. Aligned sequence is shown with amino acid position on the right. Key: * 
- identical residue; : - conserved substitution; . - non-conserved substitution; Red – 
small hydrophobic, aromatic residues; Blue – acidic residues; Magenta – basic residues; 
Green – hydroxyl, amine, basic residues. 
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Figure 1.7: Domain sequence comparison of FST and FSTL3. The domain 
sequences of FST (FS315) and FSTL3 (FSRP) are aligned and conserved cysteine 
residues ‘C’ are indicated. Tryptophan residues at positions 4 and 36, which are 
responsible for the activin-binding capacity of FST are shown as ‘W’. Source: 
Tortoriello DV, Sidis Y, et.al; Endocrinology 2001;142(8):3426-34 [302] 
 
1.9.2 Expression pattern of FSTL3 
 
FSTL3 is evolutionarily conserved and encodes a secreted glycoprotein. However, there 
have been some reports of nuclear localisation of FSTL3 in cell lines like HeLa (human 
cervical carcinoma) and HEK293 (human embryonic kidney) [302]. Figure 1.8 shows 
the sequence alignment of FSTL3 across various species, indicating evolutionary 
sequence conservation. Both FST and FSTL3 are ubiquitously expressed in a number of 
tissues and cell types, but differ in their expression pattern. Whereas highest expression 
of FSTL3 in adult tissues is found in the placenta, testis, heart and pancreas, in the fetal 
tissues FSTL3 is abundantly expressed in the lung, spleen, thymus, liver and heart 
[302]. At the same time, highest expression of FST is found in the ovary, pituitary, 
testis, kidney, fetal heart and fetal liver (Figure 1.9). During mouse heart development, 
Fstl3 expression is found in the aorta and pulmonary artery smooth muscle, ventricles as 
well as valve leaflets of the mitral and tricuspid valves [303]. 
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Figure 1.8: Evolutionary conservation of FSTL3 sequence. Protein sequences of 
FSTL3 from various species were obtained from the Ensemble database and aligned 
using Clustal W 1.83 software. Aligned sequence is shown with amino acid position on 
the right. Key: * - identical residue; : - conserved substitution; . - non-conserved 
substitution. 
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Figure 1.9: Expression pattern of Follistatin and FSTL3 in human tissues. mRNA 
expression of FST and FSTL3 (FSRP) was assessed using multiple tissue array from a 
number of adult and fetal human tissues. Source: Tortoriello DV, Sidis Y, et.al; 
Endocrinology 2001;142(8):3426-34 [302] 
 
1.9.3 Regulation of Fstl3 expression 
 
Owing to its ubiquitous expression in many tissues and cell types, the expression of 
Fstl3 is tightly regulated by a number of cytokines and growth factors. Using Fstl3 
promoter-reporter constructs, the proximal -550 base pair region of Fstl3 promoter was 
identified to be sufficient for basal promoter activity in HeLa and HEK293 cells [304]. 
This region is highly GC rich and contains five Sp1/Ap2 consensus sites as well as a 
number of Smad binding elements. The Sp1 sites are essential for basal transcriptional 
activation as their deletion results in complete abrogation of Fstl3 promoter activity in 
HepG2 cells (hepatocarcinoma) [305]. Both TGF-β and activin A stimulate the 
expression of Fstl3 via Smad proteins [305, 306]. In case of activin, this functions as a 
negative feedback loop as activin stimulated Fstl3 can further inhibit activin signalling 
[306]. Also, the Sp1 sites are essential for optimal response of Fstl3 to TGF-β 
stimulation [305]. The expression of Fstl3 is also regulated by tumor necrosis factor α 
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(TNFα) in HepG2 cells and this response in potentiated by TGF-β through Smad 
proteins. Four TNFα responsive elements are present in the Fstl3 promoter, which bind 
to nuclear factor kappa-B (NF-κB) transcription factor and regulate the expression of 
Fstl3 [307]. A schematic of the various transcription response elements in the Fstl3 
promoter is shown in Figure 1.10, wherein the proximal -2000 base pairs of the Fstl3 
promoter are represented. 
 
 
 
Figure 1.10: Transcriptional response sites in the Fstl3 promoter. The proximal -
2000 base pairs of the promoter are represented in units of 250 base pairs. The 
transcription start site if indicated. Basal promoter activity is regulated by the proximal -
550 base pairs of Fstl3 promoter containing five Sp1/Ap2 consensus sites which are 
necessary for basal promoter activity. This region also contains several smad binding 
elements which are activated by TGF-β and activin. Four TNFα response elements able 
to bind NF-κB are indicated in red. 
 
1.9.4: FSTL3 interaction with Activins 
 
Both FST and FSTL3 can bind to and inhibit the activity of TGF-β family ligands like 
activin, myostatin and bone morphogenetic proteins (BMPs) [308]. FST and FSTL3 
bind activin A with a high affinity (Kd = 23.6 – 30.2pM and 39.3pM respectively) and 
near irreversibility [308] and inhibit its binding to the activin receptors [309, 310], 
thereby regulating activin bio-availability in different tissues. FSTL3 can also bind 
activin B, but with a lower affinity compared to activin A [297]. The C-terminal domain 
of FSTL3, including the second follistatin domain is principally involved in activin 
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binding and inhibition [310-312]. However, in the case of FST, the N-terminal domain 
has been implicated in activin-binding [313], in spite of contradictory reports regarding 
the necessity of the N-terminal domain in activin-binding [314]. Recently, the crystal 
structure of activin A - FSTL3 complex was solved and illustrated the intimate contact 
and necessity of the FSTL3 N-terminal domain in binding activin A with a high affinity 
[311]. As shown in Figure 1.11, two molecules of FSTL3 surround one molecule of 
homodimeric activin A (a) in a way that blocks both the type II and type I receptor 
interaction sites on activin A (c). The N-terminal domain (ND) of FSTL3 interacts with 
the activin dimer interface while the two follistatin domains cover the convex portion of 
activin A, thereby blocking the activin type II receptor interaction site. The FSTL3 ND 
interaction with activin A was found to be stronger that that for FST ND, the 
substitution of which resulted in 60% loss of activin-binding capacity. The interaction 
of activin A-FST is shown in Figure 1.11 (b), where the ND and FSD1 and 2 interact 
with activin in a similar manner as FSTL3. However, FSD3 of one FST interacts with 
the ND of the second FST, thereby completely blocking the type I receptor interaction 
site. In conclusion, both FST and FSTL3 completely block the activin receptor 
interaction sites on activin, albeit in a dissimilar manner. Furthermore, this differential 
binding translates to differential activin-inhibition capacities for FST and FSTL3. Thus, 
exogenous FST and FSTL3 are equivalent in inhibition of exogenously added activin. 
However, if either of these is endogenously produced, then FST has superior activin-
inhibition capability, consistent with its superior cell-surface binding ability [308]. 
Thus, although FST and FSTL3 have strong overall structural and sequence similarity, 
their varied tissue distribution and activin neutralising capacities suggest that they might 
not be functional homologues. 
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Figure 1.11: The x-ray crystallographic structure of activin A-FSTL3 complex. 
(Resolution 2.5 Ao) Two molecules of FSTL3 (a) or FST (b) surround the central activin 
A dimmer through interaction of N-terminal domain (ND) with the type I receptor 
interaction site and follistatin domains (FSD) with the type II receptor interaction site 
(c). Source: Stamler R et al. J. Biol. Chem. 2008; 283: 32831-32838 [311] 
 
In vitro, Fstl3-activin binding has been shown to inhibit activin-dependent 
transcriptional activity in a dose-dependent manner [310]. However, unlike FST, it is 
unable to suppress activin-mediated secretion of follicle stimulating hormone (FSH) in 
pituitary cells [299]. In breast cancer cell lines, activin-mediated growth inhibition was 
abolished by expression of FSTL3, while silencing of FSTL3 resulted in tumor growth 
inhibition [315]. Transgenic over-expression of FSTL3 in gonads of mice resulted in 
gonadal developmental defects and reduced fertitlity – both thought to be arising from 
inhibition of activin in these tissues, which is critical for normal reproductive 
development and function [316]. On the other hand, whole-body knock-out of Fstl3 
resulted in an extensive metabolic phenotype in the form of increased pancreatic islet 
numbers and size, β cell hyperplasia, increased insulin sensitivity and glucose tolerance 
– most likely mediated by increased activin bioactivity in these tissues [317]. More 
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recently, we have reported that activin-mediated protection against ischemic injury in 
the heart is abrogated by Fstl3, and knock-out of Fstl3 in the heart resulted in smaller 
cardiac infarct size following ischemia-reperfusion injury [294]. Thus the activin A – 
Fstl3 axis is important in determining normal function and homeostasis in a number of 
tissue systems. 
 
1.9.5 Protein binding partners of FSTL3 
 
Besides activin A and B, FSTL3 is known to bind to and inhibit other members of the 
TGF-β superfamily including myostatin and BMP-2. Myostatin is a muscle growth 
inhibitor and increased expression of myostatin results in severe cachexia and reduced 
adipose tissue and muscle mass [318, 319]. Circulating myostatin in the serum is found 
as a complex with FSTL3, which inhibits myostatin activity in reporter gene assays 
[300]. Thus FSTL3 may be involved in regulating the amount of free myostatin 
availability. Whole-body Fstl3 KO mice show reduced visceral fat deposition, 
consistent with increased myostatin activity in these mice. These mice also show 
improved glucose tolerance and insulin sensitivity, which may be secondary to the 
altered fat deposition [317]. Thus the Fstl3-myostatin interaction may play an important 
role in regulating metabolic homeostasis. Fstl3 can also bind BMP-2, albeit with a lower 
affinity than activin, and repress BMP-2 induced transcriptional activity [310]. Whether 
this interaction plays a significant physiological role is currently unknown.  
 
Besides TGF-β superfamily ligands, other binding partners of Fstl3 include fibronectin, 
AF-10 and a disintegrin and metalloproteinase – 12 (ADAM-12). Yeast two-hybrid 
analysis identified fibronectin as a binding partner for FSTL3 from a placental cDNA 
library. FSTL3 binding to fibronectin type I domains via follistatin domains was found 
to increase the hematopoietic cell adhesiveness to fibronectin and increased the 
adhesiveness of primary hematopoietic progenitor cells [320]. FSTL3 may thus be 
involved in regulation of haematopoiesis. FSTL3 was also shown to bind AF10 ([ALL1 
(acute lymphoblastic leukaemia) fused gene from chromosome 10], enhance AF10 
homo-oligomerisation and thus increase AF10 dependent transcription [321]. Similarly, 
ADAM-12 was identified as a binding protein for FSTL3 using yeast two-hybrid 
screening of human placental cDNA library. ADAM-12 interaction with FSTL3 
inhibited osteoclast differentiation by reducing the number of osteoclasts as well as the 
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number of nuclei per osteoclast [322]. Whether this interaction exists in other tissues is 
unknown. Importantly, ADAM-12 is involved in ectodomain shedding of heparin-
binding epidermal growth factor (HB-EGF), which then binds to the EGF receptor and 
induces cardiac hypertrophy. Inhibition of ADAM-12 mediated HB-EGF shedding 
using a specific inhibitor was shown to inhibit the development of cardiac hypertrophy 
in response to chronic pressure overload in mice [113]. 
 
1.9.6: Expression of FSTL3 in various diseases 
 
Aberrant expression of FSTL3 is found in a number of pathologies. In women with pre-
eclampsia, increased expression of FSTL3 is found in the placenta as well as serum 
[323]. Similarly, in women with intrauterine growth restriction, the expression of 
FSTL3 was highly elevated in the placenta compared to controls [324]. In placental 
trophoblast cells, the expression of FSTL3 is induced by hypoxia [325]. On the other 
hand, reduced levels of FSTL3 are found in women with ovarian endometriosis [326], 
as well as in patients with endometrial adenocarcinoma [327]. Recently, elevated 
expression of FSTL3 was reported in patients with heart failure compared to control 
subjects [328]. Similarly, increased expression of Fstl3 was reported in mouse hearts 
subjected to ischemic injury or pressure overload induced cardiac hypertrophy [294]. 
Interestingly, the expression of Fstl3 in the serum was shown to be elevated in response 
to heavy resistance training in humans [329]. A role for Fstl3 was found in modulating 
metabolic homeostasis in mice as deletion of Fstl3 resulted in an altered metabolic 
phenotype as well as fat deposition, as described above [317]. Interestingly, mRNA 
expression of Fstl3 is increased in the subcutaneous fat in obese mice (ob/ob mice) 
while the levels in visceral fat are reduced compared to wild type mice [330]. Thus, 
Fstl3 may play a significant role in both physiological as well as pathological responses 
of the body. 
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1.10 Hypothesis and Aims 
 
Data from heart failure patients undergoing left ventricular assist device implantation 
and pharmacological treatment showed that the expression of follistatin family proteins 
was altered in the myocardium. Specifically, the expression of FSTL3 was elevated in 
heart failure and normalized following recovery. Chapter 3 presents the evidence for 
this observation. Microarray analysis on these samples indicated a potential role for 
FSTL3 in regulation of signal transduction and cell growth.  
 
Hypothesis 
 
Based on the above observations, a role for Fstl3 in regulating cardiac hypertrophy was 
hypothesized. In particular, it was hypothesized that elevated expression of Fstl3 is 
detrimental to cardiac function by regulating various signalling pathways involved in 
cardiac hypertrophy and/or remodelling. 
 
Specific Aims 
 
1. To analyze the expression of Fstl3 in animal models of cardiac stress and injury 
as well as in cardiomyocytes in response to hypertrophic stimuli. 
2. To create a mouse model of cardiac-specific loss of function of Fstl3 in order to 
understand the role of Fstl3. 
3. To examine the effects of Fstl3 absence on development of cardiac hypertrophy 
and remodelling in response to pressure overload in the heart. 
4. To identify mechanism of action of Fstl3 in the stressed myocardium. 
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CHAPTER 2: Materials & Methods 
 
2.1 Cloning of Fstl3 in pCMS-EGFP 
 
Mouse Fstl3 cDNA clone was obtained from RZPD (Berlin, Germany) and used for 
cloning Fstl3 in the following constructs: 
Table 2.1: Fstl3 construct 
 
 
2.1.1 Vector and Insert preparation 
 
For cloning of Fstl3, the cDNA containing vector and the target vector were digested 
with restriction enzymes EcoRI and XbaI (Roche Applied Sciences, UK - # 
11175084001 and 10674257001 respectively) as described below: 
Table 2.2: Restriction digestion of Fstl3 cDNA vector and target vector 
 
10X Sure/Cut buffer H: 500 mM Tris-Hcl, 100 mM MgCl2, 1 M NaCl, pH 7.5 
 
2.1.2 Agarose gel electrophoresis 
 
Following restriction digestion, the insert and vector reactions were loaded on a 1% 
agarose gel containing 0.5 μg/ml ethidium bromide (Sigma-Aldrich Co., UK - # E1510) 
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for visualization of DNA. The samples were diluted using 6X loading buffer (B7021S; 
New England Biolabs Inc.) and loaded in the wells of the gel along with 1 Kb plus 
DNA ladderTM (Invitrogen Ltd., UK - # 10787018). The samples were electrophoresed 
in 1X TAE buffer by applying a constant voltage of 100V. The gel was then visualized 
under UV light to detect the migration of DNA bands.  
 
2.1.3 DNA extraction and purification from agarose gels 
 
For extraction and purification of DNA samples from agarose gels, the QIAquick Gel 
Extraction kit (QIAGEN, UK - # 28706) was used. Following agarose gel 
electrophoresis, DNA fragment was excised from the gel by brief visualization under 
UV light in order to minimize DNA damage. The gel slice was transferred to a 1.5 ml 
microtube and weighed. Three volumes of buffer QG containing pH indicator dye were 
added to the tube e.g. 100 mg gel slice + 300 μl buffer QG. The microtube was 
incubated at 50oC for 10 minutes with intermittent shaking to help dissolve the agarose. 
After the gel slice had dissolved completely, the color of the mixture was checked to be 
yellow indicating optimal pH (<7.5) for DNA binding. One gel volume e.g. 100 μl of 
isopropanol was added to the mixture and mixed by inverting the tube 2-3 times. The 
mixture was then applied to the spin column contained in a 2 ml collection tube. The 
tube was centrifuged at 13,000 rpm for 1 minute at RT in order to enable binding of 
DNA contained in the sample to the silica membrane in the spin column. The flow 
through was discarded and 0.5 ml of buffer QG was added to the column and 
centrifuged as before in order to remove traces of agarose. Again, the flow through was 
discarded and 0.75 ml of ethanol containing wash buffer PE was added to the column 
and incubated at RT for 3 minutes. The column was centrifuged for 1 minute at 13,000 
rpm to remove salts and other impurities. The flow through was discarded and the 
column was centrifuged again for 1 minute at 13,000 rpm to remove any residual 
ethanol from the membrane. The spin column was transferred to a fresh DNase-free 1.5 
ml microtube. To elute the DNA, 30 μl of DNase-free water (pH 7.0 - 8.5) was added 
exactly at the centre of the column and allowed to incubate for 1 minute at RT. The 
column was then centrifuged for 1 minute at 13,000 rpm and DNA containing sample 
was quantified using spectrophotometry as described in section 2.2.4. 
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2.1.4 Ligation of vector-insert 
 
Ligation of EcoRI/XbaI digested vector and insert was carried out using T4 DNA ligase 
(Invitrogen Ltd., UK - # 15224-090). T4 DNA ligase catalyses the formation of 
phosphodiester bonds between double stranded DNA molecules with 5’ – phosphate 
and 3’ – hydroxyl termini, thereby ligating DNA fragments. The following reaction was 
set up using a 3:1 insert : vector molar ratio and incubated at RT for 5 minutes. 
Table 2.3: Ligation reaction setup 
 
5X ligase buffer: 250 mM Tris-HCl (pH 7.6), 50 mM MgCl2 , 5 mM ATP, 5 mM 
dithiothreitol (DTT), 25% (w/v) polyethylene glycol-8000 
 
2.1.5 Transformation of competent E.coli cells and colony selection 
 
The ligated constructs were transformed into One Shot® TOP10 Chemically 
Competent E.coli cells (Invitrogen Ltd., UK - # C4040-10) using manufacturer’s 
guidelines. One vial per reaction containing 50 μl of One Shot® TOP10 cells was 
thawed on ice. To the cells, 5 μl of ligation product was added gently and incubated for 
30 minutes on ice. Following incubation, heat-shock was given to the competent cells 
by placing them in a water bath equilibrated at 42oC for 30 seconds. The vial was 
removed from the water bath and briefly kept at room temperature. Pre-warmed 250 μl 
S.O.C medium was added aseptically to the vial. The cells were allowed to grow by 
placing them horizontally in a shaking incubator at 37oC for 1 hour at 225 rpm. The vial 
was centrifuged at 6000 rpm for 1 minute and 300 μl of the supernatant was discarded. 
The bacterial cell pellet was resuspended in the remaining volume of S.O.C medium 
and spread on a pre-warmed LB-agar plate containing 100 μg/ml ampicillin. The plate 
was inverted and placed overnight in an incubator at 37oC. Colonies growing on the 
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selective medium are properly ligated constructs capable of ampicillin resistance. The 
following day, 20 colonies were randomly picked from the plate, inoculated in 3 ml LB 
medium for plasmid DNA isolation using ‘miniprep’ protocol. DNA was sequenced to 
confirm proper ligation of the insert into the vector. Colonies containing required 
constructs were then inoculated in 200 ml LB medium for DNA isolation using 
‘maxiprep’ protocol. DNA was stored at -20oC until required. ‘Glycerol stocks’ of 
constructs were made by adding 20-25% (v/v) glycerol to LB medium containing 
required clones grown overnight. 
 
2.1.6 Map of pCMS-EGFP-Fstl3 
 
A schematic map of constructs resulting from cloning of mouse Fstl3 in the multiple 
cloning site (MCS) of pCMS-EGFP is shown in Figures 2.1  
 
 
Figure 2.1: Schematic of pCMS-EGFP-Fstl3. Adapted from BD Biosciences 
Clontech, USA. 
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2.2 Plasmid DNA extraction  
 
2.2.1 Plasmid DNA isolation from bacterial cells: Miniprep 
 
Plasmid DNA from bacterial cells (up to 20 μg) was isolated using the QIAprep spin 
miniprep kit (QIAGEN, UK - # 27106). Bacterial cultures (E.coli DH5α or TOP10) 
were inoculated in 3 ml Luria-Bertani (LB) medium containing selection antibiotics 
(e.g. Ampicillin 100 μg/ml) and grown for 12-18 hours at 37oC in a shaker at 250 rpm. 
Cells were harvested by centrifugation at 10,000 rpm for 2 minutes at RT and 
resuspended in 250 μl of buffer ‘P1’ containing 0.1 mg/ml RNase A and LyseBlue 
reagent. The cell suspension was vortexed in order to ensure complete mixing of 
LyseBlue with the cells, and was transferred into a 1.5 ml microtube. To this, 250 μl of 
SDS containing lysis buffer ‘P2’ was added and mixed by inverting the tube 5-6 times, 
resulting in a homogeneously blue colored suspension. SDS in the lysis buffer 
solubilises the protein and phospholipid components of plasma membrane, thereby 
leading to cell lysis and release of intracellular components. The lysis buffer also 
contains sodium hydroxide, which facilitates denaturing of chromosomal and plasmid 
DNA as well as intracellular proteins in the alkaline environment. Neutralisation buffer 
‘N3’, 350 μl, was added to the lysate and mixed thoroughly by inversion, as indicated 
by the lysate turning homogeneously colorless due to SDS precipitation. The high-salt 
concentration in the neutralization buffer causes denatured proteins and chromosomal 
DNA to precipitate with the SDS, while ensuring that the smaller plasmid DNA 
renatures appropriately and remains solibilised. The samples were centrifuged at 13,000 
rpm for 10 minutes at RT in a microcentrifuge, resulting in a compact white pellet of 
precipitated cell debris. The DNA containing supernatant was applied to a QIAprep spin 
column by decanting and centrifuged for 1 minute at 13,000 rpm to allow DNA 
adsorption onto the column. The flow-through was discarded and the spin column was 
washed using 0.5 ml buffer ‘PB’ by centrifugation for 1 minute at 13,000 rpm. The spin 
column was washed with 0.75 ml ethanol containing buffer ‘PE’ by centrifugation for 1 
minute at 13,000 rpm and the flow-through was discarded, thereby removing 
contaminating salts from the DNA. The spin column was centrifuged again at 13,000 
rpm for 1 minute in order to completely remove any traces of buffer ‘PE’, thus 
minimizing ethanol contamination of eluted DNA. The spin column was transferred into 
a fresh 1.5 ml collection tube and 50 μl of elution buffer ‘EB’ (10 mM Tris-Cl, pH 8.5) 
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was added directly on the centre of the silica gel membrane. The column was incubated 
for 2 minutes at RT and DNA was eluted by centrifugation at 13,000 rpm for 1 minute. 
DNA obtained was quantified using spectrophotometry and stored at -20oC until 
required. 
 
2.2.2 Plasmid DNA isolation from yeast cells 
 
For isolation of plasmid DNA from yeast cells, the QIAprep spin miniprep kit was used 
(QIAGEN, UK - # 27106) with some modifications. Single yeast colonies were 
inoculated in 5 ml YPAD medium and grown for 24 hours at 30oC in a shaker at 250 
rpm. Cells were harvested by centrifugation at 10,000 rpm for 5 minutes at RT and 
resuspended in 250 μl buffer ‘P1’ containing 0.1 mg/ml RNase A. The cell suspension 
was transferred into a 1.5 ml microtube and 100μl of acid-washed glass beads (425-600 
μm; Sigma-Aldrich Co., UK - # G8772) were added. Cell membranes were broken by 
vortexing for 5 minutes, after which the glass beads were allowed to settle at the bottom 
of the tube. The cell lysate was transferred into a fresh 1.5 ml microtube and 250 μl of 
lysis buffer ‘P2’ was added and mixed by inverting the tube. The miniprep protocol was 
followed from here onwards, as detailed in section 2.1.1. 
 
2.2.3 Plasmid DNA isolation from bacterial cells: Maxiprep 
 
When large quantities of plasmid DNA were required, a ‘Maxiprep’ protocol was 
followed to isolate up to 500 μg of DNA from bacterial cultures between 100-200 ml. 
The QIAfilter plasmid maxi kit was used (QIAGEN, UK - # 12263). Bacterial colonies 
were inoculated in 200 ml LB medium containing the appropriate selection antibiotic 
and grown overnight for 12-18 hours at 37oC in a shaker at 300 rpm. Bacterial cells 
were harvested by centrifugation at 6000 rpm for 15 minutes at 4oC and the pellet was 
resuspended in 10 ml buffer ‘P1’ containing 0.1 mg/ml RNase A and LyseBlue. 
Following complete mixing, 10 ml of lysis buffer ‘P2’ was added and mixed thoroughly 
and incubated at RT for 5 minutes, turning the cell suspension uniformly blue. 10 ml of 
chilled neutralization buffer ‘P3’ was added to the lysate and mixed immediately by 
inversion. This results in precipitation of genomic DNA, proteins and cell debris 
together with potassium dodecyl sulphate (KDS), making the lysate less viscous and 
colorless while forming a white precipitate. The lysate was immediately poured into a 
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QIAfilter cartridge and incubated at RT for 10 minutes. This results in the precipitate 
floating in a layer above the clear lysate. During this incubation, a QIAGEN-Tip was 
equilibrated by adding 10 ml equilibration buffer ‘QBT’ and allowing it to flow through 
the column under gravity. Following the 10 minute incubation of the lysate, a plunger 
was inserted gently on top of the cartridge and the cell lysate was filtered directly into 
the column of the previously equilibrated QIAGEN-Tip. The plasmid DNA from the 
lysate was allowed to bind the resin by gravity flow until the column was empty. The 
QIAGEN-Tip was washed twice with 30 ml buffer ‘QC’, allowing the column to empty 
each time under gravity flow, thus removing all impurities in the sample. The QIAGEN-
Tip was then transferred into a fresh 50 ml centrifuge tube and the plasmid DNA was 
eluted using 15 ml buffer ‘QF’, allowing the column to empty completely by gravity 
flow. To concentrate the DNA sample and remove salt contaminants, DNA was 
precipitated by addition of 0.7 volumes (10.5 ml) of isopropanol. The suspension was 
mixed properly and centrifuged at 15,000 rpm for 30 minutes at 4oC. The supernatant 
was carefully decanted and a clear, glassy pellet was observed at the bottom of the tube. 
The DNA pellet was resuspended in 300 μl TE buffer, transferred into a 1.5 ml 
microtube. The DNA was precipitated by adding 1/10th volume 3 M sodium acetate and 
3 volumes 100% ethanol. The solution was mixed and centrifuged at 13,000 rpm for 20 
minutes at 4oC. The supernatant was decanted and the pellet was washed once with 1 ml 
70% ethanol and centrifuged at 13,000 rpm for 10 minutes. The supernatant was 
removed and the pellet was air-dried for 5-10 minutes. The purified plasmid DNA was 
resuspended in 300 μl TE buffer and quantified by spectrophotometry. Plasmid DNA 
samples were stored at -20oC until required. 
 
2.2.4 DNA quantification using spectrophotometry 
 
DNA concentration can be determined by spectrophotometry by measuring the 
absorbance at 260 nm (A260). DNA samples are diluted in such a way as to get A260 
values between 0.1 and 1. One unit absorbance at A260 corresponds to 50 μg plasmid 
DNA/ml. DNA samples were diluted 1:100 (v/v) in TE buffer, pH 8.0, transferred into 
cuvettes and absorbance was measured at 260 nm and 280 nm. The concentration of 
DNA in the sample was calculated using the formula: DNA concentration (μg/ml) = 
A260 X dilution factor X 50. The purity of the DNA samples was estimated by 
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calculating the A260/280 ratio. For pure DNA samples, the value of the A260/280 ratio is 1.8 
(1.7 to1.9 is acceptable). 
 
2.3 Neonatal rat ventricular cardiomyocytes and fibroblasts isolation and culture 
 
Neonatal rat ventricular cardiomyocytes (NRVM) were prepared essentially by the 
method described by Toraason M, et.al. [331], with some modifications. All the 
procedures were performed in Class II Biological Safety Cabinet (NUAIRETM) under 
sterile conditions. Dissection tools used for removing the hearts from neonatal rats were 
sterilized by autoclaving and disinfected in 70% ethanol after each use. 10-15 Sprague-
Dawley rat pups (1-3 day old) were used per preparation. Rat pups were cleaned with 
70% ethanol, sacrificed by cervical dislocation and decapitated. The chest cavity was 
opened and beating hearts were quickly excised using forceps and placed in a petri dish 
containing ice-cold Ca2+ and Mg2+ free Hank’s buffered salt solution (CMF – HBSS; 
Sigma-Aldrich Co., UK - # H6648). Atria and surrounding connective tissue were 
removed and the ventricles were transferred to a tube containing ice-cold CMF-HBSS. 
The tissues were rinsed twice with CMF-HBSS in order to remove traces of blood and 
then transferred into a petri dish. Most of the CMF-HBSS was removed by aspiration, 
leaving about 1 ml in the dish. The ventricles were minced using sterile scalpels into 
small pieces about 1mm thick. To these, 8ml CMF-HBSS was added followed by 1 ml 
trypsin (Worthington Biochemical Corporation, USA - # LK003225) resuspended in 
CMF-HBSS, giving a final concentration of 50 μg/ml trypsin. These were incubated 
overnight (14-16 hours) at 4oC. The following morning, 0.5 ml soybean trypsin inhibitor 
(Worthington Biochemical Corporation, USA - # LK003235) resuspended in CMF-
HBSS, was added to the partially-digested tissues and incubated at 37oC in a 5% CO2 
(v/v) incubator for 20 minutes to fully inactivate Trypsin activity. Following this, the 
samples were transferred into a T75 tissue-culture grade flask (BD Biosciences, UK - # 
353136) and 2.5 ml Collagenase (Worthington Biochemical Corporation, USA - # 
LK003245), resuspended in Leibovitz L-15 serum-free medium (Sigma-Aldrich Co., 
UK - # L1518) was added, equivalent to 750 units collagenase. The tissues were then 
fully digested by placing the flask vertically in a shaking water bath at 37oC for 30-45 
minutes. Meanwhile, 20 ml serum-free L-15 medium was equilibrated by placing it in a 
T25 flask (BD Biosciences, UK - # 353108) with a vented cap, at 37oC in a 5% CO2 
incubator. After 30-45 minutes of collagenase digestion, the cells were dislodged by 
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triturating the suspension 10 times using a 10 ml serological pipette. Cells were washed 
once with equilibrated L-15 medium and filtered through a 0.70 μm cell strainer (BD 
Biosciences, UK - # 352350) in L-15 medium. Cells were collected by centrifugation at 
100 g (800 rpm) for 5 minutes. The cells were resuspended gently in 25 ml ‘complete 
medium’ - 4500 mg/L glucose containing Dulbecco’s Modified Eagle Medium 
[DMEM] with 200 mM L-glutamine (Sigma-Aldrich Co., UK - # D6429), 10% [v/v] 
fetal calf serum (Sigma-Aldrich Co., UK - # F4135), 100 units/ml penicillin and 0.1 
mg/ml streptomycin (Sigma-Aldrich Co., UK - # P4333). Cardiomyocytes were purified 
from the thus obtained mixture of cells by differential pre-plating. In this, the property 
of cardiac fibroblasts to adhere faster to tissue-culture plates was exploited to separate 
them from the cardiac myocytes. The cell mixture was sequentially pre-plated thrice in 
T75 flasks for 30, 30 and 20 minutes. The adherent fibroblasts were cultured further in 
‘complete medium’ while the cardiomyocyte enriched medium after the third pre-
plating was transferred to a separate tube. The cell density was measured after exclusion 
of dead cells with Trypan Blue (Sigma-Aldrich Co., UK - # T8154) and counting with 
the help of a Neubauer Hemocytometer. Cells were plated in type I fibronectin (Sigma-
Aldrich Co., UK - # F1141) – coated (1 μg/cm2) 6 well tissue culture plates (BD 
Biosciences, UK - # 353934) at 1 million cells/well (area = 9.6 cm2; cardiomyocyte 
density = 105,000/ cm2), in a total of 2 ml medium per well. Cardiomyocytes obtained 
by this protocol routinely had a purity of 97-99%. 
 
Cardiomyocytes were allowed to attach firmly for 3 days at which point, most cells 
were beating synchronously in culture. Cardiomyocytes were then serum-starved 
overnight – ‘complete medium’ changed to ‘serum-free’ medium – before starting 
experiments. 
 
Cardiac fibroblasts isolated using the above protocol were allowed to multiply for 1 
week, split 1:3 and cultured for another week (P1). Fibroblasts were then displaced by 
washing twice with 1X phosphate buffered saline (PBS), followed by addition of 1-2 ml 
trypsin-EDTA solution (Sigma-Aldrich Co., UK - # T3924) and incubation at 37oC in a 
5% CO2 incubator. Fibroblasts were passaged twice in this way to remove 
contaminating endothelial cells. For experimental setup, the cells were suspended in 
‘complete medium’, counted using a hemocytometer and plated at 1 million cells/well 
(density = 105,000/ cm2) of 6 well plates in a total of 2 ml medium/well. After allowing 
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them to attach for 24 hours, fibroblasts were serum-starved overnight before any 
experiments. 
 
2.4 RNA extraction from cells 
 
RNase-free eppendorfs and plastic-ware were used at all steps. All surfaces and pipettes 
were sprayed with RNaseZap® (Ambion, Inc. Applied Biosystems, UK - # AM9780), 
an RNase decontamination solution. Filtered, RNase-free pipette tips were used at every 
stage. 
 
TRIzol® reagent (InvitrogenTM, UK - # 15596-018) was used to prepare RNA samples 
from cells. It is a ready-to-use mixture of acidic phenol, guanidine isothiocyanate and 
other proprietary components which allows simultaneous isolation of total cellular 
RNA, DNA and protein. When the cellular structure is broken down in the presence of 
TRIzol®, the RNA and protein components differentially partition into the aqueous and 
organic phase of the solution respectively, while high molecular weight DNA will 
collect at the interphase [332]. This is mainly because of the acidic pH of the solution 
which ensures that RNA stays in the aqueous phase while DNA in the interphase. RNA 
is then precipitated from the aqueous phase.  
 
Neonatal rat ventricular cardiomyocytes (NRVM) or neonatal rat cardiac fibroblasts 
were cultured in 6 well tissue culture plates (well diameter = 35 mm) at a density of 1 
million/well. Cell culture medium was removed by aspiration and the cells were washed 
twice with 1X PBS. TRIzol®, 1ml per well was added to preserve RNA integrity during 
cell lysis. The cells were scraped from the wells in the presence of TRIzol® and the 
lysates were transferred into 1.5 ml RNase-free eppendorf tubes and stored at -80oC if 
required. Frozen samples were incubated at room temperature (RT) for 5 minutes to 
permit complete dissociation of nucleoprotein complexes. 200 μl of chloroform per ml 
TRIzol® was added to each sample and mixed by vortexing for 15 seconds. The samples 
were then incubated at RT for 3 minutes followed by centrifugation at 13,000 rpm for 
15 minutes at 4oC. This results in separation of the phases into lower phenol/organic 
phase, an interphase and the aqueous upper phase containing RNA. The aqueous phase 
was gently aspirated by pipetting and transferred into a fresh 1.5ml microtube and 0.5ml 
isopropanol was added to the tube for precipitation of the RNA. The tubes were 
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vortexed briefly to mix the isopropanol and then incubated at RT for 10 minutes. 
Samples were centrifuged at 13,000 rpm for 10 minutes at 4oC and the RNA pellet was 
visible at the bottom of the tube. The pellet was washed once with 1 ml of 75% ethanol 
followed by centrifugation at 8000 rpm for 5 minutes at 4oC. The RNA pellet was 
allowed to dry briefly and resuspended in 40 μl of RNase-free water. All RNA samples 
were stored at -80oC. 
 
2.5 RNA extraction from mouse cardiac tissue 
 
Myocardial samples from mouse ventricles were snap frozen in liquid nitrogen and 
stored at -80oC. RNase-free eppendorfs and plastic-ware were used at all steps. Mortar 
and pestle used for lysing frozen tissues were baked at 220oC for 4 hours to inactivate 
RNases. All surfaces and pipettes were sprayed with RNaseZap® (Ambion, Inc. Applied 
Biosystems, UK) to remove RNase. Filtered, RNase-free pipette tips were used at every 
stage. RNA was isolated by using the RNeasy Mini kit (Qiagen, UK - # 74106). The 
RNeasy kit is based upon a spin-column containing silica gel membrane fitting into a 
microtube. By altering the salt concentration in the column, RNA can be adsorbed onto 
or eluted from the membrane. The membrane enriches for longer RNA molecules by 
excluding RNA less than 200 bases. Elution is carried out in RNase-free water. 
 
2.5.1 Sample disruption and homogenization 
 
Sample disruption of frozen tissues was done using a mortar-pestle. Sample disruption 
helps to break up the extracellular matrix in the tissue samples and opens up the plasma 
membrane of cells and intracellular organelles in order to ensure complete RNA 
solubilisation. Frozen tissue samples (20-30 mg) were placed in liquid nitrogen (N2) 
containing mortar and quickly crushed with the pestle. The frozen tissue powder was 
transferred to a 1.5 ml microtube and 500 μl lysis buffer (RLT) was added quickly while 
the sample was still frozen. This is a critical parameter in obtaining high quality RNA as 
thawing of frozen tissue must be minimized prior to disruption. The lysis buffer 
contains guanidine thiocyanate, a chaotropic agent which denatures proteins by 
disrupting hydrogen bonds and thereby their secondary structure. It also contains β-
mercaptoethanol (1% v/v) which disrupts the tertiary and quarternary structure of 
proteins by breaking disulphide bonds. Together, these inhibit RNase activity and 
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promote cell lysis. The disrupted tissue in lysis buffer was kept on ice until 
homogenization. 
 
Sample homogenization ensures reduced viscosity of disrupted samples by shearing 
genomic DNA and other high molecular weight cellular components. Complete sample 
homogenization was achieved by passing the disrupted sample through a QIAshredder 
(Qiagen, UK - # 79654). The QIAshredder is a microcentrifuge spin column containing 
a proprietary biopolymer shredding system. The disrupted samples were loaded on 
QIAshredder spin columns placed in a collection tube, centrifuged at 13,000 rpm for 2 
minutes at room temperature and the homogenized lysate was collected. 
 
2.5.2 RNA isolation 
 
Homogenized lysates (500 μl) were diluted by adding 983 μl double-distilled water 
(ddH2O) and 17 μl proteinase K (20 μg/μl concentration) was added to the lysate. They 
were incubated at 55oC for 10 minutes in a water bath. The tissue debris was pelleted by 
centrifugation at 13,000 rpm for 3 minutes at room temperature. The supernatant was 
transferred to a fresh 2 ml microtube and 0.5 volumes of 100% ethanol were added and 
mixed by pipetting. To adsorb RNA from the sample onto the membrane, 700 μl of 
sample was added to an RNeasy mini column placed in a 2 ml collection tube and 
centrifuged for 15 seconds at 13,000 rpm. The flow-through was discarded and the step 
repeated until the entire sample was passed through the column for adsorption. Wash 
buffer (RW1) was added to the column (700 μl) and incubated for 5 minutes at room 
temperature followed by centrifugation for 15 seconds at 13,000 rpm. The flow-through 
was discarded and 80 μl was DNase I mixture (concentration = 0.34 U/μl; Qiagen, UK - 
# 79254) was carefully added directly on top of the membrane. The column was left at 
room temperature for 15 minutes, followed by another wash with 700 μl of wash buffer 
RW1. The column was transferred to a new collection tube and washed with 500 μl 
ethanol-containing wash buffer RPE by centrifugation at 13,000 rpm for 15 seconds 
followed by another wash with RPE by centrifugation for 2 minutes. To ensure no 
carry-over of ethanol to the eluted sample, the collection tube was changed and the 
membrane dried by centrifugation for 1 minute at 13,000 rpm. The flow-through and 
collection tube were discarded. To elute the bound RNA sample from the column, the 
column was transferred to a fresh 1.5 ml microtube and 30 μl of RNase-free water was 
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pipetted on the membrane avoiding direct contact. These were left at room temperature 
for 10 minutes before centrifugation for 1 minute at 13,000 rpm. Another elution was 
carried out similarly by adding 20 μl RNase-free water to the column and 
centrifugation. The column was discarded and the RNA sample was quantified and 
stored at -80oC until required. 
 
2.5.3 RNA quantification  
 
RNA obtained from cells or tissues was quantified by spectrophotometry by measuring 
the absorbance at 260 nm (A260nm). One unit absorbance at 260 nm is equivalent to 40 
μg RNA per ml. Samples were diluted 1:12 in RNase-free water and absorbance was 
measured at 260 nm using BioPhotometer Plus (Eppendorf, UK). The RNA 
concentration was calculated as: RNA (μg /ml) = A260nm X dilution factor X 40. For 
estimation of sample purity, the RNA samples were diluted 1:12 in TE buffer pH 8.0. 
A260nm and A280nm were measured and the ratio of A260/280 was calculated. Pure RNA 
samples usually have an A260/280 ratio of 2.0 – 2.1. 
 
2.6 Microarray analysis 
 
The GeneChip® Gene 1.0 ST Array System (Affymetrix, Santa Clara, CA) was selected 
to perform gene expression analysis on TAC and sham RNA samples from WT and 
Fstl3 KO mice. The Mouse Gene 1.0 ST Array is designed to measure the gene 
expression of well-annotated genes using approximately 25 probes/ gene (a total of 
770,317 distinct probes) designed across the full-length of 28,853 mouse genes. It uses 
a perfect match (PM)-only design where probes hybridize to the sense strands. 
Background is estimated by using approximately 17,000 generic background probes 
while standard poly-A controls and hybridization controls are represented on the arrays 
thus permitting troubleshooting throughout the experimental process. Gene-level 
analysis of multiple probes on different exons is summarized into a single expression 
value that represents all transcripts from the same gene. It thus provides a more 
complete and accurate picture of gene expression than 3’ biased expression array 
designs. It also gives a more robust analysis of the cumulative transcription activities of 
the gene of interest. The design of the array was based on the February 2006 mouse 
genome sequence (UCSC mm8, NCBI build 36) with comprehensive coverage of 
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RefSeq, putative complete CDS GenBank transcripts, all Ensembl transcript classes and 
syntenically mapped full-length mRNAs and RefSeq NMs. The Mouse Gene 1.0 ST 
(Sense Target) Array has 100 percent coverage of NM sequences present in the April 3, 
2007, RefSeq database. 
 
Microarray data analysis was performed by Dr. Enrique Lara-Pezzi. Total RNA was 
hybridized on the Mouse Gene 1.0 ST Array chip in triplicate and data was analyzed 
using the GeneSpring GX software suite (Agilent Technologies, USA). After scanning, 
raw data in each chip was normalized to the 50th percentile and to the median of the 
chip. Samples were then further normalized on a gene per gene basis to the values 
obtained for sham wild type hearts and gene lists were filtered for raw expression > 50. 
Fold change lists comparing two conditions were generated using a cut-off value of 1.4-
fold. For gene ontology (GO) analysis, the generated gene lists were compared to 
existing GO lists in GeneSpring. Only those GO lists showing a correlation p-value < 
0.01 with the studied gene list are shown. 
 
2.7 cDNA synthesis 
 
For cDNA synthesis, 0.2 μg RNA samples were used. RNA samples were always 
thawed and kept on ice. TaqMan® reverse transcription kit (Applied Biosystems, UK - # 
N8080234) was used and a master mix of all the reagents was prepared on ice as 
detailed in Table 2.4. To every tube, 13.05 μl of the master mix was added, followed by 
a total of 200 ng RNA sample and RNase-free water to make up the total volume to 20 
μl. 
Table 2.4: cDNA synthesis reaction setup 
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cDNA was synthesized in a Techne PHC-3 thermal cycler (Helix technologies Ltd., 
UK). The cycling conditions used for cDNA synthesis are as follows: 
Table 2.5: cDNA synthesis reaction conditions 
 
cDNA samples were stored at -20oC until required. 
 
2.8 Quantitative real-time RT-PCR 
 
Quantitative real-time PCR (qRT-PCR) was performed using off-the-shelf TaqMan® 
Gene Expression assays (Applied Biosystems, UK). These assays consist of target-
specific PCR primers flanking a target sequence-specific hybridization probe. The probe 
is fluorescently labeled with a reporter dye (FAM) on the 5’ end and a quencher (NFQ – 
non-fluorescent quencher) combined with a MGB (minor groove binder) moiety on the 
3’ end, which stabilizes the hybridized probe and raises the melting temperature (Tm). 
When the probe is intact, either in the target-bound or unbound state, fluorescence from 
the reporter dye is transferred to the quencher dye by a phenomenon called 
Fluorescence Resonance Energy Transfer (FRET) and is measured. When the primers 
and probe are bound to the target sequence and the extension phase begins, DNA 
polymerase cleaves the bound probe resulting in separation of the reporter dye and 
quencher dye, preventing FRET. Fluorescence from the reporter dye now predominates 
and is proportional to the amount of PCR amplicon. This is measured at every PCR 
cycle and the cycle at which fluorescence of the reporter dye exceeds background 
threshold fluorescence is called the Cycle Threshold (Ct). This value is used to calculate 
the relative gene expression by the ‘Comparative Ct method’. To enable this, 
amplification of an endogenous reference gene (18S rRNA) was carried out at the same 
time using primers and probe labeled with VIC reporter dye and TAMRA quencher dye. 
This allows measurement of Ct values for target gene and control in the same tube and 
the ΔCt is calculated as the difference between Ct of target gene and Ct of endogenous 
reference genes. From this, the relative expression of the gene is calculated as:  
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Relative gene expression = 2 ^ (-Δ [ΔCt]); where Δ [ΔCt] is the difference between ΔCt 
of test sample and ΔCt of blank/calibrator sample. Thus the abundance of the target 
gene is calculated, normalized to an endogenous reference gene like 18S. 
 
The qRT-PCR reaction was set-up as a 25 μl reaction using 1 μl cDNA prepared from 
200 ng RNA. TaqMan® Gene Expression master mix and target gene assays as well as 
18S rRNA assay were purchased from Applied Biosystems, UK. The details of all target 
gene assays are given in Appendix I. TaqMan® Gene Expression master mix is 
optimized for all TaqMan® Gene Expression assays and contains AmpliTaq Gold® 
DNA polymerase UP (ultra pure), Uracil-DNA Glycosylase (UDG), dNTPs containing 
dUTP, ROXTM passive reference and buffer components proprietary to Applied 
Biosystems. ROX functions as an internal reference against which reporter dye signal is 
normalized during amplification. UDG prevents reamplification of carryover PCR 
products by removing uracil incorporated into PCR amplicons created with a master 
mix containing dUTP, thus minimizing false positives. 
Table 2.6: Real-time PCR reaction setup 
 
 
Real-time PCR was performed using the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, UK). The cycling conditions are shown in Table 2.7. Data were 
collected and analyzed using Sequence Detection System software version 1.9.1 after 
setting the baseline and threshold for each reporter dye manually. Relative gene 
expression was calculated by the comparative Ct method.  
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Table 2.7: Real-time PCR cycling conditions 
 
 
2.9 Protein sample preparation from cells and tissues 
 
Cultured neonatal rat cardiac myocytes or fibroblasts were cultured as described above. 
Cells were serum-starved for 24 hours prior to all experiments. Cells were treated with 
inhibitors of signalling cascades for 1 hour prior to stimulation for specific time periods, 
as per experimental requirements. The culture medium was then aspirated and the cells 
were washed twice with cold 1X PBS. For cell lysis, 150 μl of cold 1X Ripa buffer 
(Cell Signaling Technology, UK - # 9806 : 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 
mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium 
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin)  
supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF; Roche Applied 
Science, UK - # 10837091001), 1X PhosSTOP Phosphatase Inhibitor Cocktail (Roche 
Applied Science, UK - # 04906837001), 1X Complete Protease Inhibitor Cocktail 
(Roche Applied Science, UK - # 04693132001) was added and the cells were scraped 
from the tissue culture plates. The cell lysate was incubated in ice for 20 minutes to 
permit complete lysis and was then centrifuged at 13,000 rpm for 2 minutes at 4oC to 
precipitate the cell debris. The resulting supernatant was used as protein extract and 
quantified as described below. 
 
For isolating total cellular proteins from frozen mouse cardiac tissues, the tissue 
samples were disrupted (powdered) in liquid nitrogen using a mortar-pestle apparatus. 
This was then transferred to a 1.5 ml microtube and 100 μl of 1X Ripa buffer 
supplemented with 1 mM PMSF, 1X PhosSTOP Phosphatase Inhibitor Cocktail and 1X 
Complete Protease Inhibitor Cocktail was added. The lysate was then briefly sonicated 
for complete homogenisation and the resulting homogenate was incubated on ice for 20 
minutes. The cell debris was removed by centrifugation at 13,000 rpm for 2 minutes at 
4oC and the supernatant was used to quantify the amount of proteins in the sample. 
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Following protein quantification, the protein samples were diluted using 3X reducing 
loading buffer (Cell signaling technology, Inc., UK - # 7722: 187.5mM Tris-HCl (pH 
6.8), 6% (w/v) SDS, 30% glycerol and 0.03% (w/v) bromophenol blue supplemented 
with 125 mM dithiothreitol (DTT)). 
 
2.10 Protein quantification 
 
Quantification of protein samples was performed using the DC protein assay (Bio-rad, 
USA - # 500-0112). This method is based on the Lowry assay with some modifications. 
The assay is compatible with a number of detergents commonly used in protein lysis 
buffers. Proteins in the sample are made detergent soluble followed by a reaction with 
alkaline copper tartrate solution. The resulting protein-copper complex is then able to 
reduce Folin reagent, consequently producing a characteristic blue color with maximum 
absorbance at 750 nm. The amount of colored product is proportional to the number of 
tyrosine and tryptophan amino acids in the protein sample. A standard assay using 
known amounts of bovine serum albumin (BSA) is performed at the same time and the 
amount of proteins in the test samples is quantified by matching the absorbance values 
of the test samples against the standard curve. BSA standards from 0 to 10 μg were 
made in 1.5 ml microtubes as follows: 
Table 2.8: Protein standards 
 
 
Test samples and lysis buffer were diluted 1:2 and 5 μl of standards and test samples 
were added to the wells of a 96-well flat-bottom plate in duplicate. Reagent ‘A’ was 
prepared by adding 20 μl of surfactant solution ‘S’ per 1ml of alkaline copper tartrate 
solution. To the standards and test samples, 25 μl of reagent ‘A’ was added, followed by 
200 μl of Folin reagent. The resulting mix was incubated for 15 minutes at room 
temperature and the absorbance was read at 750 nm (A750nm) in a microplate 
spectrophotometer: μQuant (BIO-TEK Instruments, Inc.) using the software KC Junior 
v1.41.3. The values of A750nm were plotted against the amount of proteins in the 
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standards and a standard curve was obtained using linear regression. The standard curve 
routinely had an ‘R square’ value of >0.99, confirming a good fit to linearity. The 
amounts of protein in the test sample were then obtained by matching their A750nm 
values against the standard curve. A representative standard curve obtained using BSA 
standards is shown in Figure 2.2. 
 
 
Figure 2.2: Representative standard curve for protein quantification. BSA 
standards with varying amount of protein were made and the A750nm was measured after 
protein quantification using DC protein assay. The assay was performed in duplicate 
and A750nm was plotted against the amount of protein. Linear regression analysis was 
performed and the R2 value obtained is indicated. 
 
2.11 One-dimensional Gel electrophoresis of proteins  
 
Polyacrylamide Gel Electrophoresis (PAGE) is used to separate a complex mixture of 
proteins based on their size and charge. Gels are made by crosslinking acrylamide and 
bis-acrylamide to create specific gel pore sizes through which the protein mixture can 
migrate. A discontinuous buffer system is used for making separate stacking gel and 
resolving gel in order to stack all proteins into a single starting band and then finely 
resolve and separate them. In order to separate proteins based on their molecular weight, 
sodium dodecyl sulphate (SDS) is used in the gel system. Protein samples are denatured 
by heating them in the presence of SDS and a thiol reducing agent like β-
mercaptoethanol, which reduces disulphide bonds in the proteins. This results in 
denatured proteins with a uniform charge-to-mass ratio proportional to their molecular 
weights, thus resulting in separation based on molecular weights.  
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The Mini-PROTEAN® system (Bio-Rad Laboratories, Inc.; USA) was used to prepare 
resolving gel according to the following table (2.9). The reagents were added in the 
order listed. 10% ammonium persulphate (APS; Bio-Rad # 161-0700) and N,N,N,N-
Tetramethylethylenediamine (TEMED; Bio-Rad # 161-0801) catalyse the crosslinking 
and polymerisation of the acrylamide and bis-acrylamide (40% acrylamide-bis-
acrylamide solution 29:1; Bio-Rad Laboratories, Inc. - # 161-0146).  These were added 
immediately prior to pouring the gel in the casting plates. Lower Tris: 1.5 M Tris-Cl pH 
8.8, 0.4% SDS. 12% resolving gel was made and poured into casting plates with 1mm 
spacer thickness. In order to prevent oxidation, the resolving gel was layered with 100% 
ethanol until polymerisation was complete.  
Table 2.9: Resolving gel formulation 
 
 
After polymerization of the resolving gel, the ethanol layer was poured off. The 
stacking gel was made as detailed in Table 2.10 and poured over the resolving gel. Gel 
comb of 1 mm thickness containing 10 wells for loading samples was inserted. Once 
polymerization was complete, the comb was removed and the gel was attached to the 
buffer chamber. The wells were washed with SDS-electrophoresis buffer while the 
chamber was filled with the same buffer. Upper Tris: 0.5 M Tris-Cl pH 6.8, 0.4% SDS. 
Table 2.10: Stacking gel formulation 
 
 
 72 
Equal amounts (30-60 μg) of denatured protein samples were loaded in the wells along 
with a molecular weight marker (Novex® Sharp pre-stained protein marker: 
InvitrogenTM, UK - # LC5800). SDS-electrophoresis buffer was poured in the outer 
chamber and the samples were electrophoresed at 120V until the bromophenol blue dye 
in the sample buffer reached the bottom of the gel. SDS-electrophoresis buffer     1 L: 
Tris base (3 g), Glycine (14.4 g), 0.1% SDS. 
 
2.12 Electroblotting of proteins 
 
Electroblotting of proteins is performed to transfer electrophoresed protein samples 
from polyacrylamide gels to membranes (nitrocellulose or polyvinylidene difluoride 
(PVDF)) prior to detection and analysis. Negatively charged proteins from the gel are 
transferred to membranes by applying a constant voltage through a buffer system, 
thereby facilitating electric transfer towards the anode. The transferred proteins are 
bound to the surface of the membrane, facilitating further immunodetection of specific 
proteins. The Mini Trans-Blot cell (Bio-Rad Laboratories, Inc.; USA) apparatus was 
used to assemble the transfer membrane, polyacrylamide gel and absorbent filter papers 
in Trans-blot cassettes. A ‘wet transfer’ system was used by soaking the gel, membrane 
and filter papers thoroughly in the transfer buffer. The assembly is summarized below 
in Figure 2.3. 
 
Figure 2.3: Assembly of protein transfer apparatus in trans-blot cassette. Adapted 
from Bio-Rad Laboratories Inc. USA (http://www.bio-
rad.com/webroot/web/pdf/lsr/literature/M1703930.pdf) 
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In a tray containing transfer buffer, the transfer cassette was placed with the cathode 
side (dark) downwards. The fiber pads, filter papers and the nitrocellulose membrane 
were pre-wetted in transfer buffer for 10 minutes. One fiber pad was placed on the 
cathode side and any air bubbles in the pad were removed by rolling them out. A set of 
two filter papers (Whatman) were placed above the fiber pad and air bubbles removed. 
The polyacrylamide gel containing the resolved proteins was removed from the 
apparatus, the stacking gel was cut and the resolving gel was washed thoroughly in the 
transfer buffer. The gel was placed on the filter papers – protein side upwards – 
followed by nitrocellulose membrane (Bio-Rad Laboratories Inc. USA - # 162-0112) 
The air bubbles were removed and another set of filter papers and fiber pad were placed 
on top. The air bubbles were removed and the cassette was closed and locked tightly. 
The cassette was placed in the trans-blot core with the cathode side and anode side 
rightly orientated. This was then placed in the trans-blot cell and transfer buffer was 
filled up to the top. An ice pack was placed in the remaining space in order to avoid 
overheating due to Joule’s heat produced during the electric transfer. The apparatus was 
connected to a Power-pack and transfer was carried out at 100V for 90 minutes at 
constant voltage. Transfer buffer 1 L: Tris base (3 g), Glycine (14.4 g), 20% Methanol. 
 
2.13 Western blot 
 
Following transfer of proteins to nitrocellulose membrane, the membrane was stained 
with Ponceau S – a reversible stain which allows further immunological analysis of 
protein samples – to ascertain uniform transfer of protein bands. Ponceau S binds to the 
positively charged amino groups of the proteins as well as non-covalently to non-polar 
regions. The membranes were immersed in Ponceau S staining solution (Sigma-Aldrich 
Co., UK – # P7170) for 5 minutes at room temperature. After staining, the membranes 
were quickly washed twice in 1X Tris-buffered sulphate (TBS) solution and transferred 
protein bands were observed. To destain, the membranes were immersed in TBS 
solution thrice for 5 minutes, while placing them on a rotary shaker. Ponceau S staining 
solution: 0.1% (w/v) Ponceau S in 5% (v/v) acetic acid. 
 
Following Ponceau S staining, membranes were used for specific immunological 
detection of proteins, also called ‘Western Blot’ analysis. The protein samples are 
bound to the surface of the nitrocellulose membrane and all other binding sites on the 
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membrane are blocked. The membrane is then probed for specific proteins using 
primary antibodies, followed by secondary antibodies conjugated with horseradish 
peroxidase (HRP). Chemiluminescent substrates are then added in order to visualize the 
position of the proteins by exposure to an autoradiography film. The following protocol 
was followed for western blot analysis of proteins. Membranes were blocked by 
immersing them in 5% (w/v) non-fat dry milk solution (Marvel) in TBS-Tween solution 
(TBS-T), for 2 hours at room temperature, placing them on a shaker. The blocking 
buffer was then removed and primary antibody solution (1:1000 v/v) in blocking buffer 
was added to the membranes. They were incubated overnight (12-18 hours) at 4oC with 
constant shaking to ensure uniform binding of primary antibody to the target proteins. 
The membranes were washed thrice in TBS-T solution for 5 minutes each. Secondary 
antibody directed against the primary antibody ‘Fc’ region and conjugated with HRP 
was used at a dilution of 1:2000 (v/v) in blocking buffer. Details of all antibodies used 
for western blotting are given in Appendix II. The membranes were incubated with the 
secondary antibody solution for 1 hour at room temperature with constant shaking. 
Following this, the membranes were washed thrice in TBS-T solution was 15 minutes 
each. During the last incubation, chemiluminescent substrate solution was prepared by 
mixing ECL Plus reagent A: reagent B, 40:1 (AmershamTM ECL PlusTM Detection 
Reagent kit; GE Healthcare, UK - # RPN 2132). After the last wash with TBS-T, 
chemiluminescent substrate solution was added evenly on the membrane (0.1 ml/cm2 of 
the membrane) and incubated for 5 minutes at room temperature. The excess detection 
reagent was drained off and the membrane was enclosed in Saran wrap, making sure 
there were no air bubbles on the protein side. The membrane was then exposed to 
autoradiography film (AmershamTM Hyperfilm ECLTM, GE Healthcare, UK - # 28-
9068-35) for various time periods until optimal protein bands were detected. Protein 
bands were detected by developing the film as follows: Immersion in developer solution 
for 5 minutes, water for 1 minute, fixer solution for 5 minutes (Kodak® GBX Developer 
and Fixer; Sigma-Aldrich Co., UK - # P7042, P7167). 
 
2.14 Co-immunoprecipitation (Co-IP) of proteins 
 
Co-Immunoprecipitation is a technique for analyzing protein-protein interactions. It is 
commonly used to verify protein interactions discovered through screening studies like 
yeast two-hybrid analysis. Immunoprecipitation is based on the principles of 
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precipitation of antibody-antigen complex by binding to protein A or protein G 
immobilized on agarose beads or other supports. The antibody is allowed to bind the 
target antigen in a mixture of proteins e.g. cell lysates. This antibody-antigen immune 
complex is then captured by binding of antibody Fc regions to protein A or protein G 
immobilized on a solid support. In co-IP, the antibody is used to precipitate not only the 
antigen, but also another protein that binds to the antigen. Thus the target antigen ‘co-
precipitates’ another binding protein from the lysate and is thus immobilized on the 
protein A/protein G support. Any proteins not ‘precipitated’ from the mixture are 
washed away and the components of the bound immune complex are eluted from the 
support. They are then analyzed by SDS-PAGE and western blot for precise 
identification of the bound protein. A schematic of the steps involved in co-IP is shown 
in Figure 2.4.  
 
 
Figure 2.4: Schematic of co-immunoprecipitation technique. Target protein bound to 
an antigen (protein) is precipitated from a mixture of proteins by means of an antibody 
coupled to protein A or protein G immobilised on a sold support. The bound immune 
complex is then eluted and analysed by SDS-PAGE and western blot. 
 
Co-IP was used to verify interaction between connective tissue growth factor (CTGF) 
and Fstl3. Neonatal rat ventricular fibroblasts (NRVF) cell lysate was used for co-IP. 
NRVFs were passaged twice, serum-starved for 24 hours and lysed in 1 ml cold lysis 
buffer containing 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM 
EGTA, 10 mM NaF, mM Na3VO4, 1 µg/ml leupeptin, 1 mM PMSO and 1% Triton-
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X100. The lysate was kept on ice for 15 minutes, following which it was pre-cleared 
using 50 μl protein A/G agarose beads (sc-2003 - Santacruz Biotechnology®, USA) by 
rotation at 4oC for 1 hour. Following this, the tubes were centrifuged at 2000 rpm at 4oC 
for 5 minutes and the supernatant was transferred into new microtubes kept on ice. The 
lysate was incubated with 4 μg goat polyclonal anti-CTGF immunoprecipitation 
antibody (G14, sc-34772 - Santacruz Biotechnology®, USA) or normal goat IgG 
(Santacruz Biotechnology®, USA) as control. The lysates were incubated with the 
antibodies for 3 h at 4oC with rotation, following which 50 μl protein A/G agarose beads 
were added. The tubes were incubated overnight at 4oC with rotation to 
immunoprecipitate the complexes. The following day, tubes were centrifuged at 2000 
rpm at 4oC for 5 minutes and the supernatant was carefully removed. The pellets were 
gently washed twice with cold 500 μl lysis buffer by centrifugation. The pellets were 
then resuspended in 100 μl 1X reducing loading buffer (Cell signaling technology, Inc., 
UK - # 7722) and boiled at 95oC for 5 minutes to release the bound proteins. The tubes 
were then kept on ice briefly and centrifuged at 2000 rpm at 4oC for 5 minutes. The 
supernatant was transferred into new microtubes and analysed by western blot. To 
check whether Fstl3 was co-immunoprecipitated, 1 μg/ml anti-Fstl3 antibody 
(MAB1255 – R&D systems UK) was used for detection during western blot. 
 
2.15 Cardiomyocyte cell surface area measurement 
 
To measure cell surface area, cardiomyocytes were grown in fibronectin-coated 
chamber slides (Lab-TekTM PermanoxTM 4 or 8 - well slides; Thermo Scientific Nunc, 
UK - # 177437, # 177445 respectively). The cells were cultured for 3 days, following 
which they were serum-starved for 24 hours prior to experiments. Cardiomyocytes were 
transfected with expression vector for mouse Fstl3 (pCMS-EGFP-Fstl3) or empty 
vector (pCMS-EGFP). Enhanced green fluorescent protein (EGFP) is expressed in this 
vector by use of a separate promoter (SV40) from the one used for cloning of Fstl3 
(CMV). Thus, transfected cells can be detected by visualization of EGFP. Following 
transfection, the cells were cultured for 2 days. The culture medium was aspirated and 
the cells were washed twice with 1X PBS containing 1 mM MgCl2 and 1 mM CaCl2 to 
prevent their detachment. The cells were fixed by adding 4% paraformaldehyde (PFA) 
solution containing 1 mM MgCl2 and 1 mM CaCl2 for 15 minutes at room temperature. 
Following fixation, cell were stained with troponin-I antibody for detection of 
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cardiomyocytes and DAPI as a nuclear stain. The following protocol was used for 
immunofluorescent staining. 
 
Fixed cells were washed thrice with 1X PBS solution for 2 minutes at RT. Cells were 
permeabilised by adding 0.1% (v/v) Triton X-100 in PBS for 10 minutes at RT. Cells 
were washed thrice with 1X PBS solution for 2 minutes at RT. To reduce non-specific 
binding, blocking was performed by adding 3% (w/v) BSA in PBS-T buffer for 30 
minutes at room temperature. Following this, primary antibody solution – anti-troponin 
T (Sigma - # T6277; 1:200 v/v in blocking solution) was added and incubated for 1 hour 
at RT in a humidified chamber. The antibody solution was decanted and the cells were 
washed three times with 1X PBS-T for 5 minutes. The secondary antibody solution 
(anti-sheep IgG – Alexafluor® 594; Invitrogen, UK - # 11016) was prepared by diluting 
the antibody 1:1000 (v/v) in blocking solution and incubated with the cells for 1 hour at 
RT. The cells were washed thrice with DAPI (0.1 μg/ml) containing PBS solution for 5 
minutes each. The chamber apparatus was removed from the slide and the slide was 
mounted using PermaFluorTM aqueous mounting medium (Thermo Scientific, UK - # 
TA-030-FM). The slides were observed by fluorescent microscopy using Zeiss 
Axioscope microscope fitted with a Nikon digital camera (DXM1200F). Fluorescent 
micrographs were obtained using the software NIS Elements AR 3.0 (Nikon). 
Cardiomyocytes were identified by positive staining for troponin T and cell areas were 
measured by tracing around the cells using the same software. A total of 150-190 cell 
areas were measured per sample from 10 separate fields. 
 
2.16 Measurement of cardiomyocyte protein synthesis 
 
Protein synthesis in cardiomyocytes is used as a measure of hypertrophy. Cultured 
cardiomyocytes were treated in serum-free medium with different concentration of 
recombinant Fstl3 or 100 μM phenylephrine (PE) as a positive control. Protein synthesis 
was measured by calculating radioactive 3H-Leucine incorporation using scintillation 
counting, as described in [133] with some modifications. Scintillation counts were 
normalized to cell numbers reflected by total LDH release upon cell lysis, as described 
in section 2.19 below. All radioactive procedures were performed by Dr. Renee 
Germack. Briefly, the following protocol was followed: 
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Neonatal rat cardiomyocytes were cultured in 24-well tissue culture plates in 1 ml 
complete medium and serum-starved for 24 h prior to stimulation. Cells were stimulated 
with Fstl3 and/or PE in 500 μl serum free medium for 24 h in the presence of 1 μCi 
[3H]leucine/ml. Following this, cells were washed twice with 1 ml ice cold 1 X PBS and 
incubated with 500 μl of 10% trichloroacetic acid (TCA) on ice for 1 h. Cells were 
washed twice with 1 ml ice cold 1 X PBS and 500 μl of 1N NaOH was added for 30 
minutes to dissolve precipitated proteins. The cells were then scraped and transferred to 
scintillation vials and radioactivity was calculated by liquid scintillation counting (TRI-
CARB Liquid Scintillation Analyzer 1900CA, Parkard).  
 
2.17 Mechanical stretch of neonatal cardiomyocytes and fibroblasts 
 
Mechanical stretch was applied using Flexcell® FX-4000 Tension Plus system 
(Flexcell® International Corporation, USA). The system utilizes regulated vacuum 
pressure to deform flexible bottomed culture plates, thereby applying static or cyclic 
tensile strain to cultured cells at defined frequency, amplitude and waveforms. 
Cylindrical loading posts are used to apply equibiaxial strain while arctangle loading 
posts are used for uniaxial strain. The BioFlex® culture plates utilize a flexible silicone 
elastomer membrane covalently bonded to collagen I, collagen IV, laminin, etc. if 
required. A schematic diagram of the BioFlex® plate on the loading posts is shown in 
Figure 2.5. When controlled vacuum is applied, the flexible membrane is deformed and 
stretched and the cells grown in monolayer on the membrane are equally stretched. 
 
Figure 2.5: Schematic of BioFlex® plates and application of equibiaxial strain. 
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Neonatal rat ventricular cardiomyocytes were isolated as described in section 2.3 and 
plated on Bioflex® 6-well plates coated with collagen (Flexcell® International Corp. 
USA - # BF-3001C) and fibronectin I. Cells were plated at a density of 1 x 105 /cm2 on 
the BioFlex® culture plates. Cardiomyocytes were cultured for 2 days in complete 
medium and serum-starved for 24 hours prior to experiments. Control cells were 
cultured similarly on 6-well tissue culture plates coated with collagen I and fibronectin 
I, and not subjected to stretch. The cells were treated as per experimental requirements 
in a total of 3 ml serum-free medium. The plates were loaded on 25 mm cylindrical 
loading posts and 10% equibiaxial stretch was applied at a frequency of 0.6Hz for 24 
hours. The conditioned medium was collected and stored at -80oC until required. The 
cells were washed once with cold 1X PBS and RNA samples were obtained by addition 
of 1 ml TRIzol® per well, as described in section 2.4. 
 
2.18 Measurement of collagen using Sircol collagen assay 
 
Newly synthesized soluble collagen from supernatant of fibroblast cell cultures was 
assayed using Sircol collagen assay (Biocolor Ltd., UK). It is a colorimetric assay based 
on the binding of Sirius Red dye (in picric acid) to soluble collagen. A standard curve is 
obtained by using known quantities of collagen standards and the bound dye is 
quantified using absorbance at 555 nm. The following protocol was used: 
 
Cardiac fibroblasts were cultured in 24-well tissue culture plates at 250,000 cells/well in 
1 ml complete medium. Cells were serum-starved for 24 h and the medium was changed 
to conditioned medium from stretched cardiomyocytes. Conditioned medium from 
similarly treated but un-stretched cardiomyocytes was used as control. For some 
experiments, neutralizing antibody to Fstl3 was added to the medium (AF1255 - Goat 
polyclonal IgG, 7 μg/ml; R&D systems, UK). Normal goat IgG was used at the same 
concentration as control (sc-2028 - Santacruz Biotechnology® inc., USA). Fibroblasts 
were then cultured for 72 h following which collagen released into the supernatant was 
measured using Sircol assay. Supernatant from cultured fibroblasts (1 ml), culture 
medium (blank), and collagen standards dissolved in culture medium were transferred 
into low protein binding 1.5 ml microtubes. 200 μl of isolation and concentration 
reagent from the kit was added to each tube and mixed by inversion. The microtubes 
were incubated overnight in an ice-water mix at 4oC. The tubes were removed gently 
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without shaking their contents and centrifuged at 12,000 rpm for 10 minutes at 4oC. 
This results in a pellet of hydrated and concentrated collagen which is invisible. The 
supernatant from each tube was removed slowly by pipetting without disturbing the 
pellet. To these, 1 ml of Sircol dye reagent was added and mixed by gentle agitation 
followed by brief vortexing. The tubes were centrifuged at 12,000 rpm for 10 minutes 
and the pellet of collagen bound to the dye was visible. The supernatant was carefully 
drained by inverting the tubes. Ice cold acid-salt wash reagent (750 μl/tube) was gently 
layered on the pellet in order to remove unbound dye from the inside surface of the 
microtubes. The tubes were centrifuged at 12,000 rpm for 10 minutes, the supernatant 
was decanted and the tubes were briefly dried on paper towels. To these, 250 μl of alkali 
reagent was added and the tubes were vortexed to release the collagen bound dye. 200 
μl from each tube was then transferred into individual wells of a 96-well plate and 
absorbance was measured at 555nm. Each assay was carried out in triplicates. A 
standard curve was plotted of A555nm to collagen amounts from the standards after 
subtracting the blank values. Collagen from the test samples was calculated from the 
standard curve. Figure 2.6 below shows a representative standard curve. 
 
Figure 2.6: Standard curve for collagen measurement using Sircol assay. Collagen 
standards with varying amounts were made and the A555nm was measured after 
quantification using Sircol collagen assay. The assay was performed in triplicate and 
A555nm was plotted against the amount of collagen. Linear regression analysis was 
performed and the R2 value obtained is indicated. 
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2.19 Measurement of cell death - LDH assay 
 
Cell death in cultured cardiac fibroblasts was measured using quantification of lactate 
dehydrogenase (LDH), normally present in the cytoplasm, released into the supernatant. 
The CytoTox 96® non-radioactive cytotoxicity assay kit (Promega, UK) was used 
according to the manufacturer’s guidelines. The assay is based on measurement of LDH 
using an enzymatic procedure which converts tetrazolium salt (INT) into a red coloured 
formazan product, proportional to the number of lysed cells. This is measured by 
calculating the absorbance at 490 nm (A490nm). The following protocol was followed: 
 
Cardiac fibroblasts were serum-starved for 24 h prior to stimulation with various 
concentrations of recombinant mouse Fstl3 (1255-F3-025/CF; R&D Systems, UK) or 
recombinant CTGF (5 μg/ml, 14-8503-80; eBioscience®) for 24 or 48 h in serum-free 
medium. Cells were cultured in 96-well plates at 50,000 cells/well in a total of 200 
μl/well medium and all stimulations were carried out in triplicate. To measure LDH 
released into the supernatant, 50 μl medium from each well was transferred into a 
second 96-well plate and 50 μl of reconstituted substrate mix was added to each well. 
The plate was incubated for 30 minutes at RT and protected from light. Following this, 
50 μl of stop solution was added to each well and any bubbles in the wells were popped 
using a syringe. Absorbance was measured at 490nm. Similarly, total cell numbers per 
plate were also calculated using an additional step in this procedure. For this purpose, 
cells were lysed using the lysis buffer provided in the kit by adding the 10X lysis 
solution to a final concentration of 1X and incubating the plate at 37oC for 1 hour. 
Following this, substrate solution was added to each well and the remaining protocol 
followed to measure A490nm.  Reaction blank and positive control were provided in the 
kit and used according to manufacturer’s guidelines. Thus, for each sample, LDH 
released into the supernatant was normalized to total LDH released upon cell lysis and 
compared to control untreated cells.  
 
2.20 Luciferase assay 
 
Cardiac fibroblasts were cultured in 6 well plates at 1 million cells/well and transfected 
by lipofection using LipofectamineTM 2000 (# 11668-019; Invitrogen, UK) in serum-
free medium without antibiotics. The DNA:Lipofectamine complexes were prepared 
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following the manufacturer’s guidelines at a ratio of 1:3 (μg: μl) using 3 µg of SBE-
luciferase plasmid (three tandem Smad binding elements) and 20 ng Renilla reporter 
plasmid (pRL-TK) for normalisation. These were added to the cells and incubated for 5-
6 hours. After transfection, medium was changed to complete medium with antibiotics 
and 200 ng/ml recombinant Fstl3 was added. After 72 h, cells were washed twice with 
1x PBS buffer and lysed in 100 μl 1X Passive Lysis Buffer (Promega, Madison, WI, 
USA) for 20 min on ice. The luciferase and renilla activities were measured in a 
Luminometer (TD-20/20-Turner designs) using a Dual Luciferase Kit (Promega).  
 
2.21 Cardiac-specific Fstl3 KO mice  
 
All animal procedures including breeding were carried out at the Whitaker 
Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts, 
USA in the laboratory of Professor Kenneth Walsh. Mice homozygous for a Fstl3 allele 
containing two loxP sites flanking exons 3-5 (Fstl3flox/flox) were backcrossed and 
maintained on a C57BL/6 background. These mice were crossed with α-myosin heavy 
chain (α-MHC)-Cre transgenic mice, also on a C57BL/6 background, which express Cre 
recombinase under the control of α-MHC promoter. Recombination by Cre leads to 
excision of Fstl3 exons 3, 4 and 5. Thus, progeny containing Fstl3flox/flox as well as α-
MHC-Cre lack Fstl3 expression in the post-natal cardiomyocytes, and are called 
cardiomyocyte-specific Fstl3 KO mice. Only male mice were included in the study. 
 
2.22 Trans-aortic constriction (Aortic Banding) 
 
Trans-aortic constriction (TAC) or aortic banding is performed to induce left ventricular 
pressure overload in mice. It is a good in vivo model of outflow tract obstruction (e.g. 
aortic stenosis) and systemic hypertension leading to increased cardiac afterload and 
cardiac hypertrophy. TAC was performed in 6-8 week old Fstl3 knock-out (KO) mice 
and wild type (WT) littermate controls. Prior to induction of anesthesia, all mice were 
given buprenorphine (0.25 mg/kg subcutaneously). General anesthesia was induced by 
inhalation of isofluorane (3-4% (v/v) in oxygen) and animals were restrained. The 
adequacy of anesthesia was ascertained by examination for loss of pedal and tail pinch 
reflexes. Anesthesia was maintained by 1-1.5% isofluorane inhalation throughout the 
procedure. The chest hair was removed by application of hair removal cream (Nair) and 
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the chest was disinfected with 70% ethanol followed by povidone iodine. Upper chest 
midline skin incision followed by median sternotomy was performed to open the chest 
cavity. The thymus was gently retracted until the transverse aorta was discernible. A 
loose suture (7-0 silk) was placed around the aorta and a 27 gauge blunted needle, 
between the right innominate artery and left common carotid artery (Figure 2.7). The 
suture was tightened to fully constrict the aorta and the needle was removed, thereby 
leading to partial constriction of the transverse aorta. The chest cavity, followed by the 
muscle and skin layer, was closed using 6-0 absorbable vicryl sutures. The chest was 
disinfected with povidone iodine and the animals were allowed to recover in a warm 
chamber. Analgesia (0.1 mg/kg buprenorphine) was given up to twice daily for 2-3 days 
following surgery. Some of the TAC procedures were performed by Dr. Shimano. 
‘Sham’ operation was similarly performed with the exception that the suture around the 
aorta was not constricted. 
 
Figure 2.7: Schematic of trans-aortic constriction (TAC). The transverse aorta 
between the right subclavian artery and the left carotid artery is constricted by tying a 
suture around the aorta and a 27 gauge needle. The needle is then removed to leave the 
aorta partially constricted. 
 
2.23 Echocardiography 
 
Cardiac function was measured by trans-thoracic echocardiography before and 3 weeks 
after TAC procedure. An Acuson Sequoia C-256 machine with a 15-MHz probe was 
used on conscious but restrained mice. M-mode images were obtained at the papillary 
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muscle level of the cardiac chamber. The left ventricular (LV) chamber dimensions 
during systole and diastole were marked and the percent ejection fraction (% EF) and 
fractional shortening (% FS) were calculated. Three independent measurements were 
taken per mouse and average values were used. 
 
2.24 Tissue sampling 
 
Three weeks after TAC, mice were weighed (body weight – BW) and general anesthesia 
was induced as described in section 2.22. The abdominal cavity was opened by blunt 
dissection and the inferior vena cava was identified. Up to 900 μl blood was removed 
using a 22 gauge insulin syringe. The chest cavity was opened and the lung and heart 
were removed by dissection. The lung weight (LW) and heart weight (HW) were 
measured and the LW/BW and HW/BW ratios were calculated. The heart was cut 
transversely at the papillary muscle level. The upper part, including the atria was placed 
in a 1.5 ml microtube containing 10% formalin for fixation of the tissue. The LV was 
dissected out, divided into two pieces and snap-frozen in liquid nitrogen for obtaining 
protein and RNA samples respectively. 
 
2.25 Staining of paraffin sections with Picrosirius red 
 
Picrosirius red staining was performed essentially according to the method described in 
[333] with some modifications. Sirius red is an anionic dye which binds to the basic 
groups on collagen modecules through its sulphonyl groups. In the presence of picric 
acid (pH 2.0), the dye molecules bind collagen fibers in such a way as the axis of both 
the dye and collagen are aligned parallel, thereby increasing the birefringence of the 
collagen. Observation by polarized microscopy thus makes the picrosirius red staining 
highly specific to collagen fibers (types I, II and III). Increased birefringence enables 
very thin collagen fibrils to become visible as a source of light against a dark 
background, thereby increasing the sensitivity and resolution of the technique.  
 
Picrosirius red staining was performed by Dr. Padmini Sarathchandra. Paraffin sections 
of mouse myocardium were cut at 5 μm thickness, deparaffinized and rehydrated by 
immersing them in the following solutions in the order and time specified in Table 2.11. 
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Table 2.11: Deparaffinization and rehydration of paraffin sections 
 
Following rehydration, the slides were immersed in Weigert's haematoxylin for 8 
minutes to stain the nuclei (blue). The slides were then washed for 10 minutes under 
running tap water and blot dried. Picrosirius red solution (0.1% Sirius Red F3B in 
saturated aqueous picric acid solution; Sigma-Aldrich Co. Ltd., UK - # 365548 and 
P6744 respectively) was added on the tissue sections and incubated for 1 hour at RT. 
The slides were then washed twice with 0.5% glacial acetic acid and blotted dry. The 
sections were then dehydrated in ethanol and cleared in xylene by immersing them in 
the following solutions in the order and time specified in Table 2.12. The slides were 
then mounted using DPX mounting medium (Sigma-Aldrich Co. Ltd., UK - # 44581). 
Table 2.12: Dehydration and clearing  
 
 
On the following day, the sections were viewed under a light microscope and 
fluorescent microscope. A total of 10 micrographs were captured per sample at 10X 
magnification and the fluorescence intensity and area were measured using the software 
NIS Elements AR 3.0 (Nikon). From this, the percent fibrotic area was calculated as the 
fraction of Sirius red stained area compared to the total measured area. 
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2.26 Staining of paraffin sections with wheat-germ agglutinin (WGA) 
 
Wheat-germ agglutinin (WGA) is a lectin which selectively binds to 
N‑acetylglucosamine and N‑acetylneuraminic acid (sialic acid) residues [334]. WGA 
can be used to selectively label plasma membranes of eukaryotic cells. WGA 
conjugated to fluorescein (Excitation = 494 nm; Emission = 518 nm; Sigma-Aldrich 
Co., Ltd. - # L4895) was used at a concentration of 5 μg/ml in PBS for plasma 
membrane labelling. Cardiomyocytes were identified by α-sarcomeric actin staining and 
nuclei were labelled with DNA-binding fluorescent dye DAPI. The following protocol 
was followed. 
Formalin fixed, paraffin embedded sections were cut at 5 μm thickness and allowed to 
dry for 24 hours. Deparaffinization and rehydration was performed as described in 
Table 2.11. During fixation, methylene bridges are formed which crosslink proteins and 
mask the antigenic sites. Formalin-fixed tissues therefore require an antigen retrieval 
step before immunohistochemical staining in order to break the methylene bridges and 
expose the antigenic sites. For antigen retrieval, the slides were immersed in 10 mM 
sodium citrate buffer (pH 6.0) and heated in a microwave for 5 minutes. The slides were 
then cooled down first by leaving in the citrate buffer for 10 minutes followed by 
running cold tap water in the container for 10 minutes. Following antigen retrieval, 
immunofluorescence staining was performed as detailed in Table 2.13 below.  
Table 2.13: Immunofluorescence staining 
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The slides were observed by fluorescent microscopy using Zeiss Axioscope microscope 
fitted with a Nikon digital camera (DXM1200F). Fluorescent micrographs were 
obtained using the software NIS Elements AR 3.0 (Nikon). A total of 10 fluorescent 
micrographs per sample were obtained at 40X magnification. Cell areas were measured 
by tracing around the WGA-stained plasma membranes of cells using the same 
software. A total of 225 cell areas were measured per sample from 10 separate fields. 
Figure 2.8 below shows representative fluorescent micrographs for paraffin sections 
stained with WGA (green), α-sarcomeric actin (red) and DAPI (blue) along with the 
negative control stained in a similar fashion except for lack of anti- α-sarcomeric actin 
antibody. 
 
 
Figure 2.8: Negative control for α-sarcomeric actin antibody. Sections of 
myocardium embedded in paraffin were stained with wheat-germ agglutinin, α-
sarcomeric actin antibody and DAPI. For negative control, the primary α-sarcomeric 
actin antibody was omitted and the remaining protocol was followed as described in 
section 2.26. Scale = 100 μm 
 
2.27 ELISA for Activin A 
 
Enzyme-linked immunosorbent assay (ELISA) was used for quantification of 
circulating Activin A in the serum of mice undergoing TAC. Activin A Quantikine 
ELISA kit (R&D Systems Inc., UK - # DAC00B) was used according to manufacturer’s 
instructions. The assay was performed on all samples by Dr. Shimano.  
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2.28 Yeast two-hybrid analysis 
 
A yeast two-hybrid assay was performed using the HybriZAP®-2.1 Two-Hybrid pre-
digested vector kit (Stratagene) to identify in vivo protein interaction partners for Fstl3. 
Truncated Fstl3 was used as a bait to test interaction with target proteins expressed 
artificially in the yeast from a neonatal rat cardiomyocyte cDNA library. Fstl3 was 
cloned in frame with the yeast Gal4 DNA-binding domain (BD) while the library 
proteins were expressed as hybrid proteins with the Gal4 transcriptional activation 
domain (AD). Neither hybrid protein is capable of initiating activation of the reporter 
gene by itself. When a specific interaction takes place between the bait and target 
protein, the Gal4 BD and AD co-localise and activate expression of the reporter gene 
histidine (HIS3). Colonies which are positive for the reporter are selected and analysed 
for the sequence of the encoded target protein. Details of all reagents and culture media 
used are given in Appendix III. Yeast host strain YRG-2: YRG-2 is defective in uracil, 
histidine, adenine, lysine, tryptophan and leucine.  
 
2.28.1 Cloning of Fstl3 in pBD-Gal4-Cam: Bait plasmid construction 
 
A truncated form of Fstl3 lacking the signal peptide was cloned in frame with Gal4 BD 
in the vector pBD-Gal4 Cam (Figure 2.9) and verified by sequencing. 
 
 
 
 89 
 
Figure 2.9: Schematic representation of bait plasmid encoding the Gal4-BD with 
Fstl3. The vector pBD-Gal4 Cam carries the Tryptophan synthesis gene TRP1 as a 
selection marker. It encodes Fstl3 as fusion protein with Gal4-BD 
 
2.28.2 Transformation of yeast with bait plasmid 
 
The yeast strain YRG-2 is defective in tryptophan. Transformation of YRG-2 with the 
bait plasmid results in expression of the TRP1 gene (tryptophan) and successful 
transformants are selected on Trp-deficient media. YPAD medium inoculated with a 
single colony of YRG-2 was grown overnight at 30oC in a shaking incubator. Yeast 
cells were obtained from 60 ml culture at an OD600nm of 0.5 to 0.8 by centrifugation at 
4000 rpm for 10 minutes and washed once with sterile water. The cells were 
resuspended in freshly prepared 1.5 ml TE-LiAc solution and 100 μg of denatured 
salmon sperm DNA was added with 100 ng of the bait plasmid and 600 μl of TE-LiAc-
PEG solution to a 100 μl aliquot of the cell suspension. The mixture was incubated at 
30°C for 30 minutes at 200 rpm and 70 μl dimethyl sulphoxide (DMSO, Sigma) was 
added. The cells were given a heat shock by incubation at 42oC for 15 minutes, 
harvested by centrifugation and resuspended in 0.5 ml TE buffer. A total of 150 μl of 
the sample was plated on selection medium lacking tryptophan (SD-Trp) and incubated 
at 30oC for 3-4 days. Four colonies were randomly selected and maintained on SD-Trp 
medium.  
 
Fstl3 
 90 
2.28.3 Checking leakiness of reporter gene HIS3 
 
The use of certain proteins as baits, such as transcriptional activators, may result in 
activation of the reporter gene in the absence of the target plasmid construct. To check 
for auto-activation of the reporter gene HIS3 before transformation with the target 
library, four YRG-2-Fstl3 colonies were inoculated in 1 ml of sterile water and 100 μl 
of each sample was plated on SD-Trp and SD-Trp-His agar plates at dilutions of 1:0 
(undiluted), 1:10 and 1:100. The plates were incubated at 30oC for 3-4 days and the 
colonies were counted. The YRG-2-Fstl3 samples that gave no colonies on SD-Trp-His 
medium were selected for further transformation as these colonies do not auto-activate 
the reporter gene. 
 
2.28.4 Transformation of yeast with target DNA library 
 
Tranformation of YRG-2-Fstl3 with target DNA library results in expression of the 
Leucine synthesis gene LEU2. Successful transformants in which specific interaction 
takes place between the bait Fstl3 and target protein activate the reporter gene HIS3. 
These are selected on SD-His-Trp-Leu medium deficient in Histidine, Tryptophan and 
Leucine. 
 
 
Figure 2.10: Schematic representation of the target plasmid construct. The target 
plasmid construct encodes the hybrid proteins from neonatal rat cardiomyocyte cDNA 
library linked to the Gal4-AD. The selection marker is the Leucine synthesis gene LEU2 
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YPAD medium inoculated with a single colony of YRG-2-Fstl3 was grown overnight at 
30oC in a shaking incubator at 250 rpm. Yeast cells were obtained from 500 ml of 
culture at an OD600nm of 0.8 by centrifugation at 4000 rpm for 10 minutes and washed 
once with sterile water. The cells were resuspended in 5 ml of freshly prepared LiSORB 
solution and incubated at 30oC for 10 minutes. Cells were centrifuged again and the 
pellet was resuspended in LiSORB to a final volume of 1 ml. A total of 1.2 ml of 
denatured salmon sperm LiSORB solution (3.3 mg/ml) was added, followed by 9 ml of 
TE-LiAc-PEG solution. A total of 20 µg of target library was added and the mixture 
was incubated at 30°C for 30 minutes. Samples were given a heat-shock at 42oC for 8 
minutes, followed by incubation on ice for 8 minutes and heat-shock at 42oC for 8 
minutes. Cells were incubated in 10 ml SD-Trp-Leu medium at 30°C for 1 hour in a 
shaking incubator, centrifuged and the pellet was gently resuspended in 5 ml of SD-Trp-
Leu medium. 250 μl aliquots were plated on 20 SD-His-Leu-Trp selection agar plates 
and incubated at 30°C for 4-5 days. The transformation rate was measured by plating 10 
μl of transformation sample at dilutions of 1:0, 1:10, 1:100, 1:1000, 1:10,000, and 
1:100,000 on SD-Leu agar plates and the number of colonies were counted. Colonies 
that grew on SD-His-Leu-Trp selection plates were picked and streaked on SD-His-Leu-
Trp plates to confirm positivity.  
 
2.28.5 Screening of positive colonies 
 
To obtain enough DNA from yeast colonies for sequencing and verification of 
interaction, the following steps were performed. Colonies from SD-His-Leu-Trp were 
grown overnight in YPAD medium and plasmid DNA was extracted using a standard 
miniprep protocol (QIAprep spin miniprep kit, Qiagen, UK – see section 2.2.2). This 
was then transformed into One Shot® TOP10 chemically competent E. Coli cells 
(Invitrogen) following manufacturers instructions by incubating the bacteria for 30 
seconds at 42oC (Section 2.1.5). Transformed colonies were grown in LB medium and 
plasmid DNA was extracted using the QIAprep kit and sequenced using a Gal4-AD 
primer. The sequences obtained were analyzed using the nucleotide BLAST tool (Basic 
Local Alignment Search Tool, NCBI, USA). Positive interactions were validated by co-
immunoprecipitation. Figure 2.11 summarises the important steps in a yeast two-hybrid 
analysis. 
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Figure 2.11: Flow diagram of yeast two-hybrid analysis of protein-protein 
interactions. 
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CHAPTER 3: FSTL3 in human heart failure 
 
3.1 Introduction 
 
The progression from underlying cardiac pathologies to heart failure is often 
characterised by cardiomyocyte hypertrophy, extracellular matrix remodelling and 
chamber dilatation resulting in compromised cardiac function. However, recent 
advances in the field have shown that in end-stage heart failure patients, mechanical 
unloading of the heart using left ventricular assist devices (LVAD) can reverse the 
progression to heart failure in some cases. This led to the notion that LVAD can also be 
used as a ‘bridge-to-recovery’ in addition to being used as a ‘bridge-to-transplantation’. 
Research at our institute has shown that a combination therapy using LVAD and a 
specific pharmacological regimen is highly effective in patients with non-ischemic 
cardiomyopathies and about two thirds of them showed sufficient recovery that allowed 
explantation of the LVAD, avoiding the need for heart transplantation [335]. 
Mechanical unloading of the heart combined with pharmacological therapy is aimed at 
maximising reverse remodelling of the heart, which leads to improved contractile 
function [336, 337]. Following this, induction of physiological hypertrophy by 
administration of the β2 adrenergic receptor agonist Clenbuterol has shown beneficial 
effects towards recovery [338]. In a rat model of unloaded failing hearts, treatment with 
Clenbuterol was found to enhance physiological hypertrophy, cardiomyocyte 
contractility and normalised Ca2+ handling [339]. However, the molecular mechanisms 
underlying reverse remodelling and recovery are not fully understood.  
 
TGF-β family members have been widely implicated in the pathogenesis of heart 
failure.  Activins are homodimeric cytokines of the TGF-β superfamily and are known 
to modulate diverse pathophysiological processes including inflammation and wound 
healing, cell proliferation, differentiation, metabolism, fibrosis and cardiac remodelling 
(reviewed in [292, 295, 340]). Activin signalling is inhibited by the follistatin family of 
proteins. Both Follistatin (FST) and Follistatin-like 3 (FSTL3) can bind activin with a 
high affinity and neutralise its action by preventing its binding to the activin receptors 
[297]. On the other hand, both activin and TGF-β are known to transciptionally regulate 
the expression of FST and FSTL3 through Smad proteins [305, 306]. Whereas a role for 
activin in heart disease has been proposed, the presence and possible function of 
 94 
follistatins in the heart remains obscure. In this context, we hypothesized that the 
Activin-Follistatin interplay may play a role in the pathogenesis of heart failure. This 
chapter presents evidence for the importance of follistatins in heart failure based on 
their altered expression in both human and experimental models. 
 
3.2 Patient characteristics and myocardial samples 
 
The study conforms to the principles outlined in the Declaration of Helsinki. 
Myocardial biopsies were obtained from patients after informed consent and with the 
approval of the Royal Brompton and Harefield Research Ethics Committee. Patients 
with end-stage heart failure with dilated cardiomyopathies and without any histological 
evidence of myocarditis were included. Left ventricular biopsies were obtained at the 
time of LVAD implant (n = 27: 25 male, 2 female), and after recovery at the time of 
LVAD explant (n = 13) and at a period of 1 year follow-up (n = 9). Control samples 
were obtained from biopsies from healthy donor hearts presenting good hemodynamic 
function (n = 9) [328]. Mean age of recovery patients was 37.3 years with mean 
duration of disease being 47.3 months. Prior to LVAD implant, patients were treated 
with inotropes in addition to standard heart failure drugs.  Following LVAD 
implantation, patients were treated with a pharmacological regimen which included β-
blockers, ACE inhibitors, angiotensin II receptor antagonists and spironolactone 
followed by clenbuterol to induce physiological hypertrophy [335, 341].  
 
3.3 Expression of FSTL3 is elevated in heart failure 
 
Follistatin family proteins FST and FSTL3 have high sequence homology and both are 
involved in binding activin with a high affinity, inhibiting its function [297, 299]. The 
mRNA expression of FST and FSTL3 in myocardial samples from healthy controls and 
patients with heart failure was examined using qRT-PCR [328]. As shown in Figure 3.1, 
the expression of both FST (A) and Activin βA subunit INHBA (B) mRNAs remained 
unchanged in end-stage heart failure patients and control samples. Similarly, the 
expression of Inhibin α subunit INHA also remained unchanged (C). However, FSTL3 
mRNA expression was elevated in heart failure patients (D). The expression of FSTL3 
was also examined in a cohort of patients undergoing combination therapy. As shown in 
Figure 3.2, FSTL3 mRNA expression was elevated at the time of LVAD implant. 
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However, following recovery and LVAD explant, FSTL3 expression was reduced and 
comparable to control levels after a period of 1 year following explant.  
 
 
Figure 3.1: Expression of TGF-β family ligands and their inhibitors in heart 
failure. mRNA expression of FST (A), INHBA (B), INHA (C) and FSTL3 (D) in left 
ventricular samples from patients with heart failure (HF; n = 27) and healthy controls 
(Donor; n = 8-9) was analysed using quantitative real-time RT-PCR. Results are 
expressed in relative units normalised to endogenous 18S rRNA expression. Unpaired t-
tests were used to calculate the p values, which are indicated in the figure. 
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Figure 3.2: Expression of FSTL3 in heart failure and recovery. Expression of 
FSTL3 mRNA was examined using quantitative real-time RT-PCR in heart failure 
patients undergoing LVAD implant and combination therapy (Implant; n = 13), after 
recovery during LVAD explant (Explant; n = 13) and after a period of 1 year follow-up 
(Explant + 1 yr; n = 9). Results are expressed in relative units normalised to endogenous 
18S rRNA expression. Paired t-tests were used to calculate the p value of FSTL3 
expression at different time points while unpaired t-test was used for comparison with 
donor samples. 
 
In order to examine the tissue distribution of FSTL3, immunohistochemical analysis 
was performed on myocardial sections from heart failure patients and controls with a 
specific antibody against FSTL3 [328]. As shown in Figure 3.3, sections from control 
samples showed low expression of FSTL3. However in patients with deteriorating heart 
failure, higher expression of FSTL3 was detected in cardiac myocytes and vascular 
endothelial cells while no staining was observed in either the fibroblasts surrounding the 
minor vessels or interstitial cells. FSTL3 was also found to be expressed in the nuclei of 
some cardiac myocytes (arrowheads). 
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Figure 3.3: Tissue distribution of FSTL3 in heart failure patients.  Sections of 
myocardium from control (Donor) and heart failure patients were stained using a 
specific antibody against FSTL3. Negative control represents staining in the absence of 
primary antibody. FSTL3 was found to be localised in cardiac myocytes (C) and 
endothelial cells (E), while fibroblasts (F) showed no expression of FSTL3. Some 
cardiac myocytes also showed nuclear expression of FSTL3 (arrowheads). Bar = 
100μm.    
 
3.4 Microarray analysis of FSTL3 in heart failure 
 
As shown above, FSTL3 expression in patients with heart failure was found to be 
elevated and localised in cardiomyocytes and endothelial cells. In order to gain some 
initial understanding of the function of FSTL3 in the pathogenesis of heart failure, 
microarray analysis was performed on paired samples from patients taken at the time of 
LVAD implant and explant. Following this, lists of genes were compiled whose 
expression correlated with that of FSTL3 in the different samples and compared to 
existing gene ontology (GO) lists as detailed in [328]. As shown in Figure 3.4, FSTL3 
showed good correlation with genes involved in transcriptional regulation, signal 
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transduction and protein phosphorylation, being associated mostly with the nuclear 
compartment.  
 
 
Figure 3.4: Gene ontology analysis of FSTL3-correlating genes in heart failure. 
Cardiac samples from heart failure patients were collected at the time of LVAD implant 
and explant and total RNA was analyzed using oligonucleotide microarrays. A list of 
genes correlating with FSTL3 in the different samples was compared with pre-existing 
gene ontology lists for cellular compartment and biological process. Lists with >3 genes 
common to the FSTL3 list and p<0.005 were considered. The percentage of common 
genes in a list compared to the total number of common genes in all the lists is shown (n 
= 16). 
 
3.5 Expression of Fstl3 in mouse models of cardiac injury 
 
Based on the observation of increased FSTL3 mRNA expression in human heart failure, 
Fstl3 expression was examined in small animal models of cardiac injury. These 
included left anterior coronary artery ligation as a model of myocardial infarction (MI), 
ischemia-reperfusion (IR) injury and trans-aortic constriction (TAC) as a model of 
pressure-overload induced cardiac hypertrophy in mice. The mRNA expression of Fstl3 
in the myocardium was elevated in all models of cardiac injury compared to ‘sham’ 
operated mice [294], as shown in Figure 3.5. In the myocardium of infarcted mice (A), 
Fstl3 mRNA was elevated in both the remote and infarct region three days after infarct. 
Similarly, in ischemia-reperfusion injury (B), Fstl3 mRNA expression was elevated 
after both 12 h and 24 h of reperfusion. In pressure-overload induced cardiac 
hypertrophy, a prominent model of aortic stenosis, Fstl3 mRNA expression was also 
elevated three weeks after banding (C). 
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Figure 3.5: Fstl3 mRNA expression is elevated in different models of cardiac 
injury. Expression of Fstl3 mRNA was examined by quantitative real-time RT-PCR in 
cardiac samples from mice subjected to myocardial infarction (remote and infarct zone) 
at three days post-infarct (A), ischemia-reperfusion at 12 h and 24 h reperfusion (B) and 
trans-aortic banding at three weeks after banding (C), as well as ‘sham’ operated mice at 
respective time-points. Data are presented as relative expression of Fstl3 as mean ± 
SEM and normalised to endogenous GAPDH (A, B) or 18S rRNA (C) expression. 
Unpaired t-tests were used to check statistical significance. * p < 0.05, # p < 0.01 
compared to sham. n = 3-6. 
 
Moreover, the mRNA expression of Activin βA subunit was also tested in the same 
models and found to be elevated following injury. As shown in Figure 3.6, the 
expression of Activin βA mRNA was elevated in both the remote and infarct zone at 
three days following myocardial infarction (A). Similarly, Activin βA mRNA was also 
elevated after 12 h and normalised after 24 h following ischemia-reperfusion injury (B). 
In the cardiac hypertrophy model, Activin βA mRNA expression was elevated three 
weeks after aortic banding (C). 
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Figure 3.6: Elevated Activin βA mRNA expression in different models of cardiac 
injury. Expression of Activin βA mRNA was examined by quantitative real-time RT-
PCR in cardiac samples from mice subjected to myocardial infarction (remote and 
infarct zone) at three days post-infarct (A), ischemia-reperfusion at 12 h and 24 h 
reperfusion (B) and trans-aortic banding at three weeks after banding (C), as well as 
‘sham’ operated mice at respective time-points. Data are presented as relative 
expression of Activin βA, expressed as mean ± SEM and normalised to endogenous 
GAPDH (A, B) or 18S rRNA (C) expression. Unpaired t-tests were used to check 
statistical significance. * p < 0.05, ** p < 0.005 compared to sham. n = 3-6. 
 
3.6 Regulation of Fstl3 expression by hypertrophic stimuli in the heart 
 
Expression profile of FSTL3 from both heart failure patients as well as animal models 
of cardiac injury suggested that its expression may be regulated by hypertrophic stimuli 
in the heart. In order to test this hypothesis, expression of Fstl3 mRNA was examined in 
neonatal rat cardiomyocytes in response to various pro-hypertrophic stimuli. As shown 
in Figure 3.7, the expression of Fstl3 mRNA was elevated in response to TGF-β1, a 
hypertrophic [14, 15] and pro-fibrotic cytokine (A). Stimulation with phenylephrine 
(PE), isoproterenol, angiotensin II (AngII), cardiotrophin-I (CT-1) and endothelin-I 
(ET-1) did not have any effect on the expression of Fstl3 mRNA in cardiomyocytes. 
However, stimulation of cardiomyocytes with TGF-β1 led to a time-dependent increase 
in Fstl3 mRNA expression (B). 
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Figure 3.7: Expression of Fstl3 mRNA is elevated by TGF-β1 in cardiomyocytes. 
Neonatal rat ventricular cardiomyocytes were cultured on fibronectin coated plates, 
serum-starved for 24h and treated with 100μM phenylephrine, 10μM angiotensin II, 
1μM endothelin-I, 10μM isoproterenol, 1nM cardiotrophin-I or 10ng/ml TGF-β1 for 
different time periods as indicated. Expression of Fstl3 mRNA was examined by 
quantitative real-time RT-PCR and normalised to endogenous 18S rRNA. (A) 
Expression of Fstl3 mRNA at 24h post stimulation. n = 2. (B) Time course of Fstl3 
mRNA expression in cardiomyocytes stimulated with TGF-β1. One-way ANOVA was 
used to calculate the p value compared to control untreated samples. *** p < 0.001, n = 
3-4. 
 
3.7 Discussion 
 
The activin - follistatin system is a complex regulatory network controlling the growth 
and development of many tissues. Follistatins are negative regulators of activin 
signalling and have been shown to be involved in tissue regeneration after injury in both 
the kidney and liver [16, 17], making them potential therapeutic targets. Follistatin was 
also shown to increase skeletal muscle mass and strength in dystrophic mice [342]. 
Follistatin-like 3 is a potent inhibitor of activin signalling with highest expression found 
in the placenta, testes, heart and pancreas [302]. Aberrant expression of FSTL3 has been 
reported in ovarian endometriosis [20], intrauterine growth restriction [324] and pre-
 102 
eclampsia [323]. In the failing heart, the expression of FSTL3 was highly elevated while 
that of FST remained unchanged. The expression of FSTL3 in heart failure samples was 
also found to correlate positively with α-skeletal actin and BNP, both markers of disease 
severity [328]. In heart failure recovery patients, the expression of FSTL3 after recovery 
was comparable to control samples, suggesting that FSTL3 may be used as a marker of 
heart failure. Immunostaining identified FSTL3 to be mainly expressed in the 
cardiomyocytes and endothelium in failing hearts and also in the nuclei of 
cardiomyocytes, consistent with previous reports of nuclear localisation of Fstl3 [302]. 
This is also consistent with the microarray analysis of FSTL3 expression where 
correlation was found to be highest with genes in the nuclear compartment and FSTL3 
was associated with genes involved in transcription regulation and cell signalling.  
 
Interestingly, the expression of Fstl3 was found to be elevated in response to TGF-β1 in 
cardiac myocytes. This is consistent with previous findings where TGF-β1 was found to 
increase the expression of Fstl3 in bone marrow stromal cells [343] and HepG2 cells via 
Smad proteins [305]. However, FSTL3 is known to bind activin and myostatin [300], 
both TGF-β superfamily ligands and may be involved in restricting the freely available 
amounts of these proteins. Indeed, a whole body Fstl3 knock-out mouse model was 
found to have altered visceral fat deposition attributed to increased myostatin action. 
These mice also had enhanced insulin sensitivity and glucose tolerance resulting from 
increased activin bioactivity in the pancreas [317]. Myostatin is known to regulate 
cardiac growth response and myostatin null mice show increased cardiomyocyte growth 
in response to hypertrophic stimuli [344]. Similarly, cardiac-specific over-expression of 
myostatin was found to have a negative impact on heart and skeletal muscle weights 
[345]. In the failing heart, increased expression of FSTL3 may negatively regulate 
myostatin and activin signalling. As shown above, in patients with heart failure, the 
expression of activin was found to be unchanged compared to normal control patients. 
This is in contrast to the elevated level of serum activin reported in a cohort of patients 
with heart failure caused by coronary artery disease or dilated cardiomyopathy [7]. 
However, the myocardial expression of activin was not examined in the study. The 
differences observed may also be due to the underlying nature of the disease i.e. dilated 
cardiomyopathy against coronary artery disease in which expression may be modulated 
by ischemia. As shown above, in different animal models of cardiac stress, the 
expression of both activin A and Fstl3 was elevated immediately after injury. However, 
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it is possible that activin mRNA levels are reduced as the cardiac injury progresses to 
heart failure, as seen in end-stage heart failure patients. Recently it was reported that in 
the myocardial ischemia model, Fstl3 functions to counteract the activin A-mediated 
cardioprotection against ischemic injury [294]. Similarly, in patients with angina, 
activin A was shown to have an anti-inflammatory effect, and dysregulated expression 
of activin and its receptors was suggested to be involved in the pathogenesis of coronary 
syndromes [346]. In this context, regulation of activin and related TGF-β family ligands 
by FSTL3 may have an impact on disease outcome and this signalling axis represents a 
new therapeutic target for cardiac diseases.  
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CHAPTER 4: Cardiac hypertrophy in Fstl3 KO mice 
 
4.1 Introduction 
 
Systemic hypertension and outflow tract obstruction often result in pressure-overload in 
the heart, leading to increased aortic pressure and afterload. This greatly increases the 
ventricular wall stress, gradually leading to compensatory cardiac hypertrophy, which 
develops in order to preserve cardiac function under pressure-overload [6]. However, 
sustained pressure overload in the myocardium progressively leads to ventricular 
dilation [7] as cardiac hypertrophy by itself cannot reduce the afterload mismatch and 
cardiac contractility and output is adversely affected [347]. This is accompanied by 
various molecular, cellular and neurohormonal changes, together known as cardiac 
remodelling. Evidence presented in Chapter 3 illustrates the expression pattern of Fstl3 
in response to cardiac stress. Considering the increased expression of FSTL3 in end-
stage heart failure patients as well as in mouse models of cardiac hypertrophy and 
ischemic injury, we hypothesised that knock-out (KO) of Fstl3 in the heart may be 
protective against cardiac hypertrophy. To test this hypothesis, trans-aortic constriction 
(TAC) or aortic banding was chosen as a model of pressure overload leading to cardiac 
hypertrophy. 
 
In order to examine the in vivo role of Fstl3, cardiomyocyte-specific Fstl3 KO mice 
were created by crossing floxed (LoxP - exon 3, 4, 5 – LoxP) Fstl3 mice with α-MHC 
Cre mice (section 2.21). They were subjected to TAC or ‘sham’ surgery and analysed 
three weeks later. Both physiological and functional characteristics of the myocardium 
were analysed. Molecular markers of cardiac hypertrophy and heart failure were also 
measured. Data presented in this chapter will answer the question whether Fstl3 is 
necessary for the development of cardiac hypertrophy.  
 
4.2 Baseline characteristics of cardiac-specific Fstl3 KO mice 
 
In order to determine whether knock-out of Fstl3 specifically in cardiomyocytes has an 
effect on cardiac structure or function, gravimetric analysis and echocardiography was 
performed on 6-8 week old male Fstl3 KO mice and WT littermate controls. As shown 
in Figure 4.1, the body weight (A) or heart weight/body weight ratio (B) did not differ 
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between the KO and WT mice. Echocardiography revealed no differences in the % 
Fractional Shortening (C) or % Ejection Fraction (D) in the KO and WT mice. Thus, 
knock-out of Fstl3 from cardiomyocytes did not affect the structure or function of the 
uninjured myocardium. 
 
Figure 4.1: Similar baseline cardiac size and function of wild type and cardiac-
specific Fstl3 KO mice. (A) Body weight (BW) and (B) heart weight/body weight ratio 
(HW/BW) of 6-8 week old Fstl3 KO mice and WT littermate controls was measured. 
Echocardiography was performed using an Acuson Sequoia C-256 machine with a 15-
MHz probe on conscious mice and % Fractional Shortening (C) and % Ejection 
Fraction (D) were calculated from M-mode echocardiograms. Data are presented as 
mean ± SEM. n = 4-8. 
 
4.3 Analysis of Fstl3 expression post-injury in cardiomyocyte-specific Fstl3 KO 
mice 
 
In patients with heart failure, FSTL3 expression was mainly localised in the 
cardiomyocytes and endothelium (Figure 3.3). As shown in section 3.5, the expression 
of Fstl3 was found to be highly elevated after cardiac injury and it was unclear if the 
expression was increased in any particular cell type in the myocardium. As such, knock-
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out of Fstl3 from cardiomyocytes may be functionally compensated for after injury by 
increased expression in any other cells such as endothelial cells or fibroblasts, making 
the cardiomyocyte-specific KO model ineffective. We tested this possibility by 
examining the expression of Fstl3 mRNA in both KO and wild-type (WT) littermate 
control mice after ‘sham’ operation or TAC. As shown in Figure 4.2, the expression of 
Fstl3 was elevated in WT mice after TAC compared to sham. However, in the 
cardiomyocyte-specific KO mice, Fstl3 expression remained unchanged after TAC. The 
difference in the KO group between ‘sham’ and TAC was not statistically significant. 
Thus, cardiomyocytes are the main source of increased Fstl3 in the myocardium post 
injury.  
 
Figure 4.2: Normalised expression of Fstl3 in KO mice after injury. Cardiomyocyte-
specific Fstl3 KO mice and WT littermate controls were subjected to trans-aortic 
constriction or ‘sham’ surgery to simulate pressure-overload induced cardiac 
hypertrophy. Three weeks later, myocardial expression of Fstl3 was measured by 
quantitative real-time PCR. Two-way ANOVA followed by Bonferonni post-test was 
used to calculate statistical significance. Data are presented as mean ± SEM. *** p < 
0.001 compared to WT SHAM. # # # p < 0.001 compared to WT TAC. n = 3-6. 
 
In order to determine if loss of Fstl3, an extracellular inhibitor of Activin A, had any 
effect on the expression of Activin in the heart, quantitative real-time RT-PCR was 
carried out on myocardial samples from WT and Fstl3 KO mice. As shown in Figure 
4.3 (A), the mRNA expression of Activin βA increased in response to TAC. However, 
 107 
no differences were observed between WT and Fstl3 KO mice. Similarly, the serum 
levels of Activin A were also elevated following TAC and no differences were observed 
between the WT and Fstl3 KO mice, either under ‘sham’ or TAC conditions (panel B). 
 
Figure 4.3: Myocardial expression of Activin A in WT and Fstl3 KO mice is 
unchanged. (A) Three weeks after TAC or ‘sham’, the expression of Activin A (Inhibin 
βA chains) was analysed by qRT-PCR. Data are presented as relative expression (mean 
± SEM) of Activin A normalised to endogenous 18S rRNA. (B) Serum levels of Activin 
A were measured in WT and Fstl3 KO mice 3 weeks after ‘sham’ or TAC using ELISA. 
Two-way ANOVA followed by Bonferroni post-test was used to calculate statistical 
significance. Data are presented as mean ± SEM. * p < 0.05, *** p < 0.001 compared to 
WT SHAM. n = 3-6. 
 
4.4 Analysis of cardiac hypertrophy in Fstl3 KO mice after TAC 
 
In order to examine the effect of Fstl3 deficiency on the development of cardiac 
hypertrophy, KO and WT mice were subjected to trans-aortic constriction – a common 
model of pressure-overload induced cardiac hypertrophy (Section 2.22). Three weeks 
after ‘sham’ or ‘TAC’, mice were sacrificed and their hearts were analysed. As shown 
in Figure 4.4 (A), heart weight/body weight (HW/BW) ratio was increased on average 
from 5.1 to 9.3 after TAC in WT mice thereby confirming cardiac hypertrophy. 
Although KO mice developed some degree of hypertrophy, their average HW/BW ratio 
(6.8) was significantly lower than that of WT mice after TAC, suggesting that Fstl3 is 
necessary for the full development of cardiac hypertrophy. To confirm these findings, 
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we determined the lung weight/body weight ratio (LW/BW) as a measure of pulmonary 
oedema – a marker of heart failure. As shown in Figure 4.4 (B), KO mice showed 
reduced LW/BW ratio compared to WT mice after TAC, although the values did not 
reach statistical significance.  
 
Figure 4.4: Reduced HW/BW and LW/BW ratio in Fstl3 KO mice after TAC. Fstl3 
KO mice and WT littermate controls were subjected to TAC or ‘sham’ and HW/BW 
and LW/BW ratios were measured after 3 weeks. Two-way ANOVA followed by 
Bonferroni post-test was used to calculate the p values. Data are presented as mean ± 
SEM. *** p < 0.001 compared to WT SHAM; # # p < 0.01 compared to WT TAC. n = 
3. 
 
To confirm these results at a histological level, sections of myocardium from three WT 
and Fstl3 KO mice per group, subjected to TAC or ‘sham’ were stained with α-
sarcomeric actin and wheat-germ agglutinin (WGA) to determine the cell surface area. 
As shown in Figure 4.5 (B), average cardiomyocyte area increased in response to TAC 
in WT mice from 300µm2 to 495µm2. This increase was significantly smaller in Fstl3 
KO mice, which only reached an average of 422µm2 after TAC. Taken together, these 
results confirm that the loss of Fstl3 results in attenuated cardiac hypertrophy after 
TAC. 
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Figure 4.5: Reduced cardiomyocyte cross-sectional area in Fstl3 KO mice after 
TAC. (A) Representative fluorescent micrographs of myocardial sections from WT and 
Fstl3 KO mice are shown. Sections of myocardium were stained for α-sarcomeric actin 
(red), DAPI (blue) and wheat-germ agglutinin (green). Bar = 100µm. (B) A total of 225 
cross-sectional areas (CSA) per sample were measured from fluorescent micrographs 
using NISelements software. Quantification of CSA is shown with mean ± SEM. Two-
way ANOVA followed by Bonferroni post-test was used to calculate statistical 
significance. Data are presented as mean ± SEM. *** p < 0.001 vs. WT SHAM; # # # p 
< 0.001 vs. WT TAC. n = 3. 
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4.5 Expression of markers of cardiac hypertrophy after TAC 
 
Re-expression of the fetal gene programme is a hallmark of cardiac hypertrophy [25, 
348]. To determine whether Fstl3 was necessary for the onset of this programme, the 
mRNA expression of fetal-specific genes β-myosin heavy chain (β-MHC or Myh7), α-
skeletal actin (Acta1), ANP and BNP was examined in WT and Fstl3 KO mice 3 weeks 
after aortic banding. As shown in Figure 4.6, aortic banding resulted in increased 
myocardial mRNA expression of ANP, BNP, Acta1 and β-MHC in WT mice. However, 
the expression of these markers was strongly attenuated in Fstl3 KO mice after banding, 
to levels comparable to sham operated mice, thereby indicating the necessity of Fstl3 
for induction of the fetal gene programme. The expression of BNP and β-MHC 
remained significantly elevated in the KO mice following TAC as compared to ‘sham’. 
 
Figure 4.6: Reduced expression of hypertrophic markers in Fstl3 KO mice after 
banding. Fstl3 KO mice and WT littermate controls were subjected to trans-aortic 
constriction or ‘sham’ surgery. Three weeks later, mice were sacrificed and myocardial 
expression of ANP, BNP, Acta1 and Myh7 was analyzed by qRT-PCR and normalised 
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to endogenous 18S rRNA. Two-way ANOVA followed by Bonferonni post-test was 
used to calculate statistical significance. Data are presented as mean ± SEM. * p < 0.05 
vs. KO SHAM, *** p < 0.001 vs. WT SHAM, # p < 0.05, # # # p < 0.001 vs. WT TAC. 
n = 3-6. 
 
4.6 Cardiac functional studies on Fstl3 KO mice after TAC 
 
To assess cardiac function after pressure-overload induced hypertrophy, WT and Fstl3 
KO mice were subjected to echocardiography (section 2.23). M-mode images were 
taken and percent fractional shortening and ejection fraction were calculated. As shown 
in Figure 4.7 (A), aortic banding resulted in a reduction of fractional shortening from 
55% to 32%, indicating decreased cardiac contractility. Similarly, ejection fraction was 
also lowered from 90% to 67% in WT mice (panel B). In contrast, no significant 
reduction of fractional shortening or ejection fraction was observed in Fstl3 KO mice 
after TAC compared to ‘sham’- operated mice. Compared to WT, KO mice showed 
significantly improved cardiac function following TAC. 
 
Figure 4.7: Improved cardiac function in Fstl3 KO mice after TAC. Fstl3 KO mice 
and WT littermate controls were subjected to trans-aortic constriction or ‘sham’ surgery 
and echocardiography was performed three weeks later. Percent fractional shortening 
and ejection fraction were calculated using measurements taken in M-mode. Two-way 
ANOVA was used to calculate the p values followed by Bonferonni post-tests to 
compare groups. Data are presented as mean ± SEM. ** p < 0.01, *** p < 0.001 vs. WT 
SHAM. # p < 0.05,  # # p < 0.01 vs. WT TAC. n = 3. 
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4.7 Metabolic characteristics of Fstl3 KO mice 
 
Reactivation of the fetal gene programme in cardiac hypertrophy and heart failure is 
accompanied by a switch to fetal myocardial energy substrate preference - increased 
glucose utilisation and reduced fatty acid oxidation (FAO) [178-180]. Reduced 
hypertrophy and improved cardiac contractility in Fstl3 KO mice following pressure-
overload could be, at least in part, explained by improved metabolic responses. In order 
to test this hypothesis, mRNA expression of genes involved in regulating fatty acid 
uptake and oxidation was examined. These included nuclear receptor PPARα, its target 
genes MCAD and mCPT1 (CPT1β), as well as PPARα coactivator PGC-1α. As shown 
in Figure 4.8, the mRNA expression of PPARα did not differ between WT and KO mice 
under ‘sham’ operated conditions (A). As the myocardium switches to increased 
glycolysis after pressure overload, the expression of PPARα is downregulated 
significantly in WT mice. However, in the Fstl3 KO mice, PPARα expression after 
TAC was found to be comparable to ‘sham’ levels, indicating sustained fatty acid 
oxidation. Similarly, the expression of PPARα target genes CPT1β and MCAD and the 
PPARa co-activator PGC-1α in the myocardium were reduced in WT mice after TAC 
while remaining unchanged in KO mice (B-D). Overall, these results suggest that in 
Fstl3 KO mice, fatty acid oxidation remains the dominant source of energy after TAC 
and the myocardium does not revert to the fetal metabolic gene program. 
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Figure 4.8: Normalised expression of fatty acid oxidation markers in Fstl3 KO 
mice after TAC. Fstl3 KO mice and WT littermate controls were subjected to trans-
aortic constriction or ‘sham’ surgery. Expression of PPARα, CPT1β, MCAD and PGC-
1α was analyzed by quantitative real-time RT-PCR and normalised to endogenous 18S 
rRNA. Two-way ANOVA followed by Bonferonni post-test was used to calculate 
statistical significance. Data are presented as mean ± SEM.   * p < 0.05; ** p < 0.01 vs. 
WT SHAM; # p < 0.05 compared to WT TAC. n = 3-6. 
 
4.8 Discussion 
 
This chapter examined the effect of Fstl3 ablation from cardiomyocytes on the cardiac 
structure and function following pressure-overload. The results presented here 
demonstrate the necessity of Fstl3 for the full extent of hypertrophic responses of the 
injured heart leading to heart failure.  
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We and others have previously reported that the expression of Fstl3 is elevated in 
response to myocardial ischemia, pressure-overload induced hypertrophy, and heavy 
resistance training as well as in patients with heart failure [294, 328, 329]. However, the 
cellular source of this increased myocardial Fstl3 expression was not known. Fstl3 KO 
in cardiomyocytes eliminated the increase in Fstl3 levels in the myocardium after aortic 
banding, thereby indicating that cardiomyocytes are the primary source of elevated Fstl3 
levels after injury. This is in contrast with the observations in heart failure patients 
where Fstl3 was also detected in the vascular endothelial cells. Interestingly, 2 month 
old cardiac-specific Fstl3 KO mice had normal cardiac function in the absence of injury, 
indicating that cardiomyocyte-derived Fstl3 does not play a significant role in adult 
cardiac homeostasis. This is in apparent disagreement with the findings of the study 
where whole-body Fstl3 KO mice were reported to have mild cardiac hypertension by 9 
months of age, possibly leading to the observed cardiac hypertrophy [317]. These 
differences may be attributed to the global effects of Fstl3 knock-out from the body, 
which resulted in altered metabolic homeostasis in these mice due to increased bio-
availability of Activin and Myostatin, as well as the differences in the age at which the 
mice were examined in the respective studies. 
 
The balance of TGF-β family ligands and their inhibitors is important in determining the 
bio-availability of these cytokines in different tissues. Indeed, previous studies have 
shown that Activin A plays a cardioprotective role against ischemic injury and over-
expression of Fstl3, an extracellular Activin A inhibitor, resulted in loss of activin-
mediated cardioprotection [294]. In this study, it was observed that cardiac-specific 
Fstl3 KO did not affect either the mRNA or protein levels of Activin A with or without 
injury, suggesting an activin-independent role for Fstl3 in the pressure-overloaded heart.  
 
In the absence of Fstl3 from cardiomyocytes, mice displayed attenuated hypertrophy 
demonstrated by reduced heart weight/body weight ratio and cardiomyocyte surface 
area. They also showed improved cardiac contractility and reduced lung weight/body 
weight ratio indicating reduced pulmonary congestion. Thus, Fstl3 deficiency in 
cardiomyocytes was protective against pressure-overload induced cardiac hypertrophy 
and failure. Consistent with this observation, it was previously shown that cardiac-
specific Fstl3 KO mice display reduced infarct size upon ischemia/reperfusion injury 
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[294]. Thus Fstl3 is necessary for the development of heart failure in response to 
different stimuli such as ischemia and pressure overload. Combined with the 
observation of increased Fstl3 in patients with deteriorating heart failure and 
normalisation of its expression following recovery, it follows that Fstl3 is an important 
mediator of the pathological responses to a number of underlying cardiovascular 
conditions progressing to heart failure.  
 
At the molecular level, cardiac dysfunction following pressure-overload induced 
hypertrophy is known to be triggered by the activation of pathological signalling 
pathways and is characterised by reactivation of the fetal gene program [24]. In 
particular, both ANF and BNP are recognised as markers of pathological hypertrophy 
and their expression levels have useful prognostic rationale towards disease severity 
[171]. Reduced expression of ANF and BNP in Fstl3 KO mice suggests that these mice 
do not develop heart failure following pressure overload. Under conditions of cardiac 
stress, contractile proteins also undergo an isoform switch from the fast α-MHC to slow 
β-MHC, thereby altering the α-MHC/β-MHC ratio [26], which can dramatically affect 
cardiac contractility and output. In fact, constitutive over-expression of β-MHC in 
mouse hearts was found to be sufficient to reduce systolic function [174]. Similarly, 
increased expression of α-skeletal actin has been reported following pressure overload 
at the compensated hypertrophic phase where cardiac contractility is maintained in 
response to increased pressure [176]. This has been shown to generate enough force of 
contraction despite the mechanical load and without affecting cell shortening. However, 
cardiomyocytes are unable to maintain the increased levels of α-skeletal actin in chronic 
pressure overload and this may be crucial in the transition from compensated 
hypertrophy to decompensated heart failure [177]. Thus, increased α-skeletal actin 
expression serves as a marker for decompensation and progressing to heart failure. In 
this regard, Fstl3 KO mice displayed attenuated expression of α-skeletal actin and β-
MHC, further strengthening the observation of improved contractility seen by 
echocardiography and consistent with resistance shown by these mice against 
progression to heart failure. 
 
Improved cardiac function after TAC may also be seen as a result of improved 
metabolism which is necessary to support the maintenance of cardiac contractility. 
PPARα expression is necessary for both basal and inducible expression of 
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mitochondrial and peroxisomal FAO enzymes [194, 349]. In response to pressure 
overload, the expression of PPARα and its coactivator  PGC-1α is reduced ([191] and 
Fig. 4.7.1). Besides regulating metabolic processes, PPARα has also been implicated in 
modulating cardiac hypertrophy directly. PPARα agonists like fenofibrate have been 
shown to attenuate cardiomyocyte hypertrophy by inhibiting endothelin I-induced Akt 
and GSK3β phosphorylation [350]. Similarly, PPARα KO mice show augmented 
cardiac hypertrophy in response to pressure overload [351], further validating the anti-
hypertrophic role of PPARα in the heart. Preserved expression of PPARα, PGC-1α and 
PPARα target genes CPT1β and MCAD was observed in Fstl3 KO mice following 
TAC, suggesting that they are protected from progression to pathological hypertrophy 
and heart failure and that FAO remains the major source of energy. These results 
suggest that preserved energy status in Fstl3 KO mice may be an important contributing 
factor towards improved cardiac function. However, more sophisticated metabolic 
characterisation of Fstl3 KO mice is needed to understand the exact role played by it in 
alteration of energy consumption. 
 
In summary, results presented in this chapter have identified an essential role for Fstl3 
in the development of hypertrophy and progression to heart failure. Fstl3 is also 
necessary for the initiation of the fetal gene program and change in cytoskeletal 
contractile proteins. In the absence of Fstl3, myocardial energy metabolism was also 
maintained in response to pressure overload, further diminishing the hypertrophic 
responses. Accordingly, Fstl3 may be an important player in delineating the 
compensated vs. decompensated stage of heart failure. It is also noteworthy that lack of 
Fstl3 did not affect the myocardial or systemic levels of activin A, thereby making it an 
attractive candidate for therapeutic intervention.  
 
Thus, Fstl3 action on cardiac myocytes may be necessary for induction of the 
hypertrophic program at the molecular level, thereby making it an essential factor in the 
progression of hypertrophy. Fstl3 may act directly on cardiomyocytes to induce the fetal 
gene program and the resulting cellular changes affecting cardiac hypertrophy and 
contractility. Similarly, Fstl3 may also be involved during the compensatory phase in 
the regulation of cardiac metabolism.  Thus, loss of Fstl3 from cardiomyocytes may be 
beneficial in terms of reducing the continued expression of fetal genes following the 
compensaoty phase. This may prevent progression of cardiac hypertrophy to heart 
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failure whilst maintaining a compensated state. It may also provide the necessary energy 
support in order to maintain cardiac contractility, thereby resulting in improved cardiac 
function. Thus loss of Fstl3 from the myocardium may be beneficial by preventing 
pathological hypertrophy in response to pressure overload. 
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CHAPTER 5: Fstl3 as a pro-hypertrophic factor in the myocardium 
 
5.1 Introduction 
 
Microarray analysis of heart failure patients (Section 3.4) suggested a correlation of 
FSTL3 with genes involved in cellular signalling and the nuclear compartment. 
Similarly, data presented in Chapter 4 substantiate the vital role of Fstl3 in the mouse 
heart for the development of hypertrophy in response to pressure overload. While it is 
clear that cardiomyocytes are the prominent source of increased Fstl3 due to cardiac 
injury, it remains unclear whether this has any effect on the cardiomyocytes themselves. 
Therefore, the aim of this chapter is to investigate whether Fstl3 promoted hypertrophic 
signalling in cardiomyocytes. In order to test this, neonatal rat ventricular 
cardiomyocytes (NRVM) were chosen as a model system as they display many 
characteristics of the in vivo heart in response to hypertrophic stimuli [24].  
 
5.2 Effect of Fstl3 on cardiomyocyte hypertrophy 
 
Hypertrophy of cardiomyocytes is often measured by increase in cell size and protein 
synthesis. To test the effect of Fstl3 on NRVM growth, cardiomyocytes were stimulated 
with recombinant Fstl3 and/or the α1-adrenergic receptor agonist phenylephrine (PE) as 
a positive control and protein synthesis was measured by radioactive [3H] Leucine 
incorporation normalised to total cell number calculated by LDH released upon cell 
lysis. As shown in Figure 5.1, treatment with Fstl3 for 24 h increased protein synthesis 
by about 10% compared to control untreated cells. However, the difference did not 
reach statistical significance. Treatment with PE led to a significant increase in protein 
synthesis (20%). Interestingly, treatment with Fstl3 and PE together augmented the 
hypertrophic response and increased protein synthesis compared to cells treated with PE 
alone. 
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Figure 5.1: Fstl3 induces increased protein synthesis in cardiomyocytes. Neonatal 
rat cardiomyocytes were treated with 200 ng/ml Fstl3 and/or 100 μM phenylephrine 
(PE) for 24 h and [3H] Leucine incorporation was measured by scintillation counting 
normalised to total cell number. Data are presented as mean percent ± SEM of control 
untreated cells. Two-way ANOVA followed by Bonferonni post-test was used to 
calculate statistical significance. * p < 0.05 for control vs. Fstl3 in the presence of PE. # 
# # p < 0.001 for control vs. PE. n = 3-6. 
 
To test whether cardiomyocyte overexpression of Fstl3 may have a similar effect on cell 
growth, NRVMs were transiently transfected with an expression vector for Fstl3 (also 
expressing GFP) or control vector (GFP alone), and stimulated with PE. Hypertrophy 
was measured by immunostaining and further calculation of the cell surface area of 
untransfected cells identified by absence of GFP. Transfected cells were excluded from 
the analysis as the aim was to examine the effect of secreted Fstl3 on neighbouring 
cells. Representative fluorescent micrographs are shown in Figure 5.2, panel A. 
Quantification of surface areas is shown in panel B. In the presence of Fstl3, 
cardiomyocyte surface area increased from an average 570 μm2 to 820 μm2, an increase 
of 44%. PE increased the average surface area to 1100 μm2 while the combination of PE 
and Fstl3 increased it to more than 1200 μm2. This cumulative effect of Fstl3 and PE 
reflects an additive response of their hypertrophic signalling pathways. 
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Figure 5.2: Fstl3 is sufficient to increase cardiomyocyte surface area. Neonatal rat 
cardiomyocytes were transfected with an Fstl3 expression vector (also expressing GFP) 
or a control vector and treated with 100 μM phenylephrine for 48 h. Cells were stained 
with cardiac troponin I (red) and DAPI (blue). (A) Representative fluorescent 
micrographs of cardiomyocytes. (B) Quantification of cell surface areas (60-150 cells 
per sample) presented as mean ± SEM. Two-way ANOVA followed by Bonferonni 
post-test was used to calculate statistical significance. * p < 0.05, *** p < 0.001 for 
control vs. Fstl3 in the presence and absence of PE respectively. # # # p < 0.001 for PE 
compared to control. n = 3 independent experiments. 
 
5.3 Effect of Fstl3 on cardiomyocyte signalling pathways 
 
In order to explore the molecular mechanisms underlying Fstl3-induced hypertrophy 
and its modulation by activin A, NRVMs were treated for 15 minutes with 200 ng/ml 
recombinant Fstl3 and/or recombinant activin A and protein samples were analysed by 
western blot. Phosphorylation of MAPK pathways was examined, as they are widely 
implicated in hypertrophic signalling in cardiomyocytes [85, 352]. Activation of the 
Smad pathway was also examined as a major pathway mediating signals from the TGF-
β family members [283]. As shown in Figure 5.3 (A, B and C), a trend was observed for 
Fstl3 mediated increase in the phosphorylation of MAPK p38, JNK1 and JNK2 
compared to control untreated cells. Activin A also had a similar effect on 
phosphorylation of these proteins. However, the differences did not reach statistical 
significance. When Fstl3 and activin A were added together, phosphorylation of p38, 
JNK1 and JNK2 was unchanged. This may be due to the binding of Fstl3 to activin A in 
the medium which would limit the availability of each of these proteins to activate 
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downstream signalling cascades. Fstl3 did not have any effect on ERK phosphorylation 
(panel D). 
 
Activin A triggered activation of the Smad signalling pathway in cardiomyocytes. This 
effect was blocked by Fstl3, which had a variable effect on Smad2 phosphorylation on 
its own. Neither activin A nor Fstl3 showed any effect on Smad3 phosphorylation. In 
summary, Fstl3 may activate the MAPK p38 and JNK pathways and diminish the effect 
of activin A on these targets and Smad2. 
 
 
Figure 5.3: Fstl3 may activate two MAPK pathways in cardiomyocytes. Neonatal 
rat cardiomyocytes were treated with 200 ng/ml recombinant Fstl3 and/or 100 ng/ml 
activin A for 15 minutes and analysed by western blot. Representative blots are shown 
for phosphorylated p38, JNK1, JNK2, ERK1/2, Smad2 and Smad3. Phosphorylated 
proteins were normalised to total proteins respectively (lower blots). Quantification was 
performed using ImageJ software. Relative band intensity compared to control untreated 
samples is represented as mean ± SEM. n = 3-5. 
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5.4 Discussion 
 
In vitro experiments on cardiomyocytes are often carried out to elucidate the specific 
mechanism of action of various molecules. This chapter presented evidence for the pro-
hypertrophic effect of Fstl3 on cardiomyocytes and its activation of two MAPK 
pathways. 
 
Phenylephrine, an α1-adrenergic receptor agonist, is commonly used to stimulate 
cardiomyocyte hypertrophy [24]. It functions by activating the p38 and JNK pathways, 
amongst others, and was used as a positive control for measuring the cardiomyocyte 
hypertrophic response [69, 353]. Fstl3 increased hypertrophy of cardiomyocytes as 
measured by both elevated protein synthesis and surface area, although the 
prohypertrophic effect of Fstl3 was more evident on cell surface area than on protein 
synthesis. The difference in the effect of Fstl3 observed between the two methods may 
be explained by different concentration of Fstl3, possible post-translational 
modifications of the protein or the time after which hypertrophy was measured. In the 
experiments where Fstl3 expression vector was transfected in cardiomyocytes, cells 
were given 48 h to produce and secrete Fstl3, after which hypertrophy was measured by 
calculation of their surface area. It should be noted that this effect was caused by 
secreted Fstl3 from cardiomyocytes, as transfected cells (which also expressed GFP) 
were not included in the analysis. Interestingly, the hypertrophic effect of Fstl3 was 
augmented in the presence of PE and cardiomyocytes treated with both stimuli showed 
increased growth compared to PE or Fstl3 alone. Considering that stimulation of 
cardiomyocytes with PE did not increase the expression of Fstl3 (Chapter 3), these 
results suggest an additive effect of Fstl3 and PE on hypertrophic signalling pathways. 
Further investigation will be needed to determine whether both stimuli act through 
common or independent pathways. 
 
A mechanistic insight into the effect of Fstl3 was obtained by stimulating 
cardiomyocytes and measuring the activation of different signalling pathways. Fstl3 was 
found to variably increase the phosphorylation of stress-activated MAPK proteins p38 
and JNK1 and JNK2 – known mediators of cardiomyocyte hypertrophy in response to 
neuroendocrine stimuli and catecholamines [24, 85, 354, 355]. However, Fstl3 did not 
activate the ERK1/2 pathway. This pattern of activation of MAPK pathways is 
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interesting as only the ERK pathway has been established to play a causal role in 
cardiac hypertrophy in vivo [137]. Both p38 and JNK pathways are known to be 
involved in cardiomyocyte hypertrophy in vitro [30, 356]. However, they have been 
shown not to promote or play a role in cardiac hypertrophy in vivo, although they may 
be responsible for mediating a dilated cardiomyopathy phenotype [128, 132, 357-359]. 
Thus, possible activation of p38 and JNK pathways by Fstl3 is consistent with 
promoting cardiomyocyte hypertrophy in vitro. However, this may not necessarily be 
reflected in an in vivo mouse heart scenario. 
 
The variable activation of MAPK proteins by Fstl3 following 15 minute stimulation of 
cardiomyocytes argues for a receptor-mediated action. However, to this day, a receptor 
for Fstl3 has not been identified. It is interesting to note that Fstl3, whose expression is 
elevated in response to TGF-β1 in cardiomyocytes (Chapter 3), may stimulate 
cardiomyocyte hypertrophy in vitro through activation of p38 and JNK1/2 – the same 
proteins implicated in TGF-β1 mediated cardiac hypertrophy via TAK-1 (TGF-β 
activated kinase) [251, 360, 361]. Thus Fstl3 may function to augment TGF-β-triggered 
signalling in cardiomyocytes or behave as a downstream effector through which TGF-
β1 mediates its hypertrophic action. 
 
Interestingly, activin A was also found to increase phosphorylation of MAPK proteins 
p38 and JNK1/2. Activin-mediated phosphorylation of p38 has previously been 
described in other cells such as pancreatic cells, pituitary cells and breast cancer cells 
[362-364]. Furthermore, p38 activation was shown to be necessary for activin-mediated 
inhibition of growth of breast cancer cells [363]. Activation of these pathways was, 
however, diminished when activin A was combined with Fstl3, thereby ascertaining the 
inhibitory effect of either Fstl3 or activin A on each other. Previous studies have shown 
that Fstl3 inhibits activin A signalling by binding to it and preventing its binding to the 
activin receptors [309-311]. Similarly, in the heart, Fstl3 was shown to antagonise 
activin-mediated protection from cell death following ischemic injury [294]. However, 
the inhibitory effect of activin A on Fstl3 has not been described previously and could 
be an important therapeutic mechanism for inhibition of Fstl3 action in the myocardium. 
This apparent activation of MAPK signalling pathways by activin A and Fstl3 but 
inhibition in the presence of both may be attributed to either ligand sequestering, 
resulting in limited receptor binding and activation, or competitive binding to cell 
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surface receptors by Fstl3 and activin A. A similar response has been noted in previous 
studies where sFRP1, an extracellular inhibitor of Wnt signalling, was found to either 
inhibit or potentiate the response of Wingless (a Drosophila Wnt homologue) in a 
concentration and heparin dependent manner [365]. Similarly, Dkk2 was also found to 
inhibit or activate the Wnt/Lrp6 pathway depending on the presence of Kremen2, an 
additional Dkk receptor [366]. Accordingly, the interaction and downstream signalling 
of Fstl3 and activin A may be more complex than previously thought and one or more 
co-receptors or soluble factors might be involved in mediating the Fstl3 response in 
cardiomyocytes. This could add a further level of regulation on Fstl3/Activin A action 
in the injured myocardium where their expression levels are elevated (Chapter 3) but 
cardiomyocyte response to these could thus be limited.  
 
Fstl3 diminished the effect of activin A on Smad2 phosphorylation, as reported 
previously [294]. The inhibitory effect of Fstl3 on Activin function may work as a 
negative feedback loop as activin A is known to regulate the expression of Fstl3 via 
Smad proteins in many tissues [306]. Interestingly, Fstl3-mediated activation of Smad 
pathway was sometimes observed although this could not be conclusively established. 
This is in contrast to a recent study where cardiac-specific Fstl3 knock-out mice were 
shown to have increased phosphorylation of Smad2 following pressure-overload in the 
heart, while no changes were observed in the expression of Smad1/5, Smad4 and Smad6 
[367]. However, the expression of Smad7 – reported to be downregulated in the 
hypertrophied heart [368, 369]– was not examined. Smad7 is a direct inhibitor of 
Smad2 signalling [370] and thus the observed increase in Smad2 phosphorylation 
following TAC might be explained by Smad7 downregulation. Fstl3 may also be 
directly involved in regulating Smad7 expression, although further experiments are 
needed to test this hypothesis.  
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CHAPTER 6: Cardiac remodelling in Fstl3 KO mice 
 
6.1 Introduction 
 
Chronic pressure overload and the resulting cardiac hypertrophy trigger disruption of 
the underlying cardiac structure, leading to a number of pathophysiological changes. 
These include cardiomyocyte death and changes in extracellular matrix (ECM) turnover 
and composition, and gradually lead to myocardial remodelling and heart failure [232, 
262, 371, 372]. It has been recognised that the ECM plays a dynamic role in the 
adaptation of the heart to stress and regulates the process of remodelling [373-376]. In 
the ECM, fibrillar collagens I and III form the structural network necessary for 
maintaining cardiac structural integrity and function [377, 378]. Other components 
include the basement membrane, proteoglycans and glucosaminoglycans, as well as 
soluble proteins such as TGF-β [230]. The ECM structure is maintained by a balance 
between the synthesis and degradation of its constituents. Regulators of ECM turnover 
include a family of well conserved matrix metalloproteinases (MMPs) and their tissue 
inhibitors (TIMPs), the dynamic equilibrium between which controls the abundance of 
collagens, fibronectin and other ECM constituents [379-381]. 
 
This chapter examines the phenotype of Fstl3 KO mice with respect to cardiac fibrosis 
in response to pressure overload. Microarray analysis comparing gene expression in the 
myocardium of Fstl3 KO mice vs. WT mice in response to TAC is analyzed. Moreover, 
expression of various ECM components (collagens, fibronectin) as well as regulators 
and mediators of fibrosis is examined. Similarly, the expression of MMPs and TIMPs is 
also analyzed. Data presented in this chapter will answer the question whether knock-
out of Fstl3 from cardiomyocytes is sufficient to reduce myocardial fibrosis and 
remodelling in response to pressure overload. 
 
6.2 Microarray analysis of Fstl3 KO mice  
 
In order to gain insights into the molecular mechanisms underlying the enhanced 
cardiac function following TAC in Fstl3 KO mice, global transcription profile of the 
heart was analyzed using oligonucleotide microarrays, as described in section 2.6. 
Tables 6.1 A and B show the list of genes with reduced expression in the KO compared 
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to WT hearts three weeks after TAC (KO TAC < WT TAC) and a gene ontology (GO) 
analysis of this gene list respectively. Genes and GO for the following conditions are 
listed in Appendix IV: 
 
1. WT TAC > WT SHAM 
2. WT TAC < WT SHAM 
3. KO TAC > KO SHAM 
4. KO TAC < KO SHAM 
5. KO SHAM > WT SHAM 
6. KO SHAM < WT SHAM 
7. KO TAC > WT TAC 
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Table 6.1 (A) KO TAC < WT TAC Representative Genes 
Myocardial biopsies were taken from Fstl3 KO and WT mice, three weeks after TAC 
and total RNA was hybridized on Mouse Gene 1.0 ST Array chips in triplicate and 
analyzed using GeneSpring X software suite. After scanning, raw data in each chip was 
normalized to the 50th percentile and to the median of the chip. Samples were further 
normalized on a gene per gene basis to the values obtained for sham operated WT hearts 
and gene lists were filtered for raw expression > 50. Fold change lists comparing two 
conditions were generated using a cut-off value of 1.4-fold. 
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Table 6.1 (B) KO TAC < WT TAC Gene Ontology (GO) 
Myocardial biopsies were taken from Fstl3 KO and WT mice, three weeks after TAC 
and total RNA was hybridized on Mouse Gene 1.0 ST Array chips in triplicate and 
analyzed using GeneSpring X software suite. Gene lists were generated as above and 
compared to existing gene ontology lists in GeneSpring. Only those GO lists showing a 
correlation p-value < 0.01 with the studied gene list are shown. 
 
L
egend: p - p value; n - number of counts in selection; q - percent counts in selection 
 
As shown in Table 6.1 (A), of the total 28,856 genes analysed, 338 genes showed 
reduced expression (≤1.4-fold) in Fstl3 KO hearts compared to WT hearts after TAC. 
These included fibronectin-1, lysyl oxidase, collagens and other ECM-related genes. 
Fstl3 was also included in this list, serving as a positive control. Gene ontology analysis 
of this list indicated that those genes downregulated in Fstl3 KO hearts are mainly 
involved in protein binding and extracellular region/matrix, although Fstl3 KO also 
resulted in decreased expression of genes related to the response to external stimuli and 
immune processes (Table 6.1 B). It is interesting to note that between 30 – 50% of 
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genes whose expression was reduced in KO mice belonged to categories related to the 
extracellular matrix, rather than growth or cytoskeleton categories. This suggests that 
the main pathological role of Fstl3 in the heart may not be the promotion of hypertrophy 
but the regulation of fibrosis. 
 
6.3 Analysis of cardiac fibrosis in Fstl3 KO mice in response to TAC 
 
Microarray analysis of WT and Fstl3 KO mice after TAC indicated reduced expression 
of genes involved in cardiac fibrosis in the knockout animals. In order to confirm the 
observation in vivo, myocardial sections from WT and KO mice were stained with 
Sirius red, a collagen-binding dye. As shown in Figure 6.1 (A), Sirius red staining 
showed extensive interstitial and perivascular fibrosis (Inset) in WT mice after aortic 
constriction. However, this was attenuated in Fstl3 KO mice. Percent fibrotic area was 
calculated as the ratio between collagen area and the total ventricular area in each 
section and quantified in panel B. In Fstl3 KO mice the fractional fibrotic area is 
reduced as compared to WT mice after TAC, suggesting a role for Fstl3 in modulation 
of cardiac fibrosis. 
 
Figure 6.1: Reduced cardiac fibrosis in Fstl3 KO mice after TAC. Cardiac fibrosis 
resulting from pressure overload was quantified by staining myocardial sections from 
WT and Fstl3 KO mice with Sirius red. (A) Representative photomicrographs of Sirius 
red stained sections are shown; Inset: Representative perivascular fibrosis; bar = 100μm. 
(B) Percent fibrotic area was calculated from 15 Sirius red stained sections per sample, 
as the ratio of collagen deposition area to total ventricular area in the respective sections 
and expressed as a percentage. Two-way ANOVA followed by Bonferroni post-test was 
used to calculate statistical significance. * p < 0.05 compared to WT SHAM. n = 3. 
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Furthermore, collagen mRNA expression was measured using quantitative real-time 
RT-PCR. As shown in Figure 6.2, collagen I α1 (Col1a1) and collagen III α1 (Col3a1) 
mRNA was strongly induced after TAC in WT mice (A, B). Similarly, the mRNA 
expressions of lysyl oxidase (Lox), an enzyme cross-linking collagen fibres into mature 
collagen (C) [382], and fibronectin-1, which is crucial for collagen deposition (D) [383], 
were also elevated in the WT hearts. In contrast, Fstl3 KO mice showed reduced 
expression of these markers following TAC, compared to WT, indicating reduced 
collagen deposition and fibrosis and further validating the microarray results. 
 
Figure 6.2: Reduced expression of fibrosis markers in Fstl3 KO mice. Following 
TAC or ‘sham’, quantitative real-time RT-PCR was used to measure the myocardial 
mRNA expression of Col1a1 (A), Col3a1 (B), Lox (C) and fibronectin-1 (D), 
normalised to endogenous 18S rRNA. Two-way ANOVA followed by Bonferroni post-
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tests were used to calculate statistical significance. ** p < 0.01, *** p < 0.001 vs. WT 
SHAM. # # # p < 0.001 vs. WT TAC. n = 3-6 per group.  
 
In the pressure-overloaded heart, the fibrotic response is initiated by various cytokine 
signalling pathways such as TGF-β. Therefore, the mRNA expression of typical 
mediators of fibrosis including TGF- β1 and connective tissue growth factor (CTGF), 
one of its downstream mediators, was examined. As shown in Figure 6.3, the mRNA 
expression of both TGF- β1 and CTGF was elevated after TAC in WT mice compared 
to ‘sham’ operated hearts. However, their expression remained unchanged in Fstl3 KO 
hearts after TAC. 
 
Figure 6.3: Reduced expression of pro-fibrotic cytokines in Fstl3 KO mice.  mRNA 
expression of TGF- β1 (A) and CTGF (B) was analysed in myocardial samples from 
WT and Fstl3 KO mice following TAC using qRT-PCR normalised to endogenous 18S 
rRNA. Two-way ANOVA followed by Bonferroni post-tests were used to calculate 
statistical significance. ** p < 0.01, *** p < 0.001 vs. WT SHAM.   # # p < 0.01, # # # p 
< 0.001 vs. WT TAC. n = 3-6 per group. 
 
6.4 Expression of Matrix Metalloproteinases and their inhibitors in Fstl3 KO mice 
 
Pressure-overload in the heart often leads to myocardial remodelling and progression to 
heart failure. Extracellular matrix components like matrix metalloproteinases (MMPs) 
and their tissue inhibitors (TIMPs) play an active role in this process [379, 384-386]. In 
order to check if Fstl3 was involved in the regulation of these molecules, the expression 
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of typical markers of myocardial remodelling was examined using qRT-PCR. As shown 
in Figure 6.4, the expression of gelatinases MMP2 and MMP9 increased in WT hearts 
in response to pressure overload. In contrast, Fstl3 KO hearts showed attenuated 
expression of both MMP2 and MMP9 (Panels A, B). mRNA expression of ADAM12 – 
a disintegrin and metalloprotease – followed a similar pattern and showed attenuated 
expression in Fstl3 KO hearts compared to WT hearts after TAC (Panel C), although it 
remained significantly elevated compared to ‘sham’ hearts. Furthermore, the expression 
of tissue inhibitor of MMPs 1, Timp1, was elevated in WT mice and remained 
unchanged in Fstl3 KO hearts following TAC (Panel D). These results suggest an 
attenuation of the process of extracellular matrix remodelling in Fstl3 KO mice.  
 
Figure 6.4: Reduced expression of markers of extracellular matrix remodelling in 
Fstl3 KO hearts. Ventricular samples from WT and Fstl3 KO hearts were analysed by 
qRT-PCR 3 weeks after ‘sham’ or TAC. Myocardial mRNA expression of Mmp2, 
Mmp9, Adam12 and Timp1 normalised to endogenous 18S rRNA is shown. Two-way 
ANOVA followed by Bonferroni post-tests were used to calculate statistical 
significance. * p < 0.05 vs. KO SHAM,  ** p < 0.01, *** p < 0.001 vs. WT SHAM, # p 
< 0.05, # # p < 0.01, # # # p < 0.001 vs. WT TAC. n = 3-6 per group. 
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6.5 Inflammatory response in Fstl3 KO mice after TAC 
 
Myocardial remodelling and fibrosis is often initiated and accompanied by 
inflammation [387]. To investigate whether cardiomyocyte-secreted Fstl3 was 
modulating the immune response, mRNA expression of pro-inflammatory cytokines IL-
6 and IL-1β was examined in the Fstl3 KO mice after TAC. As shown in Figure 6.5 
(A), the expression of IL-6 was elevated in response to TAC in WT mice but remained 
unchanged in Fstl3 KO mice. Interestingly, Fstl3 KO hearts seemed to have elevated 
expression of IL-1β under ‘sham’ condition compared to WT mice, further remaining 
unchanged in response to TAC (Panel B). However, this could not be conclusively 
established as there was high variation among samples. 
 
Figure 6.5: Deranged expression of inflammatory cytokines in Fstl3 KO mice. 
Myocardial samples from WT and Fstl3 KO mice were examined following TAC using 
qRT-PCR. Ventricular mRNA expression of IL-6 and IL-1β is shown as mean ± SEM 
normalised to endogenous 18S rRNA. Two-way ANOVA followed by Bonferroni post-
tests were used to calculate statistical significance. ** p < 0.01 vs. WT SHAM.  # p < 
0.05 vs. WT TAC. n = 3-6 per group. 
 
6.6 Discussion 
 
This Chapter examined the effect of Fstl3 KO from cardiomyocytes on myocardial 
fibrosis in response to pressure overload. Microarray analysis on myocardial samples 
indicated reduced expression of genes related to the extracellular space/matrix in Fstl3 
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KO hearts. This was further confirmed by qRT-PCR which demonstrated reduced 
mRNA expression of collagens (type I and III), fibronectin and lysyl oxidase in the 
Fstl3 KO hearts. It was accompanied by reduced expression of TGF-β1 and CTGF – 
known mediators of cardiac fibrosis. Aberrant expression of ECM components and 
regulators has been consistently observed in patients with dilated cardiomyopathy and 
heart failure [384, 388, 389]. TGF-β can be considered as a master regulator of cardiac 
fibrosis and remodelling, acting as a major effector of Angiotensin II in the heart with 
important roles in cardiac hypertrophy, fibroblast homeostasis, ECM remodelling and 
inflammation [249, 250]. In this respect, TGF-β not only promotes increased collagen 
and fibronectin deposition, but also reduces ECM turnover by inhibition of MMPs and 
induction of TIMP activity [247, 248, 253-255]. Moreover, both TGF-β and Activin A, 
have been implicated in regulating Lox activity and thereby collagen cross-linking [390-
392]. On the other hand, the role of CTGF as a mediator of cardiac fibrosis is 
controversial. In vitro experiments have demonstrated a role for CTGF in fibroblast 
proliferation and ECM synthesis [393, 394]. However, in overexpression studies, CTGF 
transgenic mice did not develop cardiac fibrosis. Nevertheless, they exhibited cardiac 
hypertrophy and an age-dependent progression to chamber dilation and heart failure 
[395]. CTGF expression can be used as a marker for cardiac fibrosis as its expression, 
mainly regulated by TGF-β, is elevated in heart failure patients  [396] as well as in 
different models of fibrosis [397-403]. Thus, reduced expression of CTGF in Fstl3 KO 
mice may in fact be considered beneficial against progression to heart failure. 
Interestingly, fibronectin has been shown to bind to Fstl3 leading to increased cell 
adhesion of hematopoietic stem cells [320]. However, whether this interaction also 
takes place in the myocardium and plays a role in collagen deposition or fibroblast 
proliferation is unknown. Thus, reduced expression of TGF-β and collagens in the 
hearts of Fstl3 KO mice suggests a necessary role for Fstl3 in the development of 
cardiac fibrosis in response to pressure overload. Considering the stimulatory role of 
TGF-β on Fstl3 expression (Chapter 3, [305]), it remains unclear whether the observed 
reduced fibrosis is a direct response to loss of Fstl3 in the myocardium or as a 
secondary effect arising from reduced cardiac hypertrophy. If Fstl3 is involved in direct 
regulation of fibrosis in the presence/absence of cardiac disease, it would be interesting 
to delineate this pathway in future studies using an inducible knock-out of Fstl3 after 
TAC. Using this system, the exact role of Fstl3 – whether causative – may be clarified 
by removing Fstl3 after rather than before induction of hypertrophy. At this stage 
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however, it cannot be be said confidently whether reduced fibrosis in Fstl3 KO mice is 
secondary to reduced hypertrophy or a direct effect of lack of Fstl3. Considering the 
complexity and interconnectivity of cardiac remodelling processes, it is likely that 
fibrosis in the heart may be regulated to some extent by both Fstl3 expression as well as 
the stage of disease progression. 
 
ECM homeostasis is maintained by a balance in the synthesis and degradation of ECM 
components, controlled by the activities of proteinases and their inhibitors [404]. 
Myocardial collagens have low turnover and thus are mainly regulated by synthesis or 
degradation in response to stimuli. Increased MMP expression and activity in the 
myocardium plays a major role in chamber dilation and progression to heart failure, 
which can be inhibited by increased TIMP expression [240, 379, 384, 385, 405]. 
However, TIMPs are also known to regulate the activation of MMPs, e.g. TIMP2 and 
TIMP3 are known to regulate active MMP2 and MMP9 [406-408]. Fstl3 KO mice 
showed attenuated expression of MMP2, MMP9 and Timp1 compared to WT mice after 
TAC, suggesting reduced cardiac remodelling. This does not necessarily indicate 
changes in the activity of these MMPs, as this was not examined. Both MMP2 and 
MMP9 have been implicated in induction of TGF-β expression, which subsequently 
inhibits their activity [409, 410]. The balance in the overall expression and activity of 
MMPs and TIMPs in Fstl3 KO mice may be a reflection of the overall phenotype of 
reduced fibrosis during various stages of disease progression [379, 385, 404, 411, 412]. 
This may also be affected by the profile of inflammatory cytokines in the heart, which 
can directly affect MMP activity [413, 414]. Similarly, it cannot be ruled out that the 
observed reduction in fibrosis may simply be a secondary effect of reduced cardiac 
hypertrophy in response to pressure overload. It is interesting to note that PPARα 
expression has been linked to reduced extracellular matrix remodelling, inflammation 
and oxidative stress in the heart [351, 415-417]. Fstl3 KO mice show preserved 
expression of PPARα in the heart following pressure overload (Chapter 5, Section 
5.6.1), which may at least in part be responsible for reduced cardiac fibrosis in these 
mice. 
 
Activin A has been demonstrated to play a pro-fibrotic role in various tissues leading to 
increased synthesis of collagen type I [418-420]. However, despite the elevated levels of 
Activin A in the heart and serum of Fstl3 KO mice after TAC (Chapter 4), they 
 136 
exhibited reduced fibrosis and collagen deposition, suggesting that the pro-fibrotic role 
of Activin A may be tissue-specific. Interestingly, Activin A is known to induce the 
expression of pro-MMPs 2, 3 and 9 as well as active MMP2 in endometrial stromal 
cells thereby promoting decidualization [421, 422]. Whether Activin A regulates ECM 
synthesis and MMP expression in cardiac fibroblasts remains unknown, but is unlikely 
based on the results presented here. 
 
The expression of Adam12 was also reduced in Fstl3 KO hearts following TAC. 
Interestingly, Adam12 has been suggested to play a causal role in cardiac hypertrophy 
by increasing HB-EGF shedding and subsequent activation of GPCR signalling [113]. 
Furthermore, an interaction between Fstl3 and Adam12 has been reported, and may be 
involved in Fstl3-mediated inhibition of osteoclast differentiation [322]. Although 
Adam12 binding to Fstl3 has not been tested in the myocardium, it might play a role in 
regulation of cardiac hypertrophy and remodelling. 
 
Pro-inflammatory cytokines have been suggested to play a role in ECM remodelling in 
the heart, leading to chamber dilation and heart failure [423]. Knock-out of Fstl3 in the 
myocardium reduced the expression of IL-6 following TAC. In contrast, the expression 
of IL-1β seemed to be elevated in the KO hearts even under basal conditions, although 
samples showed high variation. In mice, Activin A was found to play a critical role in 
LPS induced inflammation as well as expression of pro-inflammatory cytokines TNF-α, 
IL-1β and IL-6. This action was found to be reversible upon administration of 
follistatin, an extracellular inhibitor, or activin receptor antagonism [424, 425]. In this 
respect, Fstl3 KO mice showed elevated levels of Activin A in the serum, similar to WT 
mice in response to TAC (Chapter 4). Therefore, it is unlikely that the reduced 
expression of IL-6 in these mice is a direct consequence of the loss of Fstl3, and is 
probably secondary to reduced hypertrophy and remodelling.  
 
Knock-out of Fstl3 from cardiomyocytes and the resulting reduced fibrosis following 
TAC implies that Fstl3 may act in a cell non-autonomous manner by acting on resident 
cardiac fibroblasts. Thus, Fstl3 produced in cardiomyocytes may be secreted and thus 
have an effect on other cell types such as fibroblasts, endothelial cells and smooth 
muscle cells. Fstl3 may thus induce fibrosis by affecting fibroblast proliferation or 
regulating matrix sythesis or degradation. Fstl3 may also have an effect on 
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myofibroblast differentiation in the heart. Considering that Fstl3 expression was seen in 
the cardiac endothelial cells in heart failure patients (Chapter 3), Fstl3 may play a role in 
endothelial-mesenchymal transition to induce myofibroblast differentiation, thereby 
resulting in perivascular fibrosis. However, myofibroblast differentiation was not 
examined in the Fstl3 KO mice in this study. 
 
In summary, results presented here suggest that Fstl3 may play a role in the 
development of cardiac fibrosis in response to pressure overload. 
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CHAPTER 7: Role of Fstl3 in induction of cardiac fibrosis 
 
7.1 Introduction 
 
Fstl3 was demonstrated to be necessary for the induction of cardiac fibrosis in response 
to pressure overload, wherein reduced expression of collagens and other fibrosis 
modulators was observed in cardiomyocyte-specific Fstl3 KO mice (Chapter 6). This 
Chapter further explores the role of Fstl3 as a paracrine mediator in the induction of 
fibrosis by using in vitro models. To simulate the conditions of in vivo pressure 
overload, an in vitro model was set up using mechanical stretch applied to cells in 
culture grown on flexible membranes (Section 2.17). Either recombinant Fstl3 or 
mechanical stretch induced Fstl3 from cardiomyocytes was used in these experiments. 
Col1a1 mRNA expression was measured as type I collagen has been reported to be the 
most abundant of newly synthesized collagens and is highly elevated in response to 
different types of mechanical stimuli on fibroblasts [426, 427].  
 
7.2 Effect of recombinant Fstl3 on cardiac fibroblasts 
 
Data presented in Chapter 6 indicated a necessary role for Fstl3 in development of 
cardiac fibrosis after TAC. However, it was unclear whether Fstl3 had a direct effect on 
fibroblasts. To examine this possibility in vitro, neonatal rat cardiac fibroblasts were 
treated with recombinant Fstl3 and collagen mRNA was measured by qRT-PCR. Newly 
synthesized acid-soluble total collagen released into the culture medium was also 
measured using the Sircol collagen assay [428, 429].  As shown in Figure 7.1, Fstl3 
stimulation of fibroblasts did not increase Col1a1 mRNA or newly synthesized collagen 
release to the supernatant. However, it is possible that fibroblast stimulation was not 
established since a positive control for stimulation was not used. 
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Figure 7.1: Fstl3 is not sufficient to increase collagen synthesis in fibroblasts. 
Neonatal rat cardiac fibroblasts were treated with 200 ng/ml recombinant Fstl3. (A) 
Fibroblasts were treated with Fstl3 for 24 h and Col1a1 mRNA expression was 
measured by qRT-PCR. (B) Fibroblasts were treated with Fstl3 for 72 h and collagen 
release was measured by colorimetric collagen assay. Data are presented as mean ± 
SEM. Unpaired t-test was used to calculate the p values. Mean differences did not reach 
statistical significance. n = 3. 
 
7.2.1 Effect of Fstl3 on fibroblast death and proliferation 
 
Cardiac remodelling is usually accompanied by fibroblast turnover. To test if Fstl3 had 
an effect on cell death or proliferation, cardiac fibroblasts were treated with 
recombinant Fstl3 at various concentrations and cell death was measured by LDH 
release into the supernatant normalized to total LDH released upon cell lysis. Figure 7.2 
shows a dose response curve of fibroblast LDH release upon treatment with increasing 
concentrations of Fstl3 for 24 and 48 h. Fstl3 caused a dose and time-dependent 
increase in LDH release from fibroblasts, indicating cell death at higher concentrations. 
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Figure 7.2: Fstl3 induces a dose dependent increase in LDH release from 
fibroblasts. Neonatal rat cardiac fibroblasts were treated with various concentrations of 
Fstl3 for 24 h and 48 h. LDH released in the supernatant was determined with a 
colorimetric assay by measuring absorbance at 490 nm and normalized to total LDH 
released after cell lysis. Data are expressed as mean ± SEM. Sigmoidal dose reponse 
curve was fit to the values. n = 3. 
 
Fibroblast cell numbers depend on proliferation as well as cell death. Therefore, 
fibroblast cell proliferation in response to concentrations of Fstl3 that affected LDH 
release was examined using BrdU incorporation. As shown in Figure 7.3, Fstl3 
treatment did not affect fibroblast proliferation at the concentrations examined. This 
also verified that the increased LDH release upon Fstl3 treatment was not due to 
increased cell proliferation.  
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Figure 7.3: Fstl3 does not affect fibroblast proliferation. Neonatal rat cardiac 
fibroblasts were treated with Fstl3 at various concentrations and BrdU incorporation 
was measured over an 18 h period. Data are expressed as mean ± SEM. One-way 
ANOVA was used to calculate the p values and the difference between the means did 
not reach statistical significance. n = 3-4. 
 
7.3 Effect of mechanical stretch and Fstl3 on fibroblasts  
 
To test whether additional factors might be necessary for the action of Fstl3 on 
fibroblasts, an in vitro stimulus equivalent to pressure overload in the heart was set up 
using mechanical stretch applied to cultured cells. Fibroblasts were subjected to 15% 
equibiaxial stretch and expression of Fstl3 was measured. As shown in Figure 7.4, Fstl3 
mRNA expression was not significantly changed upon mechanical stretch of fibroblasts. 
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Figure 7.4: Mechanical stretch of fibroblasts does not induce Fstl3 mRNA 
expression. Neonatal rat cardiac fibroblasts were subjected to 15% equibiaxial stretch 
for 24 h and Fstl3 mRNA expression was measured using qRT-PCR and normalized to 
endogenous 18S rRNA. Data are expressed as mean ± SEM. Unpaired t-test was used to 
calculate the p value, which did not reach statistical significance. n = 3. 
 
Next, the effect of combining Fstl3 and mechanical stretch on fibroblasts was analyzed. 
As shown in Figure 7.5, neither Fstl3 treatment nor 15% stretch was sufficient by itself 
to induce Col1a1 mRNA expression. However Col1a1 expression was elevated when 
both the stimuli were combined. This observation indicated that Fstl3 required 
additional factor(s) that were probably released upon mechanical stretch for induction of 
Col1a1 in fibroblasts.  
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Figure 7.5: Fstl3 induces collagen synthesis in stretched fibroblasts. Neonatal rat 
cardiac fibroblasts were subjected to 15% equibiaxial stretch for 24 h and stimulated 
with 200 ng/ml recombinant Fstl3. Col1a1 mRNA expression was measured using qRT-
PCR and normalized to endogenous 18S rRNA. Data are expressed as mean ± SEM. 2-
way ANOVA followed by Bonferonni post-test was used to calculate statistical 
significance. *** p < 0.001 for stretch vs. no stretch with Fstl3 stimulation. # # p < 0.01 
for Fstl3 vs. control at 15% stretch condition. n = 3.  
 
7.3.1 Effect of Fstl3 on Smad activation in fibroblasts 
 
The Smad pathway in fibroblasts has been shown to play an active role in fibroblast 
activation and collagen synthesis. To analyze whether Fstl3 was involved in activation 
of the Smad pathway in fibroblasts, phosphorylation of Smad2 was examined by 
western blot. As shown in Figure 7.6 (A), Fstl3 treatment increased Smad2 
phosphorylation in fibroblast compared to control. Activation of Smad pathway usually 
leads to translocation of the Smad complex into the nucleus where they bind to Smad-
responsive elements in the promoters of target genes causing their transcriptional 
activation. To confirm Smad activation, fibroblasts were transiently transfected with a 
luciferase-reporter construct with three tandem Smad-binding elements (SBE) and 
stimulated with recombinant Fstl3 for 72 h. As shown in Figure 7.6 (B), Fstl3 
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stimulation caused an increase in luciferase reporter signal, normalized to control renilla 
reporter. Thus, Fstl3 activated the Smad pathway in cardiac fibroblasts. 
 
Figure 7.6: Fstl3 activates the Smad pathway in cardiac fibroblasts. (A) Neonatal 
cardiac fibroblasts were treated with 200 ng/ml Fstl3 for 15 min and phosphorylation of 
Smad2 was examined by western blot, quantified and normalized to total Smad2 (lower 
band) in the cells. Data are expressed as mean ± SEM .Unpaired t-test was used to 
calculate statistical significance. * p < 0.05, n = 3. (B) Time course showing 
phosphorylation of Smad2. (C) Fibroblasts were transfected with SBE-luciferase 
reporter construct or control renilla reporter construct and stimulated with 200 ng/ml 
Fstl3 for 72 h. Luciferase units normalized to renilla are shown as mean ± SEM. 
Unpaired t-test was used to calculate statistical significance. * p < 0.05, n = 3. 
 
7.4 In vitro model of TAC: Mechanical stretch of cardiomyocytes 
 
In vivo data from Chapter 4 demonstrated that the source of increased Fstl3 in the 
myocardium in response to TAC was cardiomyocytes. This implied that the effect on 
fibrosis could be mediated by paracrine action and/or cross-talk between cardiac 
myocytes and fibroblasts. Thus, an in vitro equivalent system was set up in which 
cardiomyocytes were subjected to mechanical stretch [430]. As shown in Figure 7.7 
(A), mechanical stretch of cardiomyocytes increased mRNA expression of Fstl3, while 
the expression of Col1a1 was unaffected and that of Col3a1 was downregulated (Panels 
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B and C). However, it could not be established whether Fstl3 was released in the 
conditioned medium as an ELISA was not performed. 
 
Figure 7.7: Mechanical stretch of cardiomyocytes induces Fstl3 mRNA synthesis. 
Neonatal rat ventricular cardiomyocytes were subjected to 10% equibiaxial stretch for 
24 h and mRNA expression of Fstl3 (A; n = 6), Col1a1 (B; n = 7) and Col3a1 (C; n = 
11) was measured by qRT-PCR and normalized to endogenous 18S rRNA. Data are 
expressed as mean ± SEM.  Unpaired t-tests were used to calculate the p values. ** p < 
0.01, *** p < 0.001 compared to ‘no stretch’ control samples.  
 
7.4.1 Effect of stretched cardiomyocytes on fibroblasts  
 
To test whether stretched cardiomyocyte-derived Fstl3 affected collagen synthesis by 
fibroblasts, the conditioned medium from stretched cardiomyocytes was added to 
cultured fibroblasts and newly synthesized collagen secreted into the culture supernatant 
was measured using Sircol collagen assay. As shown in Figure 7.8 (A), conditioned 
medium from stretched cardiomyocytes caused an increase in collagen synthesis by 
cardiac fibroblasts. To determine whether Fstl3 was necessary for increased collagen 
production by fibroblasts in response to conditioned medium from stretched 
cardiomyocytes, a neutralizing antibody against Fstl3 or isotype-matched control IgG) 
was added to the cultured fibroblasts during stimulation with cardiomyocyte 
conditioned medium. As shown in Figure 7.8 (B), neither control nor neutralizing Fstl3 
antibody had any effect on collagen synthesis by fibroblasts in the presence of 
conditioned medium from non-stretched cardiomyocytes. However, in the presence of 
stretched cardiomyocyte conditioned medium, neutralizing Fstl3 antibody reduced the 
collagen release from fibroblasts as compared to control antibody. Thus, Fstl3 was 
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found to be necessary for collagen synthesis by fibroblasts, albeit in the presence of 
unknown factors derived from stretched cardiomyocytes.  
 
Figure 7.8: Fstl3 is necessary for stretch-mediated paracrine induction of 
fibroblast collagen synthesis. Conditioned medium from stretched cardiomyocytes was 
added to neonatal rat cardiac fibroblasts and newly formed collagen released to the 
medium was measured using a colorimetric collagen assay. (A) Addition of conditioned 
medium from stretched cardiomyocytes increases collagen synthesis in fibroblasts. Data 
are expressed as mean ± SEM. Unpaired t-test was used to calculate the p value. *** p < 
0.001; n = 7. (B) Anti-Fstl3 neutralizing antibody or isotype matched control IgG were 
added to conditioned medium from stretched cardiomyocytes and collagen release from 
fibroblasts was measured. Data are expressed as mean ± SEM.  2-way ANOVA 
followed by Bonferonni post-test was used to calculate the statistical significance. * p < 
0.05 for 10% stretch vs. no stretch; # p < 0.05 for anti-Fstl3 vs. control IgG at 10% 
stretch. n = 4. 
 
7.5 Discussion 
 
This Chapter presented evidence for a role of Fstl3 in collagen production by 
fibroblasts. Both recombinant Fstl3 and endogenously produced Fstl3 increased 
collagen synthesis in cardiac fibroblasts, albeit in the presence of unknown mechanical 
stretch-derived factors.  
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Stimulation of fibroblasts with recombinant Fstl3 did not affect collagen synthesis. 
However, a dose-dependent increase in cell death, independent of proliferation, was 
observed. In this respect, Fstl3 may be similar to other neurohumoral stimuli such as 
angiotensin II, which is known for its role in cardiac hypertrophy and remodelling, and 
also in regulation of cardiomyocyte and fibroblast cell death [431-435]. Cell death, both 
necrosis and apoptosis, has been shown to play an important role in the transition from 
compensated cardiac hypertrophy to dilation and heart failure [263, 436, 437]. Whether 
Fstl3 is sufficient for induction of cell death in vivo is still unknown. However, 
cardiomyocyte-specific Fstl3 KO mice display increased expression of anti-apoptotic 
Bcl-2 in the heart as well as protection from ischemia-reperfusion induced cell death 
[294]. Thus, protection from cell death in Fstl3 KO mice may represent an important 
mechanism by which progression to heart failure is arrested. 
 
Interestingly, Fstl3 expression was not elevated in cardiac fibroblasts subjected to 
mechanical stretch. This confirmed the in vivo observation that cardiomyocytes are the 
major source of increased Fstl3 in the myocardium in response to stress (Chapter 4). 
Moreover, collagen expression remained unchanged in cardiac fibroblasts subjected to 
stretch. This may be due to the extent of stretch applied to the cells (cyclic 15% 
equibiaxial) or the duration of the stimulus [438]. This may also be affected by the 
growth substrate that the cells were cultured on and the type and maturity of fibroblasts 
[426]. However, increased collagen expression was observed in stretched fibroblasts 
stimulated with recombinant Fstl3. This indicated that Fstl3 required additional factors 
released/expressed upon mechanical loading to induce collagen expression in 
fibroblasts. Similar responses have been noted before in neonatal rat cardiac fibroblasts 
subjected to mechanical loading and stimulation with IGF-1, where increased 
expression of α1 collagen type I mRNA was observed [439]. Many humoral factors and 
cytokines including angiotensin II, endothelin-1, TNF-α and TGF-β have been known to 
be secreted by mechanically loaded fibroblasts and are crucial to collagen synthesis and 
ECM remodelling [440-443]. Although the identity of the factors cooperating with Fstl3 
remains as yet unknown, it is possible that a cell surface receptor on fibroblasts may 
only be expressed or morphologically exposed upon mechanical stretch. This regulation 
has been shown for surface integrins on fibroblasts, whose expression is changed in 
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response to mechanical stimuli and they have been known to act as receptor complexes 
for mechanosensitive signal transduction [32, 444, 445].   
 
The Smad pathway has been shown to play a major role in mediating the intracellular 
signaling triggered by  pro-fibrotic factors like TGF-β [283]. Moreover, Fstl3 has been 
known to interact with members of the TGF-β superfamily like activin, myostatin and 
BMPs [308]. It was hypothesized that Fstl3 may exert its fibrotic effect by regulating 
the Smad pathway. Fstl3 induced phosphorylation of Smad2 in fibroblasts. Luciferase 
reporter linked to tandem Smad binding elements showed increased activity at 72 h post 
transfection, further indicating that the Smad pathway was activated by Fstl3. However, 
Fstl3 was not sufficient to induce collagen production in fibroblasts, suggesting that the 
Smad pathway was not fully activated or not for long enough. A time course study of 
activation of the different components of Smad pathway is necessary to fully delineate 
its role in Fstl3-induced collagen expression. 
 
To simulate conditions of pressure overload in the heart, neonatal rat cardiomyocytes 
were subjected to mechanical loading [430]. This was found to increase the expression 
of Fstl3 from cardiomyocytes, in agreement with the observations made in vivo as 
mentioned before (Chapter 4), whereas it did not increase (type I or III) collagen α1 
mRNA expression. Conditioned medium from stretched cardiomyocytes increased 
collagen synthesis in fibroblasts in a Fstl3 sensitive manner. These results suggest that 
Fstl3 plays a crucial role in the paracrine activation of fibroblasts by cardiomyocytes, 
which would explain the in vivo observations of reduced fibrosis in Fstl3 KO mice. 
Fstl3 can thus be considered as an important mediator of cardiomyocyte – fibroblast 
cross-talk that acts in an autocrine / paracrine manner on both cell types to regulate 
cardiac remodelling. Other factors have been similarly implicated to play a role in 
cardiomyocyte – fibroblast cross-talk and regulation of cardiac hypertrophy and 
remodelling. For example, TGF-β is secreted from mechanically stressed cardiac 
fibroblasts as well as cardiomyocytes and plays an important role in cardiac 
hypertrophy and remodelling [441, 443, 446]. Similarly, angiotensin II, endothelin-1, 
IGF-1 and TNF-α have also been implicated in mediating paracrine actions in the 
stressed myocardium [440, 442, 447]. Cross-talk between cardiomyocytes and non-
cardiomyocytes in the heart has been shown to be necessary for the induction of 
hypertrophic markers ANF and BNP [448]. Similarly, angiotensin II induced 
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cardiotrophin-1, leukemia inhibitory factor (LIF) and IL-6 expression in fibroblasts was 
found to contribute to cardiomyocyte hypertrophy and also regulated fibroblast 
proliferation [449, 450]. Other factors implicated in fibroblast-cardiomyocyte 
communication include FGF2, IL-33, MMPs and TIMPs, connexin-43, etc. (reviewed in 
[451]). This model of cross-talk between the different myocardial cell types through 
paracrine factors or cell-surface and ECM proteins is probably the most comprehensive 
depiction of the in vivo complexity of responses in the stressed myocardium. Future 
studies aimed at understanding the function of specific proteins should take into 
consideration the possibility of their functional regulation by paracrine factors from 
different cell types. 
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CHAPTER 8: Yeast two-hybrid analysis for Fstl3 interaction partners 
 
8.1 Introduction 
 
Data presented in Chapter 7 demonstrated that cardiomyocyte-derived Fstl3 is necessary 
for the induction of collagen production by fibroblasts, thus playing a crucial role in 
cardiomyocyte – fibroblast cross-talk. Experiments on stretched fibroblasts as well as 
cardiomyocytes indicated that Fstl3 probably requires additional factors derived from 
mechanically stimulated cells to mediate its pro-fibrotic effects in vitro. On the basis of 
this observation, it was hypothesized that Fstl3 interaction with other myocardial 
proteins may be required for its function. To test this hypothesis, the first step was the 
identification of protein binding partners of Fstl3. The yeast two-hybrid system, also 
known as an ‘interaction trap’, is based on transcriptional activation of a reporter gene 
following interaction of the bait protein of interest with proteins expressed from a 
library. FSTL3 is believed to act, at least in part, through interaction with extracellular 
signalling components of the TGF-β - activin pathway such as myostatin, activin, 
BMPs, etc. However, there has been no systematic study on Fstl3 interacting factors, or 
of potential intracellular binding proteins in the heart. This chapter presents the setup 
and identification of Fstl3 interacting proteins from the myocardium using the yeast 
two-hybrid system and verification of their interaction in mammalian cells. Further, the 
functional consequences of the interaction are also examined.  
 
8.2 Checking for activation of reporter gene by Fstl3 
 
To identify protein interaction partners, Fstl3 was used as ‘bait’ in yeast YRG2 cells. 
Yeast cells were transformed and selection was carried out based on growth on media 
lacking tryptophan. The bait construct expressed truncated Fstl3 lacking the signal 
peptide as a chimeric protein linked to the Gal4 DNA binding domain (Gal4-DBD). To 
check if the bait protein activates the reporter gene HIS3 (encoding histidine) on its 
own, four randomly selected YRG2-Fstl3 colonies were plated on SD-Trp and SD-Trp-
His agar plates at dilutions of 1:0 (undiluted), 1:10 and 1:100. In this assay system, 
colonies that do not grow on medium lacking histidine (SD-Trp-His) do not activate the 
reporter gene and are considered ‘non-leaky’. As shown on Figure 8.1, YRG2-Fstl3 
colonies show variable growth on SD-Trp medium depending on the plating dilution, 
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indicating successful transformation with the bait plasmid encoding Fstl3. However, 
when plated on SD-Trp-His selection medium, no growth was observed at any dilutions 
tested, demonstrating that Fstl3 does not activate the reporter gene HIS3 on its own and 
thus cannot induce growth on medium lacking histidine.  
 
 
Figure 8.1: The Fstl3 bait protein does not auto-activate the reporter gene HIS3. 
Yeast colonies expressing the Fstl3-Gal4 DBD chimera were plated on SD-Trp (top 
panel) and SD-Trp-His (bottom panel) selection medium to check for auto-activation of 
the reporter gene HIS3. The cells were plated at dilutions of 1:0, 1:10 and 1:100 and 
allowed to grow for 4 days. Representative images of colony growth at different 
dilutions are shown.  
 
8.3 Identification of potential binding partners of Fstl3 
 
Next, YRG2-Fstl3 was transformed with rat cardiomyocyte cDNA library linked to the 
transcription activation domain (AD) of Gal4 and plated on medium lacking tryptophan, 
leucine and histidine, thereby ensuring that the colonies that grow express both bait and 
target proteins and show interaction between the two by activation of reporter gene 
HIS3. The yield of transformation was measured to be > 1.15 million successful 
transformants. A total of 156 clones were selected based on activation of reporter gene 
and identified by sequencing. After eliminating probable false positives in the form of 
mitochondrial, ribosomal and cloning vector targets as well as out-of-frame sequences, 
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110 likely targets were identified. Table 8.1 lists the target proteins identified as well as 
the number of clones that encoded them. 
 
As shown in Table 8.1, a number of targets identified were encoded in multiple 
individual clones, thereby indicating high likelihood of interaction with Fstl3. 
Interestingly, fibronectin 1 was encoded in 5 separate clones. This served as a positive 
control as interaction of FSTL3 with type I domains of fibronectin has been previously 
reported, although not in the heart [320]. A majority of 34 clones encoded syntenin, a 
cytoplasmic syndecan binding protein. The second most abundant transcript found was 
connective tissue growth factor (CTGF), a well-known fibrotic marker. A number of 
targets such as granulin, EFEMP2, fibronectin, laminins, fibulins or fibrillins are 
components of the extracellular matrix (ECM) and basement membranes. Thus it seems 
likely that Fstl3 may interact with members of the ECM to potentiate its downstream 
effects. 
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Table 8.1 Probable binding partners of Fstl3 
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8.4 Analysis of Fstl3 interaction with CTGF 
 
From the collection of probable interaction partners of Fstl3 identified by yeast two-
hybrid system, connective tissue growth factor (CTGF) seemed most promising due to 
its previously documented role in regulation of cardiac hypertrophy and fibrosis [395, 
397, 452]. CTGF has been implicated to play a role in angiotensin II and TGF-β 
mediated fibrosis and is known to promote fibroblast proliferation [394, 453, 454]. In 
vitro, CTGF induces cardiomyocyte hypertrophy by activation of the Akt pathway 
[452]. Moreover CTGF is a secreted factor in contrast with syntenin, and was thus 
chosen for verification of its interaction with Fstl3.  
 
To validate Fstl3 interaction with CTGF, co-immunoprecipitation (IP) was performed. 
Neonatal rat cardiac fibroblasts cell lysate was immunoprecipitated using anti-CTGF 
antibody immobilized on protein A/G beads and the bound proteins were analysed by 
SDS-PAGE followed by western blot using anti-CTGF (as control) or anti-Fstl3 
antibody. As shown in Figure 8.2, anti-CTGF antibody successfully 
immunoprecipitated CTGF from fibroblast cell lysate, represented by the 50 kD band in 
the anti-CTGF lane, which is absent in the isotype-matched control IgG 
immunoprecipitation. As the western blot was run under reducing conditions, the 50 kD 
CTGF band would have been masked by the high-intensity IgG heavy chain band (from 
IP antibody) if conventional secondary antibody linked to HRP was used for detection. 
Therefore, protein G linked to HRP was used for detection of primary western blot 
antibodies as it only binds fully intact antibody and not the heavy and light 
immunoglobulin chains that have been separated by reducing PAGE. A fibroblast lysate 
was used as a positive control. 
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Figure 8.2: Anti-CTGF antibody immunoprecipitates CTGF from fibroblast cell 
lysate. CTGF was immunoprecipitated from fibroblast cell lysate using anti-CTGF 
antibody and the bound proteins detected by western blot using protein G - HRP for 
detection. Arrow indicates the CTGF band at 50 kD. 
 
Once the CTGF antibody was successfully tested for IP of CTGF, co-
immunoprecipitation of CTGF with Fstl3 was explored using the same anti-CTGF 
antibody (or control IgG) and analysed by western blot. Anti-Fstl3 antibody followed by 
HRP-linked secondary antibody was used for detection of Fstl3. Fstl3 band of about 72 
kD was detected. This band was absent in the sample where isotype-matched control 
IgG was used for IP, thereby ruling out non-specific interaction of Fstl3 with either IgG 
fixed regions or the protein A/G beads. Recombinant Fstl3 was used as positive control 
for western blot. Thus, Fstl3 interacts with CTGF in cardiac fibroblast lysates. 
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Figure 8.3: Co-immunoprecipitation of CTGF and Fstl3 from fibroblast cell lysate. 
CTGF was immunoprecipitated from fibroblast cell lysate using anti-CTGF antibody 
immobilized on protein A/G beads and the beads were washed several times to remove 
unbound molecules. The bound molecules were then eluted and analysed using western 
blot for detection of Fstl3. Recombinant Fstl3 was used as positive control. Arrow 
indicates an Fstl3 band at 72 kD in the anti-CTGF immunoprecipitated sample that is 
absent in the control IgG precipitated lane. 
 
8.5 Functional significance of Fstl3 interaction with CTGF 
 
CTGF is well known as a fibrosis marker and Fstl3 was shown to mediate fibroblast 
activation by stretched cardiomyocytes (Chapter 7). However, additional cardiomyocyte 
derived factors seemed to be necessary for the effect of Fstl3 on collagen synthesis. 
CTGF interaction with Fstl3 led to the hypothesis that CTGF could be one of the 
cardiomyocyte-derived factors through which Fstl3 exercised its pro-fibrotic role. To 
test this hypothesis, cardiac fibroblasts were treated with recombinant Fstl3 and/or 
CTGF for 72 h and newly synthesized collagen secreted into the culture supernatant was 
measured using Sircol collagen assay. Recombinant CTGF concentration of 500 ng/ml 
was chosen as it was shown to induce mRNA expression of ECM proteins including 
fibronectin, collagen I and III in H9c2 cardiomyocytes and dermal fibroblasts [455, 
456]. As shown in Figure 8.4, neither Fstl3 not CTGF by itself was sufficient to induce 
collagen synthesis in fibroblasts. Similarly, when both Fstl3 and CTGF were present in 
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the medium, collagen synthesis remained unaffected. Thus, Fstl3 and CTGF were not 
sufficient to induce collagen synthesis in cardiac fibroblasts. However, the activity of 
recombinant CTGF was not tested. 
 
Figure 8.4: Fstl3 and CTGF together are not sufficient to enhance collagen 
synthesis in fibroblasts. Neonatal rat cardiac fibroblasts were treated with 200 ng/ml 
Fstl3 and/or 500 ng/ml CTGF for 72 h and collagen released into the culture supernatant 
was measured using Sircol assay, shown as mean ± SEM. n = 3. 
 
The cardioprotective effects of CTGF on angiotensin induced cardiac dysfunction [395] 
suggested that CTGF might be involved in regulation of cell death. Moreover, Fstl3 was 
shown to induce cell death of fibroblasts (Chapter 7). Therefore, the combined effect of 
CTGF and Fstl3 was examined on LDH release by fibroblasts in order to determine 
whether their interaction affected cell death. Recombinant CTGF was used at a 
concentration of 5 μg/ml as concentrations between 1 – 10 μg/ml have previously been 
reported to inhibit cell death both in vitro and in vivo [457-459]. Cardiac fibroblasts 
were treated with increasing concentrations of Fstl3 and/or 5 μg/ml CTGF for 24 h and 
LDH released into the culture supernatant was measured. Increasing concentrations of 
Fstl3 led to a dose-dependent increase in LDH release. However, in the presence of 
CTGF, LDH release was comparable to control cells. Thus, CTGF inhibited Fstl3-
induced cell death in fibroblasts. 
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Figure 8.5 CTGF inhibits Fstl3-induced LDH release in cardiac fibroblasts. 
Fibroblasts were treated with increasing concentrations of recombinant Fstl3 and/or 5 
μg/ml CTGF for 24 h. LDH released into the supernatant was determined with a 
colorimetric assay by measuring absorbance at 490 nm and normalised to total LDH 
released upon cell lysis. Data are presented as mean ± SEM. Two-way ANOVA 
followed by Bonferonni post-test was used to calculate statistical significance. * p < 
0.05, *** p < 0.001 for CTGF vs. no CTGF at respective Fstl3 concentrations. n = 3. 
 
8.6 Discussion 
 
Data presented in this chapter identified a number of ECM and basement member 
constituent proteins as potential binding partners of Fstl3. Moreover, interaction of Fstl3 
with CTGF was verified in cardiac fibroblasts using co-immunoprecipitation and CTGF 
was shown to inhibit Fstl3 mediated cell death in cardiac fibroblasts. 
 
Yeast two-hybrid analysis proposed a number of targets to which Fstl3 may bind, most 
of these being members of the ECM involved in homeostasis, remodelling and 
structural integrity. This suggested that Fstl3 may act through these factors to mediate 
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its effect on cardiac hypertrophy and fibrosis. It is in agreement with the results of the 
microarray analysis of Fstl3 KO hearts in which most proteins from the ECM were 
downregulated in response to pressure overload compared to WT mice (Chapter 6), 
which also suggested that Fstl3 may primarily act by regulating ECM proteins. 
Interesting targets from the yeast two-hybrid analysis include syntenin (cytoplasmic), 
CTGF, fibronectin, LTBP2, fibrillin-1, fibulin-2 and 5, etc. Identification of fibronectin 
served as a good positive control for the procedure, as binding of Fstl3 and fibronectin 
has been reported previously. Intriguingly, neither Activin A nor myostatin were 
identified from any of the colonies tested even though a strong interaction of both with 
Fstl3 has been shown in previous studies. This could be simply because of the limited 
number of colonies tested or may be due to some physiological conditions that may be 
necessary for their interaction which were not fulfilled in the yeast two-hybrid system. 
A number of these proteins have been previously shown to be regulated by mechanical 
stretch in the heart. These include CTGF, fibronectin, thrombospondin-1, fibrillin-1 
[460-464], thus making them attractive candidates for mediators of cardiomyocyte – 
fibroblast crosstalk alongside Fstl3.  
 
Although the targets identified from the yeast two-hybrid screen seem promising, 
correct interpretation of this data requires consideration of its limitations which reduce 
its reliability [465]. For example, the interactions in the yeast cells are forced to take 
place in the nucleus due to fusion of bait and target proteins to nuclear localisation 
signals, which might not reflect the physiological conditions for proper folding of 
proteins or interaction amongst proteins. Similarly, fusion itself may result in mis-
folding of proteins and false positive targets. Moreover, some true interactions may be 
missed due to differences in expression of some target proteins in the yeast. Therefore, 
identified interaction proteins from the yeast must be verified in their native state in 
mammalian systems. In this regard, the interaction of CTGF with Fstl3 was verified by 
immunoprecipitation and the functional effect of this interaction was explored.  
 
Neither Fstl3 nor CTGF were sufficient to induce fibroblast collagen synthesis and their 
interaction was not sufficient either to enhance collagen synthesis by fibroblasts. This 
suggested that CTGF may not be the stretched - cardiomyocyte derived factor, whose 
interaction with Fstl3 may regulate collagen synthesis. It may also be possible that 
additional factors are required for the CTGF and Fstl3 interaction to have a functional 
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significance in the regulation of fibrosis. Interaction of CTGF with Fstl3 was found to 
inhibit Fstl3 mediated fibroblast cell death. It should be noted that the role of CTGF in 
regulation of cell death is context-dependent as some reports have demonstrated 
increased cellular apoptosis upon treatment with CTGF [466-468]. Interestingly, a role 
for thrombospondin-1, also identified as a potential binding partner of Fstl3, has been 
reported in mechanosensitive initiation of fibroblast cell death [469]. However, in this 
study, the interaction of Fstl3 and thrombospondin-1 was not further verified. CTGF has 
been shown to play a role in fibrosis induction (in vitro) and is a recognised marker of 
in vivo fibrosis in multiple organs [398, 470]. However, transgenic mice with 
overexpression of CTGF in the heart developed age-dependent cardiac hypertrophy and 
heart failure albeit with no evidence of fibrosis. Moreover, CTGF transgenic mice 
displayed preserved cardiac function compared to littermate control mice upon 
treatment with angiotensin II, leading the authors to conclude that CTGF, by itself, is 
not profibrotic but is involved in development of cardiac hypertrophy and dysfunction 
[395]. Similarly, CTGF overexpression in the heart was shown to play a 
cardioprotective role against ischemia reperfusion injury via activation of Akt signalling 
[458]. Interestingly, Activin A has also been reported to play a cardioprotective role 
against ischemic injury and this effect was abolished by Fstl3 [294]. Thus Fstl3 may be 
involved in regulating the action of two different cardioprotective factors acting through 
diverse pathways and may thus contribute to cardiac dysfunction.  
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CHAPTER 9: General Discussion and Conclusions 
 
9.1 General discussion and concluding remarks 
 
Many aspects of the process of cardiac failure are still incompletely understood. A 
number of cardiac pathologies eventually progress to heart failure and surgical 
intervention is often needed to halt or slow down this process. This project was born out 
of an interesting clinical observation in end-stage heart failure patients undergoing 
implantation of left ventricular assist devices combined with pharmacological therapy. 
The expression of follistatin family genes was observed to be aberrant and FSTL3 
expression in particular was elevated in myocardial samples from heart failure patients, 
returning to control levels following recovery [328]. At the time, Fstl3 was thought to 
mainly function as an extracellular inhibitor of activin and myostatin [315, 317, 471]. 
Fstl3 was peculiar in this respect as the expression of other TGF-β superfamily ligands, 
including Activin βA remained unaltered in these patients. This observation was further 
replicated in mouse models of cardiac injury and suggested an activin independent role 
for the follistatin family proteins. The aim of this study was to explore the role of Fstl3 
in cardiac hypertrophy. 
 
The TGF-β superfamily regulates cardiac homeostasis as well as response to injury 
[287, 360, 472]. A complex interplay has been described between members of this 
family and their soluble inhibitors, in particular Fstl3. Both TGF-β and activin A can 
induce the expression of Fstl3 through Smad proteins [305, 306], while Fstl3 in turn 
binds to activin A with high affinity and inhibits its bioactivity by preventing the 
binding to its receptor [297]. The expression of activin A in the heart is upregulated in 
different cardiac injury models and has been demonstrated to play a cardioprotective 
role following ischemic injury [294]. In contrast, some studies have also noted a pro-
fibrotic action of activin A [418, 420], although this hasn’t been examined in the heart. 
On the other hand, cardiac specific Fstl3 KO mice showed increased expression of 
activin A following pressure overload similar to that observed in WT mice. Due to the 
absence of Fstl3 inhibition of activin, the reduced cardiac hypertrophy in these mice 
might be a direct consequence of increased activin A function. Similar observations 
were reported in the whole body Fstl3 KO mice, where the observed phenotype was 
attributed to increased tissue availability of activin A and myostatin, resulting in a 
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complex metabolic paradigm [317]. The expression of TGF-β in cardiac specific Fstl3 
KO mice was reduced following pressure overload, in contrast to activin A which 
remained elevated.  TGF-β is known to induce cardiac hypertrophy and fibrosis and 
regulates the expression of other mediators of these responses in the myocardium [249, 
252, 287, 473]. The pleiotropic effects of TGF-β in the myocardium are mediated by 
downstream effectors such as CTGF, whose expression is induced by TGF-β and is 
known to regulate cardiac hypertrophy and dysfunction [395, 474, 475]. Thus, the 
regulation of Fstl3 expression by TGF-β in cardiomyocytes and its subsequent pro-
hypertrophic and pro-fibrotic effects suggest that it may act as a downstream mediator 
of TGF-β action on cardiomyocytes and fibroblasts. The complex interplay between 
these proteins suggests that a balance in their temporal and spatial expression and 
activity may determine the course of disease progression in a context dependent 
manner. 
 
Cardiac fibrosis is often seen as part of the remodelling response of the hypertrophied 
myocardium and thus many interventional studies have noted simultaneous reduction or 
increase in both cardiac hypertrophy and fibrosis. For example, inhibition of EGF 
receptor transactivation inhibited cardiac hypertrophy and fibrosis in response to 
pressure overload [20]. Similarly, cardiac specific knock-out of Erk5 in mice resulted in 
reduced cardiac hypertrophy and fibrosis following pressure overload [142]. In 
overexpression studies, activated calcineurin subunit in the heart resulted in enhanced 
hypertrophy and fibrosis [146]. In contrast, a number of studies have also reported 
differential regulation of hypertrophy and fibrosis. The phenotype of mice with 
constitutive active PI3K or dominant negative PI3K in the heart showed increased or 
decreased cardiac size respectively without any effect on fibrosis in either models [154]. 
Cardiac specific Fstl3 KO mice displayed reduced cardiac fibrosis and remodelling 
which may be a direct effect of reduced hypertrophy following pressure overload. 
However, microarray analysis in these mice suggested that Fstl3 may function mainly 
by modulation of extracellular matrix components rather than hypertrophic mediators. 
Moreover, cardiomyocytes being the main source of increased Fstl3 in the stressed heart 
suggested that Fstl3 may function through autocrine and/or paracrine actions on other 
cell types in the myocardium. This was further supported by in vitro observations 
demonstrating a necessary role for cardiomyocyte-derived Fstl3 in fibrosis development 
through paracrine actions. 
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Recently, a number of studies have focused on exploring the function of paracrine 
factors in mediation of cardiac hypertrophy and fibrosis. For example, cardiomyocyte-
derived TGF-β has been recognized to act on fibroblasts in the presence of angiotensin 
II to enhance collagen production [476]. Furthermore, it was recently reported that 
paracrine action of TGF-β from cardiomyocytes is necessary for the protective effects 
of TGF-β type II receptor inhibition in the form of attenuated hypertrophy as well as 
fibrosis in response to pressure overload [477]. Similarly, IL-6 family cytokines have 
also been shown to play a paracrine role in fibrosis as well as cardiomyocyte 
hypertrophy. Pro-hypertrophic angiotensin II signalling induced IL-6, CT-1 and LIF 
expression in cardiac fibroblasts, which activated gp-130 signalling in cardiomyocytes 
to induce hypertrophic responses [449]. CT-1 stimulation was also sufficient to induce 
cardiac fibroblast growth and collagen synthesis and exhibited cooperation with 
endothelin-1/ETA receptor signalling [478]. Moreover, stem cells expressing paracrine 
factors like IGF-1 and VEGF have been implicated in promoting cardiac repair 
following infarction, through activation of stromal cell-derived factor-1α (SDF-1α), 
which induced stem cell recruitment and enhanced angiogenesis [479, 480]. Reduced 
expression of TGF-β and IL-6 in Fstl3 KO mice suggests that the phenotype observed 
in these mice may be a consequence of reduction in a number of paracrine regulators of 
cardiac remodelling in addition to Fstl3. Additionally, Fstl3 may also act on endothelial 
and vascular smooth muscle cells in the myocardium, as has been previously reported 
for Fstl1, another member of the follistatin family proteins. Fstl1 was demonstrated to 
be an Akt-inducible paracrine mediator of reduced apoptosis in the infarcted 
myocardium and also induced angiogenesis following ischemic injury via endothelial 
nitric oxide synthase signalling in skeletal muscle [481, 482]. Increased Fstl3 expression 
was detected in the endothelium of failing hearts, and may have adverse effects in the 
response to injury, possibly by inducing perivascular fibrosis. In summary, Fstl3 may 
now be considered as a novel cardiomyocyte-derived autocrine-paracrine mediator of 
cardiac hypertrophy and fibrosis. 
 
The dependence of paracrine action of Fstl3 on additional stretch-derived factors from 
the myocardium suggests a coordinated response of the heart undergoing remodelling.  
It was hoped that yeast two-hybrid analysis would identify potential partners essential 
for Fstl3 action on fibroblasts. Although CTGF interaction with Fstl3 was verified, it 
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did not alter collagen synthesis in fibroblasts. However, it was found to inhibit Fstl3 
induced cell death and may thus be an important protective mechanism in the heart. Due 
to the modular structure of CTGF and its interaction with several extracellular 
signalling proteins as well as cell surface molecules, it is possible that Fstl3 may use 
CTGF to sequester itself to specific cell surface proteins, thereby acting in a context-
specific manner. Cardioprotective role of CTGF was also recently demonstrated in vivo 
in a mouse model of ischemia-reperfusion injury where overexpression of CTGF in the 
heart was shown to reduce the scar size and protect the myocardium from ischemic 
injury [458]. Whether Fstl3-CTGF interaction plays a role in the cardioprotective 
actions of CTGF in vivo remains to be explored. In contrast, another study with cardiac 
restricted overexpression of CTGF reported age-dependent cardiac dysfunction but 
protection from pressure overload induced hypertrophy. Whether Fstl3 is required for 
the action of CTGF in development of heart failure could be analysed by crossing 
cardiac-specific CTGF transgenic mice with Fstl3 KO mice.  
 
 It is interesting to note the dual effect of Fstl3 on cardiac fibroblasts – activation to 
induce collagen synthesis as well as induction of cell death. Such dual effects have been 
observed before for angiotensin II action on cardiac fibroblasts. While angiotensin II 
stimulation increases fibroblast collagen synthesis and expression of TGF-β [250, 483, 
484], it has also been demonstrated to induce apoptotic cell death via PKC mediated 
mechanism [485]. Similarly, the dual effect of Fstl3 on fibroblasts may also function in 
coordination with disease progression, i.e. in the acute stage to induce collagen 
expression in fibroblasts in coordination with other factors, while in the chronic stage to 
induce cell death, thereby inducing remodelling and progression to heart failure. 
Interaction with CTGF may alter this balance. Other potential binding partners for Fstl3 
included a number of ECM and basement membrane components, further suggesting 
Fstl3 action through manipulation of these factors. Precise identification of stretched 
cardiomyocyte derived factors coordinating Fstl3 effect on collagen synthesis in 
fibroblasts will require validation of the identified potential binding partners as well as 
sophisticated proteomic analysis including liquid chromatography - mass spectrometry 
analysis on conditioned medium from stretched cardiomyocytes. 
 
Why cardiomyocytes would secrete a stress-activated factor like Fstl3 which would 
further exacerbate both hypertrophy and fibrosis is unknown. One explanation could be 
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that Fstl3 may act in response to mechanical loading to induce a compensatory 
hypertrophic state. However, in the chronically loaded myocardium, other factors would 
then be activated which in coordination with Fstl3 induce fibrosis and ECM remodeling. 
These may include Akt-1 induced factors as similar observations were made in cardiac 
specific inducible activation of Akt-1 where acute activation resulted in compensated 
and physiological hypertrophy with sustained cardiac function while chronic activation 
led to cardiac remodelling and contractile dysfunction due to angiogenic mismatch with 
cardiac growth [161]. Similarly, aberrant Smad signaling has also been suggested to 
play a role in cardiac decompensation and progression to heart failure. In this respect, 
lack of Smad3 in the heart was shown to induce compensated hypertrophy and resisted 
progression to heart failure in response to pressure overload or myocardial infarction 
[257-259]. Fstl3 may function in coordination with these factors and thus play an 
important role in cardiac remodelling. It would be interesting to explore this hypothesis 
using an inducible knock-out model of Fstl3 in the myocardium. Knock-out of Fstl3 
following the acute responses to pressure overload may be more beneficial and prevent 
cardiac remodelling as opposed to knock-out of Fstl3 before or immediately following 
pressure overload, which would prevent hypertrophy. 
 
A role for Fstl3 as a necessary mediator of cardiac hypertrophy in vivo is supported by 
similar observations in vitro in mediating phenylephrine induced cardiomyocyte 
hypertrophy [367]. In addition, cardiac specific Fstl3 KO mice exhibited reduced scar 
formation following ischemic injury [11]. Thus Fstl3 may be an important mediator of 
the cardiac response to various forms of injury. Moreover, data presented in this thesis 
argue for a sufficient role of Fstl3 in induction of cardiomyocyte hypertrophy, possibly 
through activation of p38 and JNK pathways. Whether this response is directly 
mediated by receptor activation is currently unknown. The hypertrophic effect of TGF-β 
is also known to be transduced via activation of TAK which further activates p38 and 
JNK pathways in cardiomyocytes. Thus, induction of Fstl3 by TGF-β in cardiomyocytes 
may function to amplify the pro-hypertrophic action of TGF-β.  
 
Fstl3 action on cardiomyocytes and fibroblasts and its role in their cross-talk represents 
an important target of therapeutic manipulation. In this regard, the action of Fstl3 from 
cardiomyocyte conditioned medium could be inhibited by the addition of a neutralising 
antibody. These have been recognized to be highly specific molecular tools to inhibit 
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the action of important disease regulators. For example, antibody therapy against both 
TGF-β1 and TNF-α has been shown to effectively reduce cardiac fibrosis and 
progression to heart failure [256, 486]. However, inhibition of TGF-β during ischemic 
injury has also been reported to have detrimental effects associated with increased MMP 
activation and chamber dilation [487]. In this respect, Fstl3 inhibition by neutralising 
antibody may be used as an effective therapeutic strategy to minimize the harmful 
actions of Fstl3 on cardiomyocytes as well as fibroblasts and should be further explored 
using injection of Fstl3 neutralising antibody following cardiac injury. 
 
9.2 Limitations and future work 
 
An important limitation of the work presented here is the lack of sufficient numbers of 
Fstl3 KO mice under study. This was mainly because of restricted availability of these 
mice in London due to their health status which made it imperative for all the mouse 
procedures to be performed at the Whittaker Cardiovascular Institute, Boston. Although 
post-operative mortality was only 10%, limited breeding regulations as well as available 
time introduced more restrictions in the number of KO mice available.  
 
In vitro experiments were carried out on neonatal rat ventricular cardiomyocytes and 
fibroblasts as model systems. Although these primary cells are widely used for studying 
molecular mechanisms of hypertrophy and fibrosis, it is appreciated that the responses 
seen in these cells are not always reflective of the responses in adult cells. Moreover, 
the in vivo complexity of the tissue system with multiple intercellular and intracellular 
physical and chemical communication signals can not be fully simulated in the in vitro 
experimental systems. Similarly, cell culture systems are two dimensional while the in 
vivo tissue and organ systems are three dimensional. In addition, a number of systemic 
factors such as endocrine hormones or circulating cytokines and growth factors might in 
fact affect the phenotype of Fstl3 KO mice following injury, which cannot be replicated 
in the in vitro mechanical stretch and cardiomyocyte – fibroblast cross-talk model.  
 
Examination of the effects of Fstl3 on cardiomyocytes demonstrated increased 
cardiomyocyte hypertrophy and activation of the p38 and JNK signalling pathways. A 
detailed analysis of the molecular mechanism of Fstl3 mediated cardiomyocyte 
hypertrophy could not be performed mainly due to time limitations. In the future, it 
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would be interesting to assess whether Fstl3 action on cardiomyocytes is dependent on 
p38 and JNK pathways as well as the role of Smad pathway proteins in Fstl3 action in 
relation to activin A. Cardiac-specific Fstl3 KO mice were reported to show increased 
phosphorylation of Smad2 in the heart following pressure overload, possibly explaining 
the observed reduction in cardiac hypertrophy [367]. It is possible that Fstl3 may 
directly regulate Smad7 expression and/or activation in the heart which might affect 
activation of its target protein Smad2 and thereby regulate the cardiomyocyte 
hypertrophic response. The role of Fstl3 as a cardiomyocyte – fibroblast cross-talk 
mediator was demonstrated in this study using a neutralising antibody against Fstl3. The 
exact molecular mechanism of mediating this paracrine effect should be explored to 
assess which signalling pathways are involved as well as the possibility of a cell surface 
receptor for Fstl3 through which it would transduce the pro-fibrotic signals. Similarly, 
the role of additional cardiomyocyte derived factors following mechanical loading and 
their relation with Fstl3 should also be examined. It would also be interesting to inspect 
whether Fstl3 has an effect on endothelial cell function or myofibroblast differentiation 
in the injured heart.  
 
9.3 Summary 
 
The expression of Fstl3 is elevated in the myocardium of heart failure patients as well as 
mouse models of cardiac injury, wherein cardiomyocytes were identified as the main 
source of increased Fstl3 following pressure overload. The role of Fstl3 in cardiac 
hypertrophy was tested using cardiac specific Fstl3 KO mice subjected to pressure 
overload. These mice displayed attenuated cardiac hypertrophy and remodelling, 
resulting in improved cardiac function. In vitro analysis demonstrated that secreted 
Fstl3 from cardiomyocytes acts in an autocrine manner to induce hypertrophy of 
cardiomyocytes and activation of MAPK proteins p38 and JNK. Further, paracrine 
action of Fstl3 on fibroblasts was shown to increase collagen synthesis in coordination 
with unknown factors derived from mechanically loaded cells. Fstl3 also induced cell 
death in fibroblasts, which may contribute to heart failure progression. Furthermore, 
screening for cardiomyocyte derived protein binding partners of Fstl3 led to the 
identification of CTGF interaction with Fstl3, which inhibited Fstl3 induced cell death, 
but did not affect fibroblast collagen synthesis. Thus, Fstl3 has been identified as an 
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important paracrine mediator of the responses of injured myocardium. Figure 9.1 below 
shows a schematic of the proposed action of Fstl3 in the heart. 
 
 
Figure 9.1: Schematic of Fstl3 action in the heart. Fstl3 is secreted from 
cardiomyocytes following mechanical loading and acts in an autocrine manner to induce 
cardiomyocyte hypertrophy. In coordination with unknown stretch-derived factors, 
Fstl3 acts in a paracrine manner on fibroblasts to induce collagen synthesis and cell 
death. 
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Appendix I: TaqMan® Gene Expression assays 
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Appendix II: Antibodies used for western blot analysis 
 
 
 
Appendix III: Yeast two-hybrid reagents 
 
1. Yeast culture media 
 
YPAD medium (500ml) 
 
25 g YPD media 
10 mg Adenine sulphate (to give 0.02 %) 
400 ml distilled water 
Autoclave 
100 ml 10 % glucose 
 
YPAD agar (500ml) 
 
25 g YPD media 
10 mg Adenine sulphate (to give 0.02 %) 
17.5 g agar 
400 ml distilled water 
Autoclave 
100 ml 10 % glucose 
 
SD Agar – Trp (500ml) 
 
3.35 g yeast nitrogen base without amino acids 
0.96 g yeast drop-out medium - Trp 
17.5 g agar 
400 ml distilled water 
Autoclave 
100 ml 10 % glucose 
 
SD Agar – Leu (500ml) 
 
3.35 g yeast nitrogen base without amino acids 
0.8 g yeast drop-out medium -Leu 
17.5 g agar 
400 ml distilled water 
Autoclave 
100 ml 10 % glucose 
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SD Agar –His –Trp (1L) 
 
6.7 g  yeast nitrogen base without amino acids 
20 mg L-uracil 
20 mg L-adenine hemisulfate salt 
30 mg L-lysine HCL 
100 mg L-leucine 
35 g  agar 
800 ml distilled water 
Autoclave 
200 ml 10 % glucose 
 
SD Media –His –Leu (1L):   6.7 g yeast nitrogen base without amino acids 
20 mg L-uracil 
20 mg L-adenine hemisulfate salt 
30 mg L-lysine HCL 
20 mg Histidine HCL monohydrate 
800 ml distilled water 
Autoclave 
200ml 10 % glucose 
 
SD Media –Trp –Leu (1L) 6.7 g yeast nitrogen base without amino acids 
1.54 g Yeast dropout media – Trp –Leu 
800 ml distilled water 
Autoclave 
200 ml 10% glucose 
 
SD Agar –His –Leu -Trp 
(1L) 
6.7 g yeast nitrogen base without amino acids 
20 mg L-uracil 
20 mg L-adenine hemisulfate salt 
30 mg L-lysine HCL 
35 g agar 
800 ml distilled water 
Autoclave 
200 ml 10 % glucose 
 
 
2. Yeast solutions 
 
10x Lithium acetate (LiAc 
or LiOAc) 
1 M LiAc 
Adjust pH to 7.5 with dilute acetic acid 
Autoclave 
 
10x TE 
 
100 mM Tris-HCl, pH 7.5 
10 mM EDTA, pH 8.0 
Autoclave 
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50% w/v PEG 3350 
solution 
50 g PEG (molecular weight 3350) 
Distilled water up to 100 ml 
Autoclave 
TE-LiAc solution (1x TE, 
1x LiAc) 
1 ml 10x TE 
1 ml 10x LiAc 
8 ml sterile water 
 
TE-LiAc-PEG solution  
(1x TE, 1x LiAc, 40% w/v 
PEG 3350) 
1 ml 10x TE 
1 ml 10x LiAc 
8 ml 50 % w/v PEG 3350 
 
LiSORB (500ml) 
 
100 mM   LiOAc 
10 mM     Tris-Hcl (pH 8.0) 
1 mM      EDTA 
1 M      Sorbitol 
500 ml      distilled water 
Verify pH 8.0 
Autoclave 
 
10% Glucose (500 ml) 
 
50 g glucose 
500 ml autoclaved water 
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Appendix IV: Microarray Analysis 
 
Table IV.1 (A) WT TAC > WT Sham: Representative Genes 
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Table IV.1 (B) WT TAC > WT Sham: Gene Ontology 
 
 
Table IV.2 (A) WT TAC < WT Sham: Representative Genes 
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Table IV.2 (B) WT TAC < WT Sham: Gene Ontology 
 
 
Table IV.3 (A) KO Sham > WT Sham: Representative Genes 
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Table IV.3 (B) KO Sham > WT Sham: Gene Ontology 
 
 
Table IV.4 (A) KO Sham < WT Sham: Representative Genes 
 
 
Table IV.4 (B) KO Sham < WT Sham: Gene Ontology 
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Table IV.5 (A) KO TAC > KO Sham: Representative Genes 
 
 
Table IV.5 (B) KO TAC > KO Sham: Gene Ontology 
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Table IV.6 (A) KO TAC < KO Sham: Representative Genes 
 
 
Table IV.6 (B) KO TAC < KO Sham: Gene Ontology 
 
 
Table IV.7 (A) KO TAC > WT TAC: Representative Genes 
 
 
